{"title": "Mutant Presenilin 1 Dysregulates Exosomal Proteome Cargo Produced by Human-Induced Pluripotent Stem Cell Neurons", "pubDate": "2021", "PMCID": "PMC8158845", "DOI": "10.1021/acsomega.1c00660", "PMID": "34056454", "abstract": "The accumulation and propagation of hyperphosphorylated tau (p-Tau) is a neuropathological hallmark occurring with neurodegeneration of Alzheimer's disease (AD). Extracellular vesicles, exosomes, have been shown to initiate tau propagation in the brain. Notably, exosomes from human-induced pluripotent stem cell (iPSC) neurons expressing the AD familial A246E mutant form of presenilin 1 (mPS1) are capable of inducing tau deposits in the mouse brain after in vivo injection. To gain insights into the exosome proteome cargo that participates in propagating tau pathology, this study conducted proteomic analysis of exosomes produced by human iPSC neurons expressing A246E mPS1. Significantly, mPS1 altered the profile of exosome cargo proteins to result in (1) proteins present only in mPS1 exosomes and not in controls, (2) the absence of proteins in the mPS1 exosomes which were present only in controls, and (3) shared proteins which were upregulated or downregulated in the mPS1 exosomes compared to controls. These results show that mPS1 dysregulates the proteome cargo of exosomes to result in the acquisition of proteins involved in the extracellular matrix and protease functions, deletion of proteins involved in RNA and protein translation systems along with proteasome and related functions, combined with the upregulation and downregulation of shared proteins, including the upregulation of amyloid precursor protein. Notably, mPS1 neuron-derived exosomes displayed altered profiles of protein phosphatases and kinases involved in regulating the status of p-tau. The dysregulation of exosome cargo proteins by mPS1 may be associated with the ability of mPS1 neuron-derived exosomes to propagate tau pathology.", "author": [{"author": "Sonia Podvin", "affiliation": ["Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, San Diego 92093, California, United States."], "href": "/?term=Podvin+S&cauthor_id=34056454"}, {"author": "Alexander Jones", "affiliation": ["Biomedical Sciences Graduate Program, University of California, San Diego, La Jolla, San Diego 92093, California, United States."], "href": "/?term=Jones+A&cauthor_id=34056454"}, {"author": "Qing Liu", "affiliation": ["Department of Neurosciences, School of Medicine, University of California, San Diego, La Jolla, San Diego 92093, California, United States."], "href": "/?term=Liu+Q&cauthor_id=34056454"}, {"author": "Brent Aulston", "affiliation": ["Department of Neurosciences, School of Medicine, University of California, San Diego, La Jolla, San Diego 92093, California, United States."], "href": "/?term=Aulston+B&cauthor_id=34056454"}, {"author": "Charles Mosier", "affiliation": ["Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, San Diego 92093, California, United States."], "href": "/?term=Mosier+C&cauthor_id=34056454"}, {"author": "Janneca Ames", "affiliation": ["Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, San Diego 92093, California, United States."], "href": "/?term=Ames+J&cauthor_id=34056454"}, {"author": "Charisse Winston", "affiliation": ["Department of Neurosciences, School of Medicine, University of California, San Diego, La Jolla, San Diego 92093, California, United States."], "href": "/?term=Winston+C&cauthor_id=34056454"}, {"author": "Christopher B Lietz", "affiliation": ["Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, San Diego 92093, California, United States."], "href": "/?term=Lietz+CB&cauthor_id=34056454"}, {"author": "Zhenze Jiang", "affiliation": ["Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, San Diego 92093, California, United States."], "href": "/?term=Jiang+Z&cauthor_id=34056454"}, {"author": "Anthony J O'Donoghue", "affiliation": ["Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, San Diego 92093, California, United States."], "href": "/?term=O%27Donoghue+AJ&cauthor_id=34056454"}, {"author": "Tsuneya Ikezu", "affiliation": ["Department of Pharmacology and Experimental Therapeutics, Department of Neurology, Alzheimer's Disease Research Center, Boston University, School of Medicine, Boston 02118, Massachusetts, United States."], "href": "/?term=Ikezu+T&cauthor_id=34056454"}, {"author": "Robert A Rissman", "affiliation": ["Department of Neurosciences, School of Medicine, University of California, San Diego, La Jolla, San Diego 92093, California, United States.", "Veterans Affairs San Diego Healthcare System, La Jolla, San Diego 92161, California, United States."], "href": "/?term=Rissman+RA&cauthor_id=34056454"}, {"author": "Shauna H Yuan", "affiliation": ["Department of Neurosciences, School of Medicine, University of California, San Diego, La Jolla, San Diego 92093, California, United States."], "href": "/?term=Yuan+SH&cauthor_id=34056454"}, {"author": "Vivian Hook", "affiliation": ["Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, San Diego 92093, California, United States.", "Biomedical Sciences Graduate Program, University of California, San Diego, La Jolla, San Diego 92093, California, United States.", "Department of Neurosciences, School of Medicine, University of California, San Diego, La Jolla, San Diego 92093, California, United States."], "href": "/?term=Hook+V&cauthor_id=34056454"}], "refPMID": ["26631930", "17684513", "22710920", "29467609", "27567878", "26786552", "19503072", "24531916", "25534024", "22312444", "29453339", "27298345", "16877359", "29895964", "26538351", "26436904", "27408937", "28610892", "30584143", "29339798", "26891626", "26858453", "28386213", "31229685", "22057275", "27188934", "23276979", "22278060", "28350801", "30412492", "29112196", "7596406", "9212102", "31594233", "21407814", "22278060", "25285942", "26456686", "30208291", "17703201", "25855955", "22186715", "24766612", "17182697", "30476243", "23203871", "25431153", "29542322", "28717422", "25915504", "27899662", "29860944", "29066004", "28226201", "17785673", "16369476", "8824813", "12975602", "27860287", "23213106", "24075854", "28419892", "29885460", "26025392", "30820047", "24006081", "30108311", "24141082", "20935630", "26612778", "19387070", "32132634", "24128412", "28887633", "28148929", "8441630", "17258209", "11809816", "17921318", "16195786", "21860608", "27374104", "12422231", "25849773", "31269449", "28360085", "22771380", "24653673", "29121398", "24757378", "24807918", "27644562", "17174306", "22526020", "23257289", "30747709", "30344044", "27015757", "26951610", "15064750", "29796672", "29249356", "19251628", "19251627", "9473509", "19412159", "22972301", "10087198", "17366602", "28869038", "14570571", "31181827", "26437438", "11861754", "21367856", "29729314", "30068389", "30606694", "31268600", "29218503", "11584270", "17275357", "30128052", "29606302", "3009475", "10713707", "30874837", "25246025", "30254002", "27872486", "18382889", "27997051", "28623007", "29908079", "20433353", "18704746", "31996371", "25731615", "11118206", "8157010", "19072283", "10607841", "28559789", "22227520", "27208175", "31969807", "27986928", "16763034", "29462653", "28440221", "31794946", "12486139", "50031", "28648944", "20020485", "9304800", "23860027", "29321508", "1281457", "7524401", "27942226", "23076869", "11414355", "12396000", "10079271", "25761876", "7814404", "26028559", "29723415", "8034587", "11146440", "11292377", "18505598", "31456206", "3032619", "31456206", "19166904", "24780099", "29970604", "31538344", "30658384", "10047530", "2825660", "10421373", "11239457", "15574344", "29767008", "16466929", "30816613", "31820119", "22005280", "23376432", "25205658", "27806215", "15203023", "10604479", "27929117", "15629458", "18494608", "8964583", "18956301", "21696899", "29038240", "31186638", "25358863", "22351471", "23752245", "30089789", "22687584", "12595239", "15565635", "22971926", "21981974", "32226297", "32220323", "9388245", "30416377", "25122912", "32341983", "22553493", "17168651", "19021548", "23921899", "6180679", "6204990", "21895736", "22851445", "19843518", "20877282", "16683255", "19788893", "9553770", "20932857", "12445459", "17636013", "18304378", "9624159", "12660896", "20396415", "28851640", "30128052", "29573041", "14983046", "10899427", "15192323", "25165140", "16146802", "25719457", "27402852", "3346228", "31136180", "15094111", "10842357", "14983046", "18415033", "18086858", "18077326", "15572177", "15192323", "16002217", "20386726", "11740561", "26991731", "19683501", "25588830", "19696785", "27295069", "30013181", "22881374", "12458206", "19679459", "28603077", "1836432", "7650420", "7660134", "9372205", "12230981", "30150416", "18172500", "19344625", "25881554", "27034851", "22045497", "11422376", "22753410", "30200516", "1402395", "29744576", "27356620", "30858094", "11642359", "17018530", "25810257", "31189515", "22627493", "31533003", "22174158", "30425636", "31748784", "24083347", "24211009", "23403532", "25701430", "16330568", "28815942", "32301581", "28111830", "19006241", "11958858", "29453983", "28671123", "28552558", "23110097", "15261737", "16806869", "27486134", "11181400", "16460281", "29316729", "7681396", "30341976", "20383123", "7957065", "2287949", "1370306", "21310214", "2653817", "7898047", "20385134", "15190104", "29879884", "23647050", "18505598", "32232475", "29414938", "24183672", "15854030", "23234877", "22742992", "22340724", "25426138", "18922469", "15099019", "17335084", "8503898", "31097686", "29760653", "15615649", "14999081", "11303790", "26858248", "22710920", "17684513", "22315713", "22944690"], "citedInPMID": ["34056454"], "body": " AbstractThe accumulation\nand propagation of hyperphosphorylated tau (p-Tau)\nis a neuropathological hallmark occurring with neurodegeneration of\nAlzheimer\u2019s disease (AD). Extracellular vesicles, exosomes,\nhave been shown to initiate tau propagation in the brain. Notably,\nexosomes from human-induced pluripotent stem cell (iPSC) neurons expressing\nthe AD familial A246E mutant form of presenilin 1 (mPS1) are capable\nof inducing tau deposits in the mouse brain after in vivo injection. To gain insights into the exosome proteome cargo that\nparticipates in propagating tau pathology, this study conducted proteomic\nanalysis of exosomes produced by human iPSC neurons expressing A246E\nmPS1. Significantly, mPS1 altered the profile of exosome cargo proteins\nto result in (1) proteins present only in mPS1 exosomes and not in\ncontrols, (2) the absence of proteins in the mPS1 exosomes which were\npresent only in controls, and (3) shared proteins which were upregulated\nor downregulated in the mPS1 exosomes compared to controls. These\nresults show that mPS1 dysregulates the proteome cargo of exosomes\nto result in the acquisition of proteins involved in the extracellular\nmatrix and protease functions, deletion of proteins involved in RNA\nand protein translation systems along with proteasome and related\nfunctions, combined with the upregulation and downregulation of shared\nproteins, including the upregulation of amyloid precursor protein.\nNotably, mPS1 neuron-derived exosomes displayed altered profiles of\nprotein phosphatases and kinases involved in regulating the status\nof p-tau. The dysregulation of exosome cargo proteins by mPS1 may\nbe associated with the ability of mPS1 neuron-derived exosomes to\npropagate tau pathology. IntroductionAlzheimer\u2019s\ndisease (AD) is a neurodegenerative disorder\nresulting in deficits in cognitive function. AD brain neuropathology\ndisplays progressive neuronal loss and severe neurodegeneration, with\nthe accumulation of amyloid plaque deposits and neurofibrillary tangles\n(NFTs). NFTs result from the accumulation of hyperphosphorylated tau\n(p-Tau)1\u22125 which lacks the ability to interact with microtubules, leading to\ndetrimental effects on neuronal synaptic functions. Tau oligomers\nimpair long-term potentiation and result in memory loss.6 Tau undergoes cell\u2013cell propagation in\nthe brain cortex and hippocampus,7\u221210 which leads to memory deficits and synaptic\nimpairment.11\u221215Recent evidence demonstrates that exosomes are involved in\ntau\npropagation.16\u221219 Exosomes are released from neurons, glia, and many cell types and\nare characterized as extracellular vesicles of the endosomal origin20\u221223 for the removal of cellular components. Exosomes participate in\nthe transcellular shuttling of exosome cargo molecules consisting\nof proteins, RNAs, lipids, and metabolites.24 Tau is present in exosomes from the cerebrospinal fluid of AD patients.25 Studies of neuron-derived exosomes (NDEs) isolated\nfrom the plasma of AD patients demonstrate that p-Tau levels in NDE\npredict conversion from mild cognitive impairment to dementia of AD.17 Significantly, the intracranial injection of\nAD patient-derived plasma NDEs into the mouse brain results in AD-like\ntau neuropathology. Furthermore, the inhibition of the exosome synthesis\nretards tau propagation in the mouse brain involving microglia.16 These findings show that exosomes can mediate\ntranscellular spreading of tau in the brain.Familial AD (FAD)\nrepresents genetic forms of AD and sporadic AD\nrepresents AD patients with no known genetic mutation(s).26\u221228 Gene mutations of FAD have provided much insight into molecular\nmechanisms of AD. These FAD gene mutations consist primarily of mutations\nof presenilin 1 (PS1), which represent most FAD, together with the\nmutations of presenilin 2 (PS2) and the amyloid precursor protein\n(APP).29\u221231 Such FAD mutations result in progressive cognitive\ndysfunction and brain neuropathology consistent with AD.To\ngain an understanding of the role of a FAD mutant PS1 (mPS1)\nin exosome-mediated tau neuropathology, we previously examined the\nrole of the A246E mPS132,33 in regulating exosomal p-Tau\nproduced by mPS1 patient-derived induced pluripotent stem cell (iPSC)\nneurons.34 The mPS1 iPSC neurons displayed\nelevated p-Tau and secreted exosomes containing p-Tau. The intracranial\ninjection of these exosomes into the mouse brain resulted in aggregated\np-Tau in the hippocampus.34 These results\nshow that the A246E mPS1 participates in the exosome-mediated transmission\nof tau pathology.These findings lead to the important question:\nWhat is the composition\nof the protein cargo of mPS1 NDEs? We hypothesized that the A246E\nmPS1 mutation may dysregulate the protein cargo of exosomes. To test\nthis hypothesis, we performed a study to define the proteome\nof exosomes produced by patient-derived iPSC neurons with or without\nthe mPS1 A246E mutation, which is achieved by nano-liquid chromatography\nwith tandem mass spectrometry (LC\u2013MS/MS)-based proteomics.Significantly, our results demonstrate that mPS1 dysregulated the\nexosome cargo proteins. Global proteomic data were acquired by LC\u2013MS/MS\ntandem mass spectrometry with label-free quantification and assessed\nfor gene ontology (GO), STRING protein networks, brain functions,\nand AD mechanisms. Results showed that mPS1 alters the profile of\nexosome cargo proteins to result in (1) proteins present only in mPS1\nexosomes, and not in controls, (2) the absence of proteins in the\nmPS1 exosomes, which were present only in controls, and (3) shared\nproteins which were upregulated or downregulated in the mPS1 exosomes\ncompared to controls. These findings show that the A246E mutation\nof PS1 dysregulates the protein cargo of exosomes generated by human\niPSC neurons. ResultsMutant PS1 Exosomes Induce\nTau Deposits in the Mouse BrainDeposits of accumulated tau\nin the brain is a characteristic of\nAD pathology and neurodegeneration. We found that when exosomes produced\nfrom iPSC neurons expressing the mutant A246E presenilin (mPS1) were\ninjected into the mouse brain, tau pathology resulted which was observed\nas deposits of tau in the brain hippocampus (Figure S1). In contrast, control exosomes (from wild-type iPSC neurons)\ninjected into the mouse brain had no effect.34The functional difference of the mPS1 exosomes to induce tau\ndeposits, compared to control exosomes, led to the purpose of this\nstudy to assess the proteome cargoes of mPS1 exosomes compared to\nthe control exosomes.Workflow Strategy to Assess the Protein Cargo\nof Exosomes Produced\nby mPS1 iPSC Neurons Compared to ControlsThe proteomic strategy\nfor analyses of exosomes generated by mPS1 and control iPSC neurons\nis conducted, as shown in Figure \u200bFigure11, using label-free quantitative mass spectrometry and\nbioinformatics tools for data analyses. This study was conducted by\n(a) isolation of exosomes from mPS1 iPSC neurons and from control\niPSC neurons, with the confirmation of neuronal markers (Table S1), (b) nano-LC\u2013MS/MS tandem mass\nspectrometry of tryptic digests of exosomes, and (c) bioinformatics\nto assess biological processes by GO and protein interaction networks\nby STRING-db.Open in a separate windowFigure 1Proteomic study design of exosomes generated by mPS1 iPSC\nneurons\nand by control iPSC neurons. (a) mPS1 human neurons and control wild-type\nPS1 human neurons for exosome isolation. The iPSC neurons were derived\n(by a reprograming protocol) from a patient with A246E mPS1 and from\na healthy control patient with wild-type PS1, as we have reported\nearlier.19,34\u221237 It is known that reprograming\nof the fibroblast from biopsies into pluripotent stem cells and differentiation\ninto neurons erases the aging phenotype and generates \u201cage-equivalent\u201d\niPSC neurons.38,39 The neuronal phenotype of the\niPSC neurons has been confirmed by the presence of multiple neuronal\nmarkers representing synaptic neurotransmission. Exosomes generated\nby the neurons were released into media (three biological replicates)\nwhich was collected for exosome isolation. (b) Nano-LC\u2013MS/MS\ntandem mass spectrometry of exosomes. Proteins of exosomes were collected\nby MeOH precipitation, digested with trypsin/LysC by peptide solid-phase\nextraction (SPE),40 and subjected to nano-LC\u2013MS/MS\ntandem mass spectrometry.41 (c) Bioinformatics\nof proteomic data. MS/MS mass spectrometry data were analyzed for\nthe peptide spectrum matching and protein identification, combined\nwith quantification, by PEAKS (v. 8.5) software.42,43 Proteomic data were analyzed for biological systems by GO44,45 and for protein interaction networks by STRING-db.46\u221248Exosomes Secreted from\nmPS1 and Control Human iPSC NeuronsExosomes isolated from\nmPS1 and control iPSC neurons were subjected\nto nanoparticle tracking analysis (NTA) to assess the distribution\nof exosome particle sizes (Figure S2).\nThe mPS1 NDEs had a peak of particles with a diameter of \u223c160\nnm (\u223c100\u2013300 nm). The control exosomes had a peak of\nparticles with a diameter of \u223c170 nm (\u223c100\u2013300\nnm). These vesicle diameters fell within the reported ranges of exosome\ndiameters of approximately 50\u2013150 nm.49\u221251 These vesicles\nare enriched for exosome components including CD63 and CD81, as shown\nin the proteomic data for these exosomes (see Supporting Information Data S1). These markers indicate exosomes\nderived from endosomes.20\u221223Protein Counts for Proteomic Data of mPS1\nand Control ExosomesNano-LC\u2013MS/MS-based proteomics\nidentified 1117 total proteins\nfrom exosomes secreted by mPS1 and control iPSC neurons (Figure \u200bFigure22). For the mPS1 and\ncontrol exosomes, 842 and 1008 proteins were identified, respectively.\nProteins uniquely present in only the mPS1 exosomes numbered 109 and\nproteins present in only the control exosomes numbered 275. The mPS1\nand control exosomes shared 733 proteins present in both groups.Open in a separate windowFigure 2Protein\nidentification counts of mPS1 and control exosome proteomic\ndata. (a) Protein counts. The numbers of proteins identified in mPS1\nand control exosomes are shown, including proteins present only in\nmPS1 or control exosomes, as well as shared proteins. (b) Venn diagram\nof unique and shared proteins of mPS1 and control exosomes. Proteins\npresent only in mPS1 or control exosomes, or shared in both types\nof exosomes are shown.Proteins Present Only in\nmPS1 ExosomesThe mPS1 exosomes\ncontained 109 unique proteins (Figure \u200bFigure22, and listed in Supporting Information Data S1), which were absent in the control exosomes. GO analyses45 revealed a significant enrichment of the mPS1\nonly proteins in biological pathways of the extracellular matrix (ECM)\nand structural organization, cell adhesion, development, and multicellular\nprocesses (Figure \u200bFigure33). The mPS1 only proteins were also enriched in the molecular binding\nof glycosaminoglycans, ECM, calcium, as well as endopeptidase activity.\nKyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses52 indicated significant enrichment in protein\nhomeostasis, ECM receptor interaction, glycosaminoglycan degradation,\nas well as protein degradation and processing in the lysosome and\nendoplasmic reticulum (ER), respectively. These findings suggest that\nproteins present in only mPS1 exosomes participate in ECM binding\nand endopeptidase functions, which involve protein processing by lysosomes\nand ER.Open in a separate windowFigure 3GO analyses of proteins present only in mPS1 exosomes. GO analyses\nof proteins found only in mPS1 exosomes indicate involvement in (a)\nbiological process pathways, (b) molecular function pathways, and\n(c) KEGG pathway. GO enrichment is significant with FDR <1%.Protein network analyses of proteins present in\nonly the mPS1 exosomes\nwas evaluated by STRING.46,47 The analysis showed\nthat 38 out of the 109 mPS1 only proteins are in significant protein\nnetworks as nodes, as illustrated in Figure \u200bFigure44. The predicted protein interactions include\nfunctions of the extracellular structure and ECM and sulfur binding\n(Figure \u200bFigure44).Open in a separate windowFigure 4Protein network\nanalyses of proteins\npresent only in mPS1 exosomes. STRING-db protein interaction analyses\nindicate that 38 proteins (out of the 109 proteins identified only\nin mPS1 exosomes) are enriched for known protein\u2013protein interactions.\nInteractions utilized scores set to high confidence (0.7) that predicted\nlinks existing among proteins.The top network hub proteins with the largest number of interactors\ndisplayed three to seven interactions for each hub (Table 1). The interactors for each\nhub protein are listed in Supporting Information Data S1. Among these top 11 hub proteins, a large portion represented\ncollagen genes of COL8A1, COL5A3, COL6A2, COL6A3, and COL14A1, combined\nwith proteases involved in procollagen processing [PCOLCE and tolloid-like\n1 (TLL1)] and collagen fibril assembly [decorin (DCN)]. Collagen proteins\nare secreted from cells and deposited into the ECM as structural proteins\nand signaling molecules.53 COL8A1 is a\nnetwork-forming collagen involved in vessel wall integrity.53 COL5A3 is a fibril-forming collagen.53 COL6A2 is a beaded filament53 and has been found as a marker in cerebral amyloid angiopathy.54 COL6A3 is also a beaded filament53 and has roles in dystonia, alcohol dependence,\nand congenital muscular dystrophy55\u221257 COL14A1 is a fibril-associated\ncollagen.53 The TLL1 metalloendopeptidase\npotentiates a procollagen processing protease known as bone morphogenetic\nprotein.53,58 The procollagen C-endopeptidase enhancer\n1 protein (PCOLCE) promotes procollagen C-protease activity that cleaves\ntype I procollagen C-propeptide.59 DCN\nparticipates in the collagen fibril assembly and has a stimulatory\neffect in autophagy and inflammation.60,61 Serine protease\n23 (PRSS23) is a vascular protease.62Table 1Hub Proteins of Networks Present Only\nin mPS1 Exosomesagene nameprotein description#\u00a0nodesfunctions\nin the brain, AD, relatedCOL5A3collagen type\u00a0V \u03b1-3 chain6fibril-forming collagen53COL6A2collagen type\u00a0VI \u03b1-2 chain3beaded filament collagen53\u00a0\u00a0\u00a0marker present in cerebral\namyloid angiopathy54COL6A3collagen type\u00a0VI \u03b1-3 chain5beaded filament collagen53\u00a0\u00a0\u00a0related to dystonia, alcohol\ndependence, and congenital muscular dystrophy55\u221257COL8A1collagen type\u00a0VIII \u03b1-1 chain7network-forming collagen53\u00a0\u00a0\u00a0involved in vessel wall\nintegrity53COL14A1collagen type\u00a0XIV \u03b1-1 chain4fibril-associated collagen with interrupted triple helices53DCNdecorin4role in collagen fibril\nassembly60\u00a0\u00a0\u00a0stimulatory effect\nin autophagy\nand inflammation61TLL1tolloid-like\u00a01, metalloendopeptidase4metalloprotease that cleaves\nfibrillar procollagens\u00a0I, II, III,\nV, and VI58\u00a0\u00a0\u00a0role in neurogenesis58PCOLCEprocollagen endopeptidase enhancer\u00a014enhances procollagen C-proteinase activity that cleaves type\u00a0I procollagen C-propeptide59PRSS23serine protease\u00a0234vascular protease62IGFBP7insulin-like growth factor-binding protein\u00a073attenuates function of ILPs63\u00a0\u00a0\u00a0upregulated in human AD\nbrain63\u00a0\u00a0\u00a0inhibition of IGFBP7 in\nAD mice restores memory impairment and associative learning behavior63\u00a0\u00a0\u00a0biomarker for AD63APOA2apolipoprotein\nA23role in lipid metabolism64\u00a0\u00a0\u00a0associated with lifespan\nand cognitive function64Open in a separate windowaProteins identified only in the\nmutant PS1 exosomes are listed by gene name, number of interacting\nproteins terms \u201cnodes\u201d, and description of the protein\nfunction. All proteins were identified with FDR less than 1% (see Experimental Procedures).Several of the hub proteins have been shown to participate\nin AD-related\nfunctions of cognition and learning. IGFBP7, insulin-like growth factor-binding\nprotein 7, a protein that attenuates the function of insulin-like\npeptides (ILPs), is upregulated in the brains of AD patients and in\na mouse model of AD (APP/S1-21 mice containing the Thy1 promoter-driven\nAPP KM670/671NL and Thy1 promoter driven PS1 L166P transgenes);63 the expression of IGFBP7 in mice results in\nimpaired memory and significantly, the inhibition of IGFBP7 restores\nmemory deficits. These findings support a role for IGFBP7 in AD-related\nmemory loss, involving IGFBP7 attenuation of ILP function. With respect\nto APOA2, a protein involved in lipid metabolism, this protein is\nassociated with cognitive function and lifespan.64The mPS1 exosomes also contain ADAMTS1, ADAMTS7,\nand ADAMTS12 (Figure \u200bFigure44) which are not present\nin control exosomes. These three proteins are members of the ADAMTS\nprotease family of zinc metallopeptidases, which are secreted and\nact on ECM components.65,66 These components have been found\nto be associated with AD and related human diseases in genome-wide\nassociation studies (GWAS). Notably, ADAMTS1 has been found to be\nassociated with the risk for late-onset AD in GWAS evaluations.67 ADAMTS1 is also linked to degenerative intervertebral\ndisc disease.68 ADAMTS12 has been found\nto be associated with cerebral vascular aneurysm and pediatric stroke.69 ADAMTS7 is linked to atherosclerosis and arterial\ndisease.67,70,71Among\nother proteins present only in mPS1 exosomes, several are\ninvolved in ECM functions. TGFBI (transforming growth factor-\u03b2-induced\nprotein ig-h3) is an abundant protein based on its quantification\n(Figure \u200bFigure55, and Supporting Information Data S1). TGFBI is a secreted\nECM protein that binds to type I, II, and IV collagens in cell\u2013collagen\ninteractions.72\u221274 Type I and IV collagens are both present in mPS1\nand control exosomes (see Supporting Information Data S1).Open in a separate windowFigure 5Abundance of quantifiable proteins present only in mPS1\nexosomes.\nQuantifiable proteins are assessed for their abundance in the mPS1\nexosomes by bar graphs and indicated by intensity areas from mass\nspectrometry data (conducted as described in the Experimental Procedures section).The EXT2 protein, exostosin-2, is also present in only the mPS1\nexosomes (Figure \u200bFigure55,\nand Supporting Information Data S1). EXT2\nis a glycosyltransferase involved in the biosynthesis of heparin sulfate\nfound at cell surfaces and in the ECM, participating in cell\u2013matrix\ninteractions.75 Another protein of similar\nabundance is POSTN, which is a secreted ECM protein involved in cell\nadhesion and tissue regeneration;76 POSTN\nparticipates in epithelial/mesenchymal interactions which are important\nin inflammation through the activation of NF-\u03baB.Overall,\ndistinct proteins present in only the mPS1 exosomes (and\nnot in control exosomes) possess ECM functions which include collagen\nisoforms and proteases for procollagen processing, ADAMTS zinc metallopeptidases\nwhich act on ECM substrates, and abundant TGFBI, EXT2, and POSTN which\nparticipate in ECM mechanisms. These findings suggest that the mPS1\nexosomes uniquely contain protein cargo components involved in the\nECM structure, function, and regulation.Proteins Present Only in\nControl Exosomes and Absent in mPS1\nExosomesProteomic analyses of the control exosomes identified\n275 unique proteins (Figure \u200bFigure22, and listed in Supporting Information Data S1), which were absent in the mPS1 exosomes. GO analyses\nindicated significant enrichment of the control only proteins in biological\npathways of the cellular component organization and biogenesis in\ncellular processes, protein localization, and translational initiation\n(Figure \u200bFigure66). The control\nonly proteins were also enriched in the molecular binding functions\nfor protein, RNA, ribosomes, chromatin, and cell adhesion. Control\nonly proteins were also enriched in proteasome activity. KEGG analyses\nindicated significant enrichment in ribosome, proteasome, and amino\nacid biosynthesis pathways. These results suggest that proteins present\nin only the control exosomes, and absent in the mPS1 exosomes, function\nin cellular protein localization and translational mechanisms, combined\nwith binding functions of diverse molecules consisting of proteins,\nRNA, ribosomes, chromatin, as well as cell adhesion.Open in a separate windowFigure 6GO analyses of proteins\npresent only in control exosomes. GO analyses\nof proteins present only in control exosomes indicate involvement\nin (a) biological process pathways, (b) molecular function pathways,\nand (c) KEGG pathway. GO enrichment is significant with FDR at <1%.Protein network analyses of proteins present in\nonly the control\nexosomes were assessed by STRING for predictions of protein\u2013protein\ninteraction networks. STRING analyses showed that 141 out of the 275\ncontrol only proteins are associated with significant protein networks,\nas illustrated in Figure \u200bFigure77. The top network hub proteins displayed 10 to 26 protein\ninteractions\nfor each hub (Table 2). The interacting proteins for the top hub proteins are listed in Supporting Information Data S1. The hub proteins\nwith high numbers of protein interactions (Table 2) represent clustered networks of ribosomal\nproteins, protein phosphatases, translation initiation factors, RNA\nbinding proteins for RNA processing and regulation, proteasome functions,\nand others (Figure \u200bFigure77). The presence of these hubs in only control exosome networks highlights\nthe absence of these protein functions in the mPS1 exosomes.Open in a separate windowFigure 7Protein network\nanalyses of proteins present only in control exosomes.\nSTRING-db network analyses indicate that 141 proteins (out of the\n275 proteins present in only control exosomes) were enriched for known\nprotein\u2013protein interactions. Interactions utilized scores\nset to high confidence (0.7) to predict protein networks.Table 2Hub Proteins of Networks Present Only\nin Control Exosomesanetwork clustergene nameprotein description#\u00a0nodesreported\nfunctions in AD or neurodegenerationribosomesRPL460S ribosomal protein L422None\u00a0RPL760S ribosomal protein L717forms aggregates with tau\npathology119\u00a0RPL1260S ribosomal protein L1215associated with AD transcriptional\nchanges120\u00a0RPL13A6S ribosomal protein L13a11None\u00a0RPL18A60S ribosomal protein L18a26None\u00a0Rribosomal protein\nL1924decreased synthesis in p-tau neurons121\u00a0RPL27A60S ribosomal protein L27a16None\u00a0RPS240S ribosomal protein S216Nonetranslation initiationElF2S3eukaryotic translation initiation factor\u00a02 subunit\u00a0317None\u00a0ElF3Beukaryotic translation initiation factor\u00a03 subunit\u00a0B10None\u00a0EIF3Jeukaryotic translation initiation factor\u00a03 subunit\u00a0J15NonephosphatasePPP2R2Aserine/threonine-protein phosphatase 2A 55\u00a0kDa regulatory subunit\u00a0B\u00a0\u03b117dephosphorylation of p-tau92RNA binding and processingSRSF1serine/arginine-rich-splicing factor\u00a0117participates in binding\nto tau pre-mRNA117\u00a0SRSF7serine/arginine-rich-splicing factor\u00a0710role in regulation of tau\nRNA alternative splicing118\u00a0FUSRNA-binding protein FUS15mutations in FUS are linked\nto familial ALS and FTLD96\u221299,105,106\u00a0HNRNPUheterogeneous nuclear ribonucleoprotein\u00a0U15None\u00a0PA2G4/EBP1proliferation-assoc. protein 2G414None\u00a0DHX9ATP-dependent RNA helicase12None\u00a0NUDT21cleavage\nand polyadenylation\nspecificity factor subunit\u00a0512NoneproteasomePSMC126S proteasome regulatory subunit\u00a0412None\u00a0PSMC426S proteasome regulatory subunit\u00a06814dysregulated in AD and accumulates\nin Lewy bodies in PD122\u00a0PSMD1126S proteasome non-ATPase regulatory subunit\u00a01113NoneOpen in a separate windowaProteins identified\nonly in the\ncontrol PS1 exosomes are listed by gene name, number of interacting\nproteins terms \u201cnodes\u201d, and description of protein function.\nAll proteins were identified with FDR less than 1% (see Experimental Procedures).Among proteins present in only the control exosomes,\nribosome binding\nproteins comprise the largest group of hub proteins each having large\nnumbers of interacting proteins (11\u201326 interactions for each\nhub). Such hub proteins consist of the 60S ribosomal proteins RPL4,77 RPL7,78,79 RPL12,80 RPL13A81 RPL18A82 RPL19,83 and RPL27A,84 combined with the 40S ribosomal protein RPS2.85 This ribosomal cluster of protein hubs (shown\nin Figure \u200bFigure77) includes\nthe translation initiation factors EIF2S3, EIF3B, and EIF3J86\u221288 as hub proteins (Table 2). This cluster of hubs for ribosomal and initiation factors\nparticipates in protein translation. The presence of these ribosomal\nproteins in only control exosomes suggests that the mPS1 exosomes\nmay be compromised in protein translation functions.Of notable\ninterest is that only the control exosomes contain the\nhub protein PPP2R2A, serine/threonine protein phosphatase 2A regulatory\nsubunit B \u03b1, a subunit of PP2A (Table 2), which is the major tau phosphatase.89\u221291 PP2A is a heterotrimeric complex composed of catalytic, regulatory,\nand scaffolding subunits.89,90 The PPP2R2 regulatory\nsubunit of PP2A targets p-Tau as a substrate for PP2A.92 Along with PPP2R2A, the control exosomes (not\nmPS1 exosomes) contain the three phosphatase catalytic subunits of\nPP1\u03b1, PP1\u03b2, and PP2B (calcineurin) (Supporting Information Data S1). The exclusion of these phosphatase\nsubunits from the mPS1 exosomes, compared to their presence in the\ncontrol exosomes, suggests that the absence of phosphatase components\nmay promote p-Tau and its neuropathology, as previously observed with\nmPS1 exosome injections into the mouse brain.36The control exosomes also uniquely contain hub proteins of\nnetworks\nfor RNA binding and processing proteins (Table 2), which are absent in the mPS1 exosomes.\nThese RNA-modulating hub proteins consist of SRSF193 and SRSF794 pre-messenger RNA\n(mRNA) splicing factors, the HNRNPL95 component\nof ribonucleoprotein complexes of heterogeneous nuclear RNA in the\nnucleus, the RNA-binding proteins FUS96\u2212101 and PA2G (EBP1),102 the ATP-dependent\nRNA helicase DHX9,103 and the NUDT21104 factor for 3\u2032-RNA cleavage and polyadenylation.Notably, the FUS RNA binding protein is significantly elevated\nin human brains of AD and frontotemporal lobular degeneration (FTLD)\nsubjects.96 Mutant forms of FUS are linked\nto amyotrophic lateral sclerosis (ALS) and FTLD.97\u221299,105,106 The RNA-binding ability\nof mutant FUS is necessary for neurodegeneration.97 Mutant FUS results in the defective RNA metabolism99,100 and suppresses axonal protein synthesis.99 FUS is normally present in nuclei96 but\nmutant FUS accumulates in the cytoplasm of ALS and FTLD human brains97,99\u2212101 and results in an increase of toxicity involving\nsynaptic dysfunction and behavioral deficits in motor and cognitive\nfunctions.99\u2212101The control exosomes contain components\nof the proteasome complex\nconsisting of a cluster of hub proteins consisting of PSMC1, PSMC4,\nand PMSD11 regulatory subunits of the 26S proteasome107\u2212109 (Table 2). This cluster\ninteracts with COPS2, COPS3, and COPS7B110\u2212112 (Figure \u200bFigure77), components\nof the COP9 signalosome complex,113,114 which is\ninvolved in the ubiquitin conjugation pathway through the regulation\nof E3 ligase complexes for the regulation of ubiquitin-targeted proteasome\ndegradation of proteins.113,115,116The absence of these protein network hubs in the PS1 exosomes,\ncompared to their presence in only the control exosomes (Table 2), demonstrate that\nmPS1 exosomes display alterations in ribosomal proteins, serine/threonine-protein\nphosphatase, translation initiation factors, RNA binding proteins,\nand proteasome functions. Furthermore, several of the proteins present\nonly in control exosomes are associated with tau with respect to binding\nto tau pre-mRNA by SRSF1,117 the regulation\nof tau RNA alternative splicing by SRSF7,118 RPL7 formation of aggregates with tau pathology,119 association of RPL12 with AD transcriptional changes,120 decreased synthesis of RPL19 in neurons containing\np-Tau,121 dysregulation of PSMC4 in AD,122 and de-phosphorylation of tau by PPP2R2A.92Proteins Shared by mPS1 and Control Exosomes:\nUpregulation and\nDownregulation by mPS1Proteomic data showed that the shared\nproteins present in both the mPS1 and control exosomes consisted of\n733 proteins (Figure \u200bFigure22, and listed in Supporting Information Data S1). GO analyses indicate that mPS1 and control exosomes share proteins\nfunctioning in biological processes of vesicle-mediated transport\nand localization, exocytosis and secretion, combined with biogenesis\nand organization of cellular components (Figure \u200bFigure88). Molecular functions of the shared proteins\nconsist of binding proteins, anions, carbohydrates, protein complexes,\nsignaling, GTP, and small molecules (Figure \u200bFigure88). KEGG pathway analyses indicate protein\nsystems for endocytosis, ECM\u2013receptor interaction, actin regulation,\nproteasome, and signaling systems.Open in a separate windowFigure 8GO analyses of proteins shared by mPS1\nand control exosomes. GO\nanalyses of proteins identified in mPS1 and control exosomes indicate\ninvolvement in (a) biological process pathways, (b) molecular function\npathways, and (c) KEGG pathway. GO enrichment is significant with\nFDR <1%.The quantitated shared proteins\nwere assessed for the upregulation\nor downregulation in mPS1 compared to control exosomes by heat maps\n(Figure \u200bFigure99). We also\nassessed proteins with log2(mPS1/control) ratios of \u22652,\nor ratios \u2264\u22122, in another heat map illustration (Figure S3) that shows the high portion of proteins\nthat were increased by 4- to 140-fold, or decreased by 75 to 99% in\nmPS1 exosomes compared to controls. Clearly, the substantial upregulation\nand downregulation of proteins occurred in mPS1 exosomes compared\nto control.Open in a separate windowFigure 9Upregulation and downregulation of shared proteins in mPS1 and\ncontrol exosomes. Heat map illustration was conducted for the quantifiable\nproteins assessed by log2(mPS1/control) values (significance\nof p < 0.05). Quantified proteins shared between\nmPS1 and control exosomes were evaluated by comparing log2(mPS1/control), shown in heat maps.Upregulated ProteinsThe most highly upregulated proteins\nin the mPS1 exosomes compared to controls consisted of HSP90B1, AEBP1,\nand ALB. HSP90B1 (GRP94), heat shock protein 90 \u03b2 family member\n1, is a molecular chaperone that functions in the processing and transport\nof secreted proteins;123,124 brain levels of this chaperone\nare increased in a mouse model of AD and may participate in A\u03b2\nclearance.125 AEBP1, AE binding protein,\nis a carboxypeptidase-like protein involved in collagen metabolism.126 ALB, albumin, functions as a carrier protein\nfor small molecules and for stabilizing extracellular fluid, such\nas blood.127 STRING analyses of upregulated\nproteins in mPS1 compared to control exosomes, revealed APP which\nyields \u03b2-amyloid, as a hub protein interacting with HSP90B1,\nALB, TF (transferrin), A2M (\u03b12-macroglobulin protease inhibitor),\nTGFB1 (transforming growth factor \u03b2 1), as well as glyceraldehyde-3-phosphate\ndehydrogenase (GAPDH) (Figure \u200bFigure1010a).Open in a separate windowFigure 10Network analyses of upregulated and downregulated proteins\nin mPS1\ncompared to control exosomes. (a) Upregulated proteins in mPS1. STRING-db\nanalyses indicate that 17 proteins (out of the 46 upregulated shared\nproteins) were enriched with respect to known protein\u2013protein\ninteractions. (b) Downregulated proteins in mPS1. STRING-db analyses\nshow that 17 proteins (out of the 39 downregulated shared proteins)\nwere enriched with respect to known protein\u2013protein interactions.Specific functions of the upregulated proteins\nand their relationships\nto tau and APP/\u03b2-amyloid of AD are provided in Table S2.89,128\u2212243 Biological functions of upregulated proteins consisting of trafficking\nand cell morphology (AEBP1, COL11A1, FAT4, GDI1, GPC6, GSN, SPTAN1,\nTHSD7A, TLN1, TUBB4A, VIM, and WDR1), biochemical and binding (ALB,\nDECR1, ENO1, GAPDH, GPC6, MDH1, PHGDH, SHBG, SRI, TF, and UGP2), chaperone\nprotein folding (CCT4, HSP90B1, PDIA4, and STIP1), proteases and protease\ninhibitors (A2M, C1R, PRCP, and THSD7A), synaptic function (CRMP1,\nNTPX2, and PLXNB1), development and growth (CCDC80, IGSF8, and TGFBI),\ntranscriptional and nuclear regulation (DIP2B, SUPT16H, and TNPO1),\ncell signaling (ARL3), RNA features (HNRNPK), protein translation\n(EIF3B), and immune response (LGALS3BP) are listed in order of the\nlargest to lowest number of proteins in these categories. Among these\nupregulated functions, several proteins are associated with p-Tau\nand APP/\u03b2-amyloid of AD. PPP2R1A functions as a PP2A tau phosphatase128,129 and, thus, the upregulation of PPP2R1A may increase p-Tau. The GAPDH\nprotein has been shown to bind to tau.130,131 Several proteins\nhave been suggested as possible biomarkers of p-Tau or aggregated\ntau in NFTs which consist of A2M,132,133 AEBP1,134 MDH1,135 and PLXNB.136 Furthermore, APP and associated proteins with\nrelationships with APP and \u03b2-amyloid were upregulated, consisting\nof A2M,132,133 GAPDH,130,131 GSN,137,138 LGALS3BP,139 PLXNB1,136 and VIM.140Downregulated\nProteinsThe most downregulated proteins\nin mPS1 compared to control exosomes consisted of NUMA1 (nuclear mitotic\napparatus protein 1), COL4A2 (collagen type IV \u03b1 2 chain), PYGB\n(glycogen phosphorylase B), SPON1 (spondin 1), CTNNB1 (catenin \u03b2\n1), AHSG (\u03b1 2-HS glycoprotein), and KIF5B (kinesin family member\n5B) (see heat map in Figure \u200bFigure99). STRING network analyses of the downregulated proteins illustrated\nknown interactions of COL1A2 and COL4A2 with PLOD1 (Figure \u200bFigure1010b). Among the downregulated\nproteins, several participate in mechanisms of AD; SPON1 interacts\nwith APOE and APP;244,245 CTNNB1 interacts with presenilins246 and participates in apoptosis;247 and KIF5B kinesin participates in the axonal\ntransport of APP.248Specific functions\nof the downregulated proteins are provided in Table S3.166,249\u2212340 Biological functions of downregulated proteins consist of trafficking\nand cell morphology (AHSG, AP2A2, COL1A2, COL4A2, DCN, FAT1, KIF5B,\nLLGL1, NID1, NUMA1, SEPT2, and TPM4) biochemical and binding activities\n(ALDOA, ANXA5, ASS1, ATP1A2, CKB, CLIC1, LOXL3, PLOD1, PSAP, PYGB,\nSLC9A3R1, and SPOCK1), synaptic regulation (CTTNNA2 and SPON1), chaperone\nprotein folding (HSP90B1 and HSPD1), development and growth (CTTNNA2,\nSPON1, and YES1), transcriptional nuclear regulation (PARP1, SSBP1,\nand XRCC5), and cell signaling (CTTNNB1, GPC1, and MFGE8).Exosome\nPhosphatases and Kinases Associated with Tau PhosphorylationProteomic data from mPS1 and control exosomes were evaluated for\nphosphatase and kinase components known to participate in de-phosphorylation\nand phosphorylation of tau, respectively.89,341,342 Several protein phosphatase\ncomponents were absent in the mPS1 exosomes and present in only the\ncontrol exosomes; these components consist of the phosphatase catalytic\nsubunits PPP1CA, PPP1CB, and PPP3CA [serine/threonine protein phosphatase\nPP1-\u03b1 catalytic subunit, serine/threonine protein phosphatase\nPP1-\u03b2 catalytic subunit, and phosphatase PP2B catalytic subunit\n(calcineurin), respectively]89,341\u2212343 (Table 3), combined\nwith the regulatory phosphatase subunit of PPP2R2A (serine/threonine\nprotein phosphatase 2A 55 kDa regulatory subunit B \u03b1 isoform).89,342\u2212345 In addition, PPP2R1A (serine/threonine-protein phosphatase 2A 65\nkDa regulatory subunit A \u03b1) is upregulated in mPS1 exosomes\ncompared to the control (Table 3). Roles for these phosphatase components for de-phosphorylation\nof tau have been reported.89,342\u2212345 The absence of numerous protein phosphatase components may be consistent\nwith facilitation of p-Tau formation by mPS1 exosomes.36Table 3Tau Phosphatases\nand Kinases in mPS1\nand Control Exosomes\u00a0\u00a0mPS1 or\ncontrol exosomes\u00a0\u00a0gene namedescriptiononly mPS1only controlshared, log2 of mPS1/controlrole in tau\nphosphorylationreferencesPhosphatasesPPP1CAserine/threonine protein phosphatase PP1-\u03b1 catalytic\nsubunit\u00a0+\u00a0PP1\u00a0\u03b1 catalytic subunit contributes\nto de-phosphorylation of tau(89,342,343)PPP1CBserine/threonine protein phosphatase PP1-\u03b2 catalytic\nsubunit\u00a0+\u00a0PP1\u00a0\u03b2 catalytic subunit contributes\nto de-phosphorylation of tau(89,342,343)PPP3CA (calcineurin)serine/threonine-protein phosphatase PP2B catalytic subunit\u00a0+\u00a0calcineurin de-phosphorylates pS262 and pS396 on tau, which are\nboth found in parahelical filaments(89,342,343)PPP2R2Aserine/threonine protein phosphatase 2A 55\u00a0kDa regulatory subunit\u00a0B\u00a0\u03b1\u00a0+\u00a0B55\u03b1 regulatory subunit\nof PP2A recognizes p-tau substrate\nfor PP2A de-phosphorylation(89,92,342,345)PPP2R1Aserine/threonine-protein phosphatase 2A 65\u00a0kDa regulatory subunit\u00a0A\u00a0\u03b1\u00a0\u00a0+, 1.670this subunit of PP2A is\nrequired for tau (and other substrate) de-phosphorylation(89,92,342,345)KinasesPRKDCDNA-dependent protein kinase catalytic subunit\u00a0+\u00a0DNA-PK catalytic subunit phosphorylates tau in vitro(347)CSNK2Bcasein kinase\u00a0II subunit\u00a0\u03b2\u00a0+\u00a0CK2 phosphorylates\nSET to\ninduce PP2A inhibition resulting in hyper-phosphorylation of tau; CK2 is overactive in AD(349)CDK1cyclin-dependent kinase\u00a01\u00a0+\u00a0CDK has high affinity for\nphosphorylation of SP motifs of tau; CDK1 also inhibits PP2A via SET(346, 348)FYNtyrosine protein kinase\nFyn\u00a0\u00a0+, 0.131Fyn phosphorylates tau and\nalso inhibits the main tau phosphatase PP2A by phosphorylation(341,350,351)MAPK3 (ERK1)mitogen-activated protein kinase\u00a03\u00a0\u00a0+, \u22120.156Erk1 is involved in abnormal\ntau phosphorylation at sites identified in AD brains(341,352)MAPK1 (ERK2)mitogen-activated protein kinase\u00a01\u00a0\u00a0+, \u22120.768Erk2 can phosphorylate tau\nat 15\u00a0sites in vitro and its increased activity can contribute to tauopathy(341,352,353)SRCproto-oncogene tyrosine-protein kinase Src\u00a0\u00a0+, naSrc phosphorylates\ntau present\nin NFTs(350)Open in a separate windowSeveral protein kinases with roles\nin the phosphorylation of tau\nwere identified in only control exosomes, consisting of PRKDC, CSKN2,\nand CDK1 (DNA-dependent protein kinase catalytic subunit, casein kinase\nII subunit \u03b2, and cyclin-dependent kinase 1, respectively)341,346\u2212349 (Table 3). Among\nthe proteins present in both mPS1 and control exosomes, FYN was moderately\nupregulated in mPS1 compared to control exosomes (Table 3). FYN has dual functions for\nthe direct phosphorylation of tau and also phosphorylation of PP2A,\nwhich inhibits the PP2A-mediated de-phosphorylation of p-Tau.341,350,351 The MAPK3 and MAPK1 (Erk1 and\nErk2 protein kinases involved in tau phosphorylation)341,352,353 are moderately downregulated\nin mPS1 compared to control exosomes (Table 3). The SRC kinase (proto-oncogene tyrosine-protein\nkinase Src) was present in both mPS1 and control exosomes; SRC participates\nin the phosphorylation of tau.350 These\nfindings suggest that the balance of several kinases is modified in\nthe mPS1 exosomes compared to the control exosomes. DiscussionThe exosome cargo produced by patient-derived iPSC neurons with\nthe presenilin mutation A246E (mPS1) was investigated by proteomics\nand protein network analyses and compared to exosomes generated by\nnormal human iPSC neurons derived from a nondemented control patient.\nThese studies were designed to gain insights into the protein cargo\nof mPS1 exosomes which induce the propagation of tau pathology in\nthe mouse brain.34 Significantly, findings\nshowed that mPS1 alters the profile of exosome cargo proteins to result\nin (1) proteins present only in mPS1 exosomes and not in controls,\n(2) the absence of proteins in the mPS1 exosomes which were present\nonly in controls, and (3) shared proteins which were upregulated or\ndownregulated in the mPS1 exosomes compared to controls (Figure \u200bFigure1111). These data show\nthat mPS1 dysregulates the proteome cargo of exosomes which result\nin the acquisition of proteins involved in ECM functions, deletion\nof proteins involved in RNA, and protein translation systems along\nwith protease and related functions, combined with the upregulation\nand downregulation of shared proteins (Figure \u200bFigure1111). Notably, mPS1 exosomes display dysregulation\nof protein phosphatases and kinases known to be involved in regulating\nthe phosphorylation status of tau. The altered profile of exosome\ncargo proteins by mPS1 may be associated with the ability of the mPS1\nexosomes to propagate p-Tau neuropathology in the mouse brain.34Open in a separate windowFigure 11Mutant PS1 dysregulates exosome cargo through the acquisition\nand\nloss of proteins, combined with the upregulation and downregulation\nof proteins shared with control exosomes. The A246E mPS1 dysregulates\nthe proteome cargo of exosomes generated by patient-derived iPSC neurons.\nProteomic data demonstrated that mPS1 exosomes contain (1) proteins\npresent only in mPS1 exosomes (pink circles) and not in controls,\nwhich included ECM collagen, proteases, and related components, (2)\nloss of proteins in the mPS1 exosomes (gray circles) which were present\nonly in controls (gray circles), consisting of phosphatases, ribosomal,\nand protein translation proteins, RNA binding and processing proteins,\nproteasomes, and related, and (3) shared proteins (blue circles) for\nexocytotic, secretory, and related functions, many of which were upregulated\nor downregulated in the mPS1 exosomes compared to controls. The mPS1\nexosomes induce tau pathology in the mouse brain after the in vivo injection,34 but the\ncontrol exosomes have no effect.Tau undergoes phosphorylation and de-phosphorylation by protein\nkinases and phosphatases, respectively, to regulate the amount of\np-Tau in AD and healthy brains. Hyperphosphorylation of tau occurs\nin AD and results in disrupted microtubule stability and deficits\nin axonal and synaptic functions.354,355 Because the\nmPS1 exosomes result in the propagation of p-Tau in the mouse brain,34 evaluation of mPS1 exosomes for regulators of\nphosphorylation was conducted. The most notable finding was that only\nthe mPS1 exosomes lacked many phosphatase components known to participate\nin the de-phosphorylation of p-Tau that were present in control exosomes.\nThe PPP2R2A regulatory subunit of protein phosphatase 2A was exclusively\nfound in the control exosomes and not in mPS1 exosomes. PPP2R2A is\na regulatory subunit that specifically targets p-Tau as the substrate\nfor de-phosphorylation. The regulatory subunit with the catalytic\nand scaffolding subunits comprise the heterotrimeric phosphatase complex.\nThere are numerous regulatory subunits for substrate recognition;\ntherefore, it is significant that the tau-targeting subunit was present\nin only the control exosomes. In addition, the phosphatase catalytic\nsubunits PPP1CA, PPP1CB, and PPP3CA were also exclusively found in\nthe control exosomes and not in mPS1. The distinct loss of PPP2R2A\nby mPS1 exosomes for targeting tau as the substrate, combined with\nthe loss of several catalytic subunits of protein phosphatases, may\nfacilitate p-Tau involved in AD pathology.With respect to protein\nkinases known to participate in phosphorylation\nof tau,89 the PRKDC, CSKN2, and CDK1 kinases\nwere identified in only the control exosomes and not the mPS1 exosomes.\nThe tyrosine kinase FYN was moderately upregulated in mPS1 exosomes\ncompared to controls; FYN has dual functions which include direct\nphosphorylation of tau and inhibiting PP2A the de-phosphorylation\nof p-Tau.341,350,351 The MAPK3 and MAPK1 kinases were moderately downregulated in the\nmPS1 exosomes compared to controls. These findings suggest the dysregulation\nof the balance of several tau protein kinases in the mPS1 compared\nto control exosomes.The mPS1 exosomes acquire distinct proteins\nwhich were absent in\nthe control exosomes. Unique proteins present in only the mPS1 exosomes\npossess ECM functions consisting of collagen isoforms (collagen types\nV, VI, VIII, and XIV) and proteases (DCN protease and TLL1 metalloendopeptidase)\nfor procollagen processing, ADAMTS zinc metallopeptidases which act\non ECM substrates, and abundant TGFBI, EXT2, and POSTN which participate\nin ECM mechanisms. These findings suggest that the mPS1 exosomes uniquely\ncontain protein cargo components involved in the ECM structure and\nfunction. Such ECM functions may participate in mPS1 exosome-mediated\npropagation of tau pathology in the brain.Losses of proteins\nin mPS1 exosomes were observed because such\nproteins were present only in control exosomes. The control exosomes\ncontain clusters of protein networks which function in ribosomal and\ninitiation factors in protein translation systems, RNA binding and\nRNA processing systems, and proteasome components for protein degradation.\nThe absence of these functional systems in the mPS1 exosomes suggests\ntheir lack of biosynthetic capacity for RNA processing and protein\ntranslation. Furthermore, the lack of proteasome components in the\nmPS1 exosomes could possibly contribute to the accumulation of misfolded\nproteins in tau pathology via the proteasome regulation\nof the misfolded protein response. Clearly, the mPS1 exosomes lack\nprotein components integral to RNA-based protein translation combined\nwith protein homeostasis. These findings demonstrate that mPS1 redirected\nthe routing of approximately one-fourth of the normal exosomal proteins\nin a manner such that it prevents packaging into the mPS1 exosomes.With respect to proteins that were absent in mPS1 exosomes compared\nto control exosomes, or absent in control exosomes compared to mPS1\nexosomes, it is realized that such data are dependent on the mass\nspectrometry detection limits and dynamic range for data acquisition.\nTherefore, the \u201cabsence\u201d of proteins is based on the\nmass spectrometry method. It is possible that proteins may be present\nat levels below the quantitative detection limit of the mass spectrometry\nmethod.The proteomic data also show that a large portion of\nmPS1 and control\nexosome cargoes are common to both exosome types. These shared proteins\nrepresent fundamental exosome activities consisting of vesicle-mediated\ntransport, exocytosis, and secretion processes, which involve molecular\nprotein binding functions and enzymes. Among the shared proteins,\nmPS1 exosomes displayed a significant upregulation and downregulation\nof protein components (Figure \u200bFigure1010). It is of interest that the APP was upregulated in\nmPS1 exosomes. APP serves as substrate of PS1, which is the aspartyl\nprotease subunit of the \u03b3-secretase complex which catalyzes\nprocessing of APP to generate A\u03b2 peptides.222 Thus, mPS1 elevates its APP substrate in exosomes. It will\nbe of interest in future studies to examine whether mPS1 exosomes\ninduce A\u03b2 neuropathology combined with the propagation of tau\npathology in the brain.Along with APP, the mPS1 exosomes (compared\nto control exosomes)\nalso display the strong upregulation of HSP90B1, AEBP1, and ALB proteins.\nBrain levels of the HSP90B1 chaperone are increased in a mouse model\nof AD and may participate in A\u03b2 clearance.243 The strong downregulation of proteins also occurs in the\nmPS1 exosomes (compared to controls) which consist of NUMA1 (nuclear\nmitotic apparatus protein 1), COL4A2 (collagen type IV \u03b1 2 chain),\nPYGB (glycogen phosphorylase B), SPON1 (spondin 1), CTNNB1 (catenin\n\u03b2 1), AHSG (\u03b1 2-HS glycoprotein), and KIF5B (kinesin family\nmember 5B). Among these downregulated proteins, several participate\nin AD, consisting of SPON1 interaction with APOE and APP,244,245 CTNNB1 interacts with presenilins246 and\nparticipates in apoptosis,247 and KIF5B\nparticipates in the axonal transport of APP.264,265The A246E mPS1 is one of the numerous mutations reported for PSEN1 in AD.32,33,356,357 The results of this study demonstrating\nthe mPS1 dysregulation of exosome proteins lead to the question of\nwhether other PSEN1 mutations of AD might dysregulate\nexosome cargo molecules. PSEN1 mutations are the\nmost common cause of early onset FAD. Mutant presenilins comprise\nthe majority of the 150 presenilin mutations, which include about\na dozen mutations of the homologous PS2 (PSEN2).\nIt will be of interest to gain further insights into possible relationships\nof numerous presenilin mutations and exosome cargoes for the propagation\nof tau and related pathology in AD. Experimental ProceduresExperimental\nDesignThe workflow for proteomic analyses\nof exosomes isolated from human iPSC neurons expressing the A246E\nmPS1 or from control human iPSC neurons is shown in Figure \u200bFigure11. Human iPSC neurons were derived\nfrom the respective patient or healthy control tissue biopsies.34,35 Each mPS1 and control group consisted of three biological replicates\nof neuronal cultures (n = 3) which allowed statistical\nevaluations (by Student\u2019s t-test, significance\nof p < 0.05). Exosomes were isolated from the\nmedia of neuronal cell cultures of the mPS1 and control groups using ExoQuick-TC (System Biosciences,\nPalo Alto, CA) (Figure \u200bFigure11a). Exosome proteins were digested with trypsin/LysC and subjected\nto nano-LC\u2013MS/MS tandem mass spectrometry analysis on a Dionex\nUltiMate 3000 nano LC and an Orbitrap Q-Exactive mass spectrometer\n(Thermo Fisher Scientific, Carlsbad, CA) (Figure \u200bFigure11b). Samples were injected twice (in randomized\norder) into the nano-LC\u2013MS/MS system for global proteomic analyses.\nBioinformatic analyses of MS1 and MS2 data\nfor peptide and protein identification and label-free quantitation\n(LFQ) used PEAKS Studio 8.5 (Bioinformatics Solutions Inc., Waterloo\nON, Canada). PEAKS searched the human protein sequence database (UniprotKB/SwissProt\n2018_2 with 71,783 entries) for peptide spectrum matches and protein\nidentification with LFQ (Figure \u200bFigure11c).The criteria for the inclusion of an identified\nor quantifiable protein in a biological replicate sample required\nthat the protein was identified in at least one of the two technical\nreplicates per biological sample. The criteria for the inclusion of\nan identified or quantifiable protein in either the mPS1 or control\ngroups required that the protein was identified in at least two out\nof the three biological replicates per group. Quantifiable data of\nthe mPS1 and control groups were compared by Student\u2019s t-test.Human iPSC Neuronal Cultures: mPS1 and ControlHuman\niPSC neuronal cells were prepared from a control patient biopsy (non-demented)\nand from a patient possessing the A246E mutation in the PSEN1 gene, using our published protocol.19,34,35 The control iPSC neurons were derived from a biopsy\nof a non-demented male subject aged 86 years36 and the mPS1 neurons were derived from a biopsy of a male subject,\nage d56 years, harboring the A246E mPS1 with AD onset at about 50\nyears;37 all subject data have been deidentified.\nIt is known that reprograming of the fibroblast from biopsies into\npluripotent stem cells and differentiation into neurons erases the\naging phenotype and generates \u201cage-equivalent\u201d iPSC\nneurons.38,39 Therefore, the mPS1 and control iPSC neurons\nprepared for this study are \u201cage-equivalent.\u201dFor the culture of iPSC neurons, neural stem cells plated at a density\nof 1.5 \u00d7 105 cells/cm2 on Matrigel-coated\n(70 \u03bcg/mL, BD Bioscience) dishes and were grown to \u223c80%\nconfluence. Neuronal differentiation was initiated by the removal\nof basic fibroblast growth factor (bFGF, Biopioneer) from the media\n(DMEM\u2013F-12, 1% N-2, 2% B-27, Pen\u2013Strep, 20 ng/mL bFGF).\nDifferentiation into neurons was indicated by neuronal markers of\nsynaptic neurotransmission (shown in Table S1). Conditioned culture media was collected from cells at 3\u20134\nday intervals. Cell viability in cultures was typically greater than\n90\u201395% viable.Exosome Isolation and NTAThe isolation\nof exosomes\nfrom cell culture medium used ExoQuick-TC (System Biosciences, Inc.)\naccording to the provided protocol. The medium was incubated with\nExoQuick-TC with rotation overnight at 4 \u00b0C, then centrifuged\nat 1500g for 30 min at 4 \u00b0C. The pellet was\nplaced in phosphate-buffered saline with EDTA-free protease and a\nphosphatase inhibitor cocktail and stored at \u221270 \u00b0C. Protein\nlevels of exosome preparations were measured using the bicinchoninic\nacid protein assay kit (Pierce Biotechnology). Exosomes (10 \u03bcg)\nwere evaluated for the size distribution and concentration by NTA\nwith a NanoSight LM10 instrument.Trypsin/LysC Digestion\nand LC\u2013MS/MSProteins\nof exosome samples (100 \u03bcg each) were precipitated in 90% ice-cold\nmethanol on ice for 15 min, and then centrifuged for 30 min at 14,000g (4 \u00b0C). The resulting protein pellet was dried in\na vacuum centrifuge, resuspended in urea buffer (8 M urea, 50 mM Tris\u2013HCl,\npH 8), and sonicated. For reduction, dithiothreitol (DTT, 100\nmM stock) was added to obtain 5 mM DTT and samples were incubated\nat 55 \u00b0C for 45 min, and cooled at room temperature (RT) for\n5 min. For cysteine alkylation, iodoacetamide (IAA, 200 mM stock in\n50 mM Tris\u2013HCl, pH 8) was added to obtain 15 mM IAA, incubated\nin the dark at RT for 30 min, and quenched by the addition of DTT\nto 5 \u03bcM. To lower the urea to less than 1 M, samples were diluted\nwith 50 mM Tris\u2013HCl, pH 8. Trypsin/LysC (Promega) was added\nto each sample at a ratio of 50:1 protein/trypsin (w/w) and incubated\nat RT for 18\u201324 h, and quenched by the addition of trifluoroacetic\nacid (TFA) to less than 0.5%. Samples were stored at \u221270 \u00b0C.Tryptic peptides were purified and desalted on C18 stage tip SPE\nusing Empore C18 wafers (3M), as reported in the field.40 The stage tip was washed with acetonitrile (ACN)\nand equilibrated with 0.1% TFA. Samples were loaded, washed with 0.1%\nTFA, eluted with 50% ACN/0.1% TFA, dried in a vacuum centrifuge, resuspended\nin water and sonicated, and peptide levels were determined by the\ntotal peptide assay kit (Thermo Fisher). Samples were dried in a SpeedVac\nand stored at \u221270 \u00b0C.LC\u2013MS/MS Tandem\nMass SpectrometryLC\u2013MS/MS\nwas performed on a Dionex UltiMate 3000 nano-LC and an Orbitrap Q-Exactive\nmass spectrometer (Thermo Fisher Scientific). Peptide samples were\nre-suspended in 2% ACN, 0.1% TFA to 0.6 \u03bcg/\u03bcL peptide\nconcentration. Each sample was injected twice (2.5 \u03bcg per injection)\nonto the nanoLC column (75 \u03bcm inner diameter, 360 \u03bcm outer\ndiameter, and 25 cm length) packed with the BEH C18 (1.7 \u03bcm\ndiameter) solid-phase material and heated to 65 \u00b0C with a column\nheater.41 LC used a flow rate of 0.3 \u03bcL/min\nusing a 120 min linear gradient of 5 to 25% ACN/0.1% formic acid,\nfollowed by a 5 min linear gradient of 25 to 95% ACN/0.1% formic acid.\nMS and MS/MS spectra were obtained in positive ion data-dependent\nmode. MS1 was acquired in the profile mode with a 3 \u00d7 106 automatic\ngain control target, 100 ms maximum injection time, a 310\u20131250 m/z window, and 70,000 resolution (at m/z 200). MS2 was acquired in the centroid\nmode with 1 \u00d7 105 AGC target, 50 ms maximum time for\ninjection, 2 \u00d7 103 minimum precursor intensity, 35\ns per 10 ppm dynamic exclusion, 17,500 resolution (at m/z 200), a first mass of m/z 150, and HCD collision energy of 28. A LC\u2013MS/MS\nreport is provided\nin Supporting Information S1. LC\u2013MS/MS\nfiles are available at www.proteomexchange.org with the\ndataset identifier PXD019424, or at www.massive.ucsd.edu with dataset identifier MSV000085478 or ID = 229a900a721d40ada5e6fc806241ba2b.Protein IdentificationMS and MS/MS data files were\nqueried by PEAKS (v. 8.5) bioinformatic software42 for peptide identification and label-free quantitation\n(LFQ) analyses (next section). The data files were searched against\nthe UniprotKB/SwissProt human protein sequence database (release 2018_02)\nhaving 71,783 entries. Peptide identifications included searching\nof a decoy-fusion spectrum library of human proteins, generated by\nPEAKS v. 8.5 from the human protein database of UniprotKB/SwissProt.\nPEAKS parameters for protein and peptide identification consisted\nof trypsin (cleavages at Arg and Lys, and two missed or nonspecific\ncleavages allowed), carbomidomethylation on Cys, oxidation of Met,\npGlu, and N-terminal acetylation, and phosphorylation were included\nin the search parameters. Precursor mass error tolerance was 25 ppm,\nmass tolerance for the fragment ion was 0.01 Da, and threshold peptide\nscores of \u2212log10P \u2265 32.\nThe threshold score was <1% FDR (false discovery rate), equivalent\nto \u2212log10P > 20. The report\nof\nthe PEAKS analyses is in Supporting Information S2. The threshold score for protein identification was \u2212log10P \u2265 55, equivalent to 1% FDR. The Supporting Information provides assigned peptide\nsequences and protein identifications (Supporting Information Data S1). Supporting Information Data S1 (master table of data) summarizes the identified and\nquantified proteins in mPS1 and control exosomes. Single peptides\npassing the criteria for protein identification are provided with\nMS/MS spectra in Supporting Information S3.Protein QuantificationLabel-free quantitation (LFQ)\nof proteins was assessed by PEAKS (v. 8.5) (Supporting Information Data S1). Extracted ion chromatographs of MS2 peaks\nwere converted to the area under the curve, and the peak areas of\nMS2 of each peptide spectrum were summed to determine protein relative\nabundances. Spectra were filtered for quality parameters prior to\nLFQ, consisting of peptide quality of >0.3, abundance of 1 \u00d7\n104, and present in 25% or more of technical replicates.\nReplicates were compared for retention time and isotope pattern for\ninclusion in quantitation analysis. The normalization of technical\nvariations used the LOESS-G application.43Analytical replicate reliability was restricted by \u2212log10P and quality assessed as 1/log(\u03c3),\nwhere \u03c3 is the variance between technical runs; \u2212log10P > 20 represents 1% FDR. The imputation\nof the quantitative area with a value of 0 was achieved with a value\nrepresenting the lower 5% of values within standard deviation (SD)\nof |1|. Multiple isoforms within a protein group were inspected to\nassure that the isoforms were assigned the same quantitation data.\nBiological replicate values for protein quantifications of mPS1 and\ncontrol groups were averaged and SD computed, using Student\u2019s t-test to assess the significance (p <\n0.05) of mPS1 compared to the control for significantly regulated\nproteins.The PEAKS bioinformatic data analyses are provided\nin the master\ntable of data (Supporting Information Data S1), which identifies the proteins present only in mPS1 exosomes, only\nin control exosomes, and proteins shared by the two groups. The Supporting Information Data S1 master table contains\nthe lists of identified proteins, quantifiable proteins with their\nsummed peak area values, and details of protein properties including\n% coverage and number of peptides per protein group.GO and STRING-db\nNetwork AnalysesIdentified and quantified\nproteins in experimental groups were evaluated for GO systems and\nprotein\u2013protein interactions using STRING-db (https://string-db.org/).GO analyses indicated the significant enrichment of exosome protein\ngroups to GO terms with FDR <1% using Benjamini\u2013Hochberg.44,45 FDR was assessed by hypergeometric testing, a probability distribution\nthat assesses the significance of having hits within experimental\ngene sets compared to total genes in the GO pathway.Protein\nnetworks were assessed by STRING (version 11.0)46 (www.string-db.org). STRING utilizes a database of protein interactions data sets (DIP,\nBioGRID, HPRD, IntAct, MINT, and PDB). Significant protein\u2013protein\nnetwork enrichment was assessed by a probability p-value to indicate whether an experimental group of proteins have\nmore interactions compared to interactions expected from a randomly\nselected protein group of the same size at a high confidence score\nof 0.7.47Heat Maps of Significantly\nUpregulated and Downregulated Proteins\nin mPS1 and Control ExosomesQuantifiable proteins shared\nby the mPS1 and control groups were analyzed by log2(mPS1/control)\nratios and shown in heat maps for significant differences between\nmPS1 and control (p < 0.05). Power analysis of\nquantitative data were conducted using the pwr.2p.test function of\nthe pwr package in R, with n = 3, significance set\nto 0.05 (p < 0.05), and power of 0.8 or greater.\nHeat maps were generated with the heat map function in R studio (https://www.rstudio.com/products/rstudio/).48 Data AvailabilityLC\u2013MS/MS files are available at www.proteomexchange.org for identifier number PXD019424, or at www.massive.ucsd.edu under\nthe identifier number MSV000085478 or ID = 229a900a721d40ada5e6fc806241ba2b. AcknowledgmentsThis research was supported by\nthe NIH grant R56AG057469\n(awarded to R.A.R., V.H., and T.I.), NIH R01NS094597 and R01NS109075\n(awarded to V.H.), and ITN start-up funds to S.H.Y. A.J. was supported\nby NIH T32GM007752 (awarded to J. H. Brown), and C.B.L. was supported\nby NIH T32MH019934 (awarded to D. Jeste). GlossaryAbbreviationsADAlzheimer\u2019s diseaseAPPamyloid precursor proteinFDRfalse discovery rateiPSCinduced pluripotent\nstem cellKEGGKyoto\nEncyclopedia of Genes and\nGenomesMAPTtauMSmass spectrometryNTAnanoparticle tracking\nanalysisPS1presenilin\n1SPEsolid-phase\nextraction Supporting Information AvailableThe Supporting Information is\navailable free of charge at https://pubs.acs.org/doi/10.1021/acsomega.1c00660.Induction of tau deposits\nin the mouse brain by the\ninjection of mPS1 exosomes obtained from iPSC neurons, NTA of mPS1\nand control exosomes, substantial upregulation and downregulation\nof shared proteins in mPS1 and control exosomes, neuronal markers\nof mPS1 and control iPSC neurons representing synaptic neurotransmission,\nupregulated proteins in mPS1 exosomes compared to controls, downregulated\nproteins in mPS1 exosomes compared to controls, LC\u2013MS/MS report,\nPEAKS report, and annotated MS/MS spectra for single-peptide identification\nof proteins (PDF)Master table of data (XLSX) Author Present Address# N. Bud Grossman\nCenter for Memory Research and Care, Institute\nfor Translational Neuroscience, University of Minnesota, Twin Cities,\nDepartment of Neurology, Minneapolis, MN, Minneapolis VA Healthcare\nSystem, Minneapolis, MN. Author ContributionsV.H., S.H.Y.,\nand R.A.R. conceived the project idea, with scientific input from\nT.I. S.P., Q.L., B.A., and C.W., and C.B.L. performed the experiments.\nS.P., A.J., Z.J., and A.J.O. conducted analyses of proteomic data.\nS.P., A.J., and V.H. wrote the manuscript; S.H.Y., R.A.R., and T.I.\nedited the manuscript. S.P., A.J., C.M., J.A., Z.J., A.J.O., and V.H.\nanalyzed the relevant literature on the proteomic data. NotesThe authors declare no\ncompeting financial interest. ReferencesWang Y.; Mandelkow E.\nTau in physiology\nand pathology. Nat. Rev. Neurosci.\n2016, 17, 22\u201335. 10.1038/nrn.2015.1. [PubMed] [CrossRef] [Google Scholar]Ballatore C.; Lee V. M.-Y.; Trojanowski J. Q.\nTau-mediated neurodegeneration in\nAlzheimer\u2019s disease and related disorders. Nat. Rev. Neurosci.\n2007, 8, 663\u2013672. 10.1038/nrn2194. [PubMed] [CrossRef] [Google Scholar]Wang J.-Z.; Xia Y. Y.; Grundke-Iqbal I.; Iqbal K.\nAbnormal hyperphosphorylation\nof tau: sites, regulation, and molecular mechanism of neurofibrillary\ndegeneration. J. Alzheimer\u2019s Dis.\n2013, 33, S123\u2013S139. 10.3233/JAD-2012-129031. [PubMed] [CrossRef] [Google Scholar]Kimura T.; Sharma G.; Ishiguro K.; Hisanaga S. I.\nPhospho-tau\nbar\ncode: analysis of phosphoisotypes of tau and Its application to tauopathy. Front. Neurosci.\n2018, 12, 44.10.3389/fnins.2018.00044. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Rajmohan R.; Reddy P. H.\nAmyloid-beta and\nphosphorylated tau accumulations cause\nabnormalities at synapses of Alzheimer\u2019s disease neurons. J. Alzheimer\u2019s Dis.\n2017, 57, 975\u2013999. 10.3233/jad-160612. [PMC free article] [PubMed] [CrossRef] [Google Scholar]F\u00e1 M.; Puzzo D.; Piacentini R.; Staniszewski A.; Zhang H.; Baltrons M. A.; Li Puma D. D.; Chatterjee I.; Li J.; Saeed F.; Berman H. L.; Ripoli C.; Gulisano W.; Gonzalez J.; Tian H.; Costa J. A.; Lopez P.; Davidowitz E.; Yu W. H.; Haroutunian V.; Brown L. M.; Palmeri A.; Sigurdsson E. M.; Duff K. E.; Teich A. F.; Honig L. S.; Sierks M.; Moe J. G.; D\u2019Adamio L.; Grassi C.; Kanaan N. M.; Fraser P. E.; Arancio O.\nExtracellular tau oligomers produce\nan immediate impairment of LTP and memory. Sci.\nRep.\n2016, 6, 19393.10.1038/srep19393. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Clavaguera F.; Bolmont T.; Crowther R. A.; Abramowski D.; Frank S.; Probst A.; Fraser G.; Stalder A. K.; Beibel M.; Staufenbiel M.; Jucker M.; Goedert M.; Tolnay M.\nTransmission and spreading of tauopathy in transgenic\nmouse brain. Nat. Cell Biol.\n2009, 11, 909\u2013913. 10.1038/ncb1901. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Ahmed Z.; Cooper J.; Murray T. K.; Garn K.; McNaughton E.; Clarke H.; Parhizkar S.; Ward M. A.; Cavallini A.; Jackson S.; Bose S.; Clavaguera F.; Tolnay M.; Lavenir I.; Goedert M.; Hutton M. L.; O\u2019Neill M. J.\nA novel in vivo model of tau propagation with rapid\nand progressive neurofibrillary tangle pathology: the pattern of spread\nis determined by connectivity, not proximity. Acta Neuropathol.\n2014, 127, 667\u2013683. 10.1007/s00401-014-1254-6. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Boluda S.; Iba M.; Zhang B.; Raible K. M.; Lee V. M.-Y.; Trojanowski J. Q.\nDifferential\ninduction and spread of tau pathology in young PS19 tau transgenic\nmice following intracerebral injections of pathological tau from Alzheimer\u2019s\ndisease or corticobasal degeneration brains. Acta Neuropathol.\n2015, 129, 221\u2013237. 10.1007/s00401-014-1373-0. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Liu L.; Drouet V.; Wu J. W.; Witter M. P.; Small S. A.; Clelland C.; Duff K.\nTrans-synaptic\nspread of tau pathology\nin vivo. PLoS One\n2012, 7, e3130210.1371/journal.pone.0031302. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Biundo F.; Del Prete D.; Zhang H.; Arancio O.; D\u2019Adamio L.\nA role for\ntau in learning, memory and synaptic plasticity. Sci. Rep.\n2018, 8, 3184.10.1038/s41598-018-21596-3. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Yin Y.; Gao D.; Wang Y.; Wang Z.-H.; Wang X.; Ye J.; Wu D.; Fang L.; Pi G.; Yang Y.; Wang X.-C.; Lu C.; Ye K.; Wang J.-Z.\nTau accumulation induces synaptic\nimpairment and memory deficit by calcineurin-mediated inactivation\nof nuclear CaMKIV/CREB signaling. Proc. Natl.\nAcad. Sci. U.S.A.\n2016, 113, E3773\u2013E3781. 10.1073/pnas.1604519113. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Schindowski K.; Bretteville A.; Leroy K.; B\u00e9gard S.; Brion J.-P.; Hamdane M.; Bu\u00e9e L.\nAlzheimer\u2019s\ndisease-like tau neuropathology leads to memory deficits and loss\nof functional synapses in a novel mutated tau transgenic mouse without\nany motor deficits. Am. J. Pathol.\n2006, 169, 599\u2013616. 10.2353/ajpath.2006.060002. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Congdon E. E.; Sigurdsson E. M.\nTau-targeting\ntherapies for Alzheimer disease. Nat. Rev. Neurol.\n2018, 14, 399\u2013415. 10.1038/s41582-018-0013-z. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Schroeder S. K.; Joly-Amado A.; Gordon M. N.; Morgan D.\nTau-Directed Immunotherapy:\nA Promising Strategy for Treating Alzheimer\u2019s Disease and Other\nTauopathies. J. Neuroimmune Pharmacol.\n2016, 11, 9\u201325. 10.1007/s11481-015-9637-6. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Asai H.; Ikezu S.; Tsunoda S.; Medalla M.; Luebke J.; Haydar T.; Wolozin B.; Butovsky O.; K\u00fcgler S.; Ikezu T.\nDepletion of microglia\nand inhibition of exosome synthesis halt tau\npropagation. Nat. Neurosci.\n2015, 18, 1584\u20131593. 10.1038/nn.4132. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Winston C. N.; Goetzl E. J.; Akers J. C.; Carter B. S.; Rockenstein E. M.; Galasko D.; Masliah E.; Rissman R. A.\nPrediction of conversion\nfrom mild cognitive impairment to dementia with neuronally derived\nblood exosome protein profile. Alzheimer\u2019s\nDementia\n2016, 3, 63\u201372. 10.1016/j.dadm.2016.04.001. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Reilly P.; Winston C. N.; Baron K. R.; Trejo M.; Rockenstein E. M.; Akers J. C.; Kfoury N.; Diamond M.; Masliah E.; Rissman R. A.; Yuan S. H.\nNovel human\nneuronal tau model exhibiting\nneurofibrillary tangles and transcellular propagation. Neurobiol. Dis.\n2017, 106, 222\u2013234. 10.1016/j.nbd.2017.06.005. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Winston C. N.; Aulston B.; Rockenstein E. M.; Adame A.; Prikhodko O.; Dave K. N.; Mishra P.; Rissman R. A.; Yuan S. H.\nNeuronal\nexosome-derived human tau is toxic to recipient mouse neurons in vivo. J. Alzheimer\u2019s Dis.\n2019, 67, 541\u2013553. 10.3233/jad-180776. [PMC free article] [PubMed] [CrossRef] [Google Scholar]van\nNiel G.; D\u2019Angelo G.; Raposo G.\nShedding light on the\ncell biology of extracellular vesicles. Nat.\nRev. Mol. Cell Biol.\n2018, 19, 213\u2013228. 10.1038/nrm.2017.125. [PubMed] [CrossRef] [Google Scholar]Budnik V.; Ruiz-Ca\u00f1ada C.; Wendler F.\nExtracellular vesicles round off\ncommunication in the nervous system. Nat. Rev.\nNeurosci.\n2016, 17, 160\u2013172. 10.1038/nrn.2015.29. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Kowal J.; Arras G.; Colombo M.; Jouve M.; Morath J. P.; Primdal-Bengtson B.; Dingli F.; Loew D.; Tkach M.; Th\u00e9ry C.\nProteomic\ncomparison defines novel markers to characterize\nheterogeneous populations of extracellular vesicle subtypes. Proc. Natl. Acad. Sci. U.S.A.\n2016, 113, E968\u2013E977. 10.1073/pnas.1521230113. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Levy E.\nExosomes in\nthe Diseased Brain: First Insights from In vivo Studies. Front. Neurosci.\n2017, 11, 142.10.3389/fnins.2017.00142. [PMC free article] [PubMed] [CrossRef] [Google Scholar]You Y.; Ikezu T.\nEmerging roles of extracellular\nvesicles in neurodegenerative disorders. Neurobiol.\nDis.\n2019, 130, 104512.10.1016/j.nbd.2019.104512. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Saman S.; Kim W.; Raya M.; Visnick Y.; Miro S.; Saman S.; Jackson B.; McKee A. C.; Alvarez V. E.; Lee N. C. Y.; Hall G. F.\nExosome-associated\ntau is secreted in tauopathy models\nand is selectively phosphorylated in cerebrospinal fluid in early\nAlzheimer disease. J. Biol. Chem.\n2012, 287, 3842\u20133849. 10.1074/jbc.m111.277061. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Masters C. L.; Bateman R.; Blennow K.; Rowe C. C.; Sperling R. A.; Cummings J. L.\nAlzheimer\u2019s disease. Nat.\nRev. Dis. Primers\n2015, 1, 15056.10.1038/nrdp.2015.56. [PubMed] [CrossRef] [Google Scholar]Piaceri I.; Nacmias B.; Sorbi S.\nGenetics of\nfamilial and sporadic\nAlzheimer\u2019s disease. Front. Biosci.,\nElite Ed.\n2013, 5, 167\u2013177. 10.2741/e605. [PubMed] [CrossRef] [Google Scholar]Israel M. A.; Yuan S. H.; Bardy C.; Reyna S. M.; Mu Y.; Herrera C.; Hefferan M. P.; Van Gorp S.; Nazor K. L.; Boscolo F. S.; Carson C. T.; Laurent L. C.; Marsala M.; Gage F. H.; Remes A. M.; Koo E. H.; Goldstein L. S. B.\nProbing\nsporadic and familial Alzheimer\u2019s disease using induced pluripotent\nstem cells. Nature\n2012, 482, 216\u2013220. 10.1038/nature10821. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Lanoisel\u00e9e H.-M.; Nicolas G.; Wallon D.; Rovelet-Lecrux A.; Lacour M.; Rousseau S.; Richard A.-C.; Pasquier F.; Rollin-Sillaire A.; Martinaud O.; Quillard-Muraine M.; de la Sayette V.; Boutoleau-Bretonniere C.; Etcharry-Bouyx F.; Chauvir\u00e9 V.; Sarazin M.; le Ber I.; Epelbaum S.; Jonveaux T.; Rouaud O.; Ceccaldi M.; F\u00e9lician O.; Godefroy O.; Formaglio M.; Croisile B.; Auriacombe S.; Chamard L.; Vincent J.-L.; Sauv\u00e9e M.; Marelli-Tosi C.; Gabelle A.; Ozsancak C.; Pariente J.; Paquet C.; Hannequin D.; Campion D.\nAPP, PSEN1, and PSEN2\nmutations in early-onset Alzheimer disease: A genetic screening study\nof familial and sporadic cases. PLoS Med.\n2017, 14, e100227010.1371/journal.pmed.1002270. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Jiang H.; Jayadev S.; Lardelli M.; Newman M.\nA Review of the Familial\nAlzheimer\u2019s Disease Locus PRESENILIN 2 and Its Relationship\nto PRESENILIN 1. J. Alzheimer\u2019s Dis.\n2018, 66, 1323\u20131339. 10.3233/jad-180656. [PubMed] [CrossRef] [Google Scholar]Hunter S.; Brayne C.\nUnderstanding the roles of mutations in the amyloid\nprecursor protein in Alzheimer disease. Mol.\nPsychiatry\n2018, 23, 81\u201393. 10.1038/mp.2017.218. [PubMed] [CrossRef] [Google Scholar]Sherrington R.; Rogaev E. I.; Liang Y.; Rogaeva E. A.; Levesque G.; Ikeda M.; Chi H.; Lin C.; Li G.; Holman K.; Tsuda T.; Mar L.; Foncin J.-F.; Bruni A. C.; Montesi M. P.; Sorbi S.; Rainero I.; Pinessi L.; Nee L.; Chumakov I.; Pollen D.; Brookes A.; Sanseau P.; Polinsky R. J.; Wasco W.; Da Silva H. A. R.; Haines J. L.; Pericak-Vance M. A.; Tanzi R. E.; Roses A. D.; Fraser P. E.; Rommens J. M.; St George-Hyslop P. H.\nCloning of a gene bearing missense mutations in early-onset\nfamilial Alzheimer\u2019s disease. Nature\n1995, 375, 754\u2013760. 10.1038/375754a0. [PubMed] [CrossRef] [Google Scholar]Lee M. K.; Borchelt D. R.; Kim G.; Thinakaran G.; Slunt H. H.; Ratovitski T.; Martin L. J.; Kittur A.; Gandy S.; Levey A. I.; Jenkins N.; Copeland N.; Price D. L.; Sisodia S. S.\nHyperaccumulation of FAD-linked presenilin\n1 variants in vivo. Nat. Med.\n1997, 3, 756\u2013760. 10.1038/nm0797-756. [PubMed] [CrossRef] [Google Scholar]Aulston B.; Liu Q.; Mante M.; Florio J.; Rissman R. A.; Yuan S. H.\nExtracellular\nvesicles isolated from familial Alzheimer\u2019s disease neuronal\ncultures induce aberrant tau phosphorylation in the wild-type mouse\nbrain. J. Alzheimer\u2019s Dis.\n2019, 72, 575\u2013585. 10.3233/jad-190656. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Yuan S. H.; Martin J.; Elia J.; Flippin J.; Paramban R. I.; Hefferan M. P.; Vidal J. G.; Mu Y.; Killian R. L.; Israel M. A.; Emre N.; Marsala S.; Marsala M.; Gage F. H.; Goldstein L. S. B.; Carson C. T.\nCell-surface marker\nsignatures for the isolation of neural stem cells, glia and neurons\nderived from human pluripotent stem cells. PLoS\nOne\n2011, 6, e1754010.1371/journal.pone.0017540. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Israel M. A.; Yuan S. H.; Bardy C.; Reyna S. M.; Mu Y.; Herrera C.; Hefferan M. P.; Van Gorp S.; Nazor K. L.; Boscolo F. S.; Carson C. T.; Laurent L. C.; Marsala M.; Gage F. H.; Remes A. M.; Koo E. H.; Goldstein L. S. B.\nProbing\nsporadic and familial Alzheimer\u2019s disease using induced pluripotent\nstem cells. Nature\n2012, 482, 216\u2013220. 10.1038/nature10821. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Liu Q.; Waltz S.; Woodruff G.; Ouyang J.; Israel M. A.; Herrera C.; Sarsoza F.; Tanzi R. E.; Koo E. H.; Ringman J. M.; Goldstein L. S. B.; Wagner S. L.; Yuan S. H.\nEffect\nof potent \u03b3-secretase modulator in human neurons derived from\nmultiple presenilin 1-induced pluripotent stem cell mutant carriers. JAMA Neurol.\n2014, 71, 1481\u20131489. 10.1001/jamaneurol.2014.2482. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Mertens J.; Paquola A. C. M.; Ku M.; Hatch E.; B\u00f6hnke L.; Ladjevardi S.; McGrath S.; Campbell B.; Lee H.; Herdy J. R.; Gon\u00e7alves J. T.; Toda T.; Kim Y.; Winkler J.; Yao J.; Hetzer M. W.; Gage F. H.\nDirectly\nReprogrammed Human Neurons Retain Aging-Associated Transcriptomic\nSignatures and Reveal Age-Related Nucleocytoplasmic Defects. Cell Stem Cell\n2015, 17, 705\u2013718. 10.1016/j.stem.2015.09.001. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Mertens J.; Reid D.; Lau S.; Kim Y.; Gage F. H.\nAging in\na Dish: iPSC-Derived and Directly Induced Neurons for Studying Brain\nAging and Age-Related Neurodegenerative Diseases. Annu. Rev. Genet.\n2018, 52, 271\u2013293. 10.1146/annurev-genet-120417-031534. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Rappsilber J.; Mann M.; Ishihama Y.\nProtocol for\nmicro-purification,\nenrichment, pre-fractionation and storage of peptides for proteomics\nusing StageTips. Nat. Protoc.\n2007, 2, 1896\u20131906. 10.1038/nprot.2007.261. [PubMed] [CrossRef] [Google Scholar]Richards A. L.; Hebert A. S.; Ulbrich A.; Bailey D. J.; Coughlin E. E.; Westphall M. S.; Coon J. J.\nOne-hour proteome\nanalysis in yeast. Nat. Protoc.\n2015, 10, 701\u2013714. 10.1038/nprot.2015.040. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Zhang J.; Xin L.; Shan B.; Chen W.; Xie M.; Yuen D.; Zhang W.; Zhang Z.; Lajoie G. A.; Ma B.\nPEAKS DB:\nDe Novo Sequencing Assisted Database Search for Sensitive and Accurate\nPeptide Identification. Mol. Cell. Proteomics\n2012, 11, M111.010587.10.1074/mcp.m111.010587. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Chawade A.; Alexandersson E.; Levander F.\nNormalyzer: a tool for rapid evaluation\nof normalization methods for omics data sets. J. Proteome Res.\n2014, 13, 3114\u20133120. 10.1021/pr401264n. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Benjamini Y.; Hochberg Y.\nControlling the false\ndiscovery rate: A practical and\npowerful approach to multiple testing. J. R.\nStat. Soc. Series B Stat. Methodol.\n1995, 57, 289\u2013300. 10.1111/j.2517-6161.1995.tb02031.x. [CrossRef] [Google Scholar]Rivals I.; Personnaz L.; Taing L.; Potier M.-C.\nEnrichment or depletion\nof a GO category within a class of genes: which test?. Bioinformatics\n2007, 23, 401\u2013407. 10.1093/bioinformatics/btl633. [PubMed] [CrossRef] [Google Scholar]Szklarczyk D.; Gable A. L.; Lyon D.; Junge A.; Wyder S.; Huerta-Cepas J.; Simonovic M.; Doncheva N. T.; Morris J. H.; Bork P.; Jensen L. J.; Mering C. V.\nSTRING v11: protein-protein\nassociation networks with increased coverage, supporting functional\ndiscovery in genome-wide experimental datasets. Nucleic Acids Res.\n2019, 47, D607\u2013D613. 10.1093/nar/gky1131. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Franceschini A.; Szklarczyk D.; Frankild S.; Kuhn M.; Simonovic M.; Roth A.; Lin J.; Minguez P.; Bork P.; von Mering C.; Jensen L. J.\nSTRING v9.1: protein-protein interaction\nnetworks, with increased coverage and integration. Nucleic Acids Res.\n2013, 41, D808\u2013D815. 10.1093/nar/gks1094. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Jayadeepa R. M.; Ray A.; Naik D.; Sanyal D. N.; Shah D.\nReview and research\nanalysis of computational target methods using BioRuby and in silico\nscreening of herbal lead compounds against pancreatic cancer using\nR programming. Curr. Drug Metab.\n2014, 15, 535\u2013543. 10.2174/138920021505141126103546. [PubMed] [CrossRef] [Google Scholar]Paulaitis M.; Agarwal K.; Nana-Sinkam P.\nDynamic Scaling\nof Exosome Sizes. Langmuir\n2018, 34, 9387\u20139393. 10.1021/acs.langmuir.7b04080. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Zabeo D.; Cvjetkovic A.; L\u00e4sser C.; Schorb M.; L\u00f6tvall J.; H\u00f6\u00f6g J. L.\nExosomes\npurified from a single cell\ntype have diverse morphology. J. Extracell.\nVesicles\n2017, 6, 1329476.10.1080/20013078.2017.1329476. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Agarwal K.; Saji M.; Lazaroff S. M.; Palmer A. F.; Ringel M. D.; Paulaitis M. E.\nAnalysis\nof exosome release as a cellular response\nto MAPK pathway inhibition. Langmuir\n2015, 31, 5440\u20135448. 10.1021/acs.langmuir.5b00095. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Kanehisa M.; Furumichi M.; Tanabe M.; Sato Y.; Morishima K.\nKEGG: new\nperspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res.\n2017, 45, D353\u2013D361. 10.1093/nar/gkw1092. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Karsdal M. A.Biochemistry of Collagens,\nLaminins, and Elastin, 1st ed.; Academic Press, 2016. [Google Scholar]Hondius D. C.; Eigenhuis K. N.; Morrema T. H. J.; van der Schors R. C.; van Nierop P.; Bugiani M.; Li K. W.; Hoozemans J. J. M.; Smit A. B.; Rozemuller A. J. M.\nProteomics analysis identifies new\nmarkers associated with capillary cerebral amyloid angiopathy in Alzheimer\u2019s\ndisease. Acta Neuropathol. Commun.\n2018, 6, 46.10.1186/s40478-018-0540-2. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Jochim A.; Li Y.; Zech M.; Lam D.; Gross N.; Koch K.; Zimmer C.; Winkelmann J.; Haslinger B.\nMicrostructural\nwhite matter abnormalities in patients with COL6A3 mutations (DYT27\ndystonia). Parkinsonism Relat. Disord.\n2018, 46, 74\u201378. 10.1016/j.parkreldis.2017.10.008. [PubMed] [CrossRef] [Google Scholar]Adkins A. E.; Hack L. M.; Bigdeli T. B.; Williamson V. S.; McMichael G. O.; Mamdani M.; Edwards A. C.; Aliev F.; Chan R. F.; Bhandari P.; Raabe R. C.; Alaimo J. T.; Blackwell G. G.; Moscati A.; Poland R. S.; Rood B.; Patterson D. G.; Walsh D.; Whitfield J. B.; Zhu G.; Montgomery G. W.; Henders A. K.; Martin N. G.; Heath A. C.; Madden P. A. F.; Frank J.; Ridinger M.; Wodarz N.; Soyka M.; Zill P.; Ising M.; N\u00f6then M. M.; Kiefer F.; Rietschel M.; Gelernter J.; Sherva R.; Koesterer R.; Almasy L.; Zhao H.; Kranzler H. R.; Farrer L. A.; Maher B. S.; Prescott C. A.; Dick D. M.; Bacanu S. A.; Mathies L. D.; Davies A. G.; Vladimirov V. I.; Grotewiel M.; Bowers M. S.; Bettinger J. C.; Webb B. T.; Miles M. F.; Kendler K. S.; Riley B. P.\nGenomewide\nassociation study of alcohol dependence identifies risk loci altering\nethanol-response behaviors in model organisms. Alcohol.: Clin. Exp. Res.\n2017, 41, 911\u2013928. 10.1111/acer.13362. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Okada M.; Kawahara G.; Noguchi S.; Sugie K.; Murayama K.; Nonaka I.; Hayashi Y. K.; Nishino I.\nPrimary collagen VI\ndeficiency is the second most common congenital muscular dystrophy\nin Japan. Neurology\n2007, 69, 1035\u20131042. 10.1212/01.wnl.0000271387.10404.4e. [PubMed] [CrossRef] [Google Scholar]Siero\u0144 A. L.; Sta\u0144czak P.\nASD--lessons\non genetic background from transgenic\nmice with inactive gene encoding metalloprotease, Tolloid-like 1 (TLL1). Med. Sci. Monit.\n2006, 12, RA17\u2013RA22. [PubMed] [Google Scholar]Takahara K.; Osborne L.; Elliott R. W.; Tsui L.-C.; Scherer S. W.; Greenspan D. S.\nFine mapping of the human and mouse genes for the type\nI procollagen COOH-terminal proteinase enhancer protein. Genomics\n1996, 31, 253\u2013256. 10.1006/geno.1996.0043. [PubMed] [CrossRef] [Google Scholar]Reed C. C.; Iozzo R. V.\nThe role of decorin\nin collagen fibrillogenesis and\nskin homeostasis. Glycoconjugate J.\n2002, 19, 249\u2013255. 10.1023/a:1025383913444. [PubMed] [CrossRef] [Google Scholar]Schaefer L.; Tredup C.; Gubbiotti M. A.; Iozzo R. V.\nProteoglycan neofunctions:\nregulation of inflammation and autophagy in cancer biology. FEBS J.\n2017, 284, 10\u201326. 10.1111/febs.13963. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Chen I.-H.; Wang H.-H.; Hsieh Y.-S.; Huang W.-C.; Yeh H.-I.; Chuang Y.-J.\nPRSS23 is essential\nfor the Snail-dependent endothelial-to-mesenchymal\ntransition during valvulogenesis in zebrafish. Cardiovasc. Res.\n2013, 97, 443\u2013453. 10.1093/cvr/cvs355. [PubMed] [CrossRef] [Google Scholar]Agbemenyah H. Y.; Agis-Balboa R. C.; Burkhardt S.; Delalle I.; Fischer A.\nInsulin growth\nfactor binding protein 7 is a novel target to treat dementia. Neurobiol. Dis.\n2014, 62, 135\u2013143. 10.1016/j.nbd.2013.09.011. [PubMed] [CrossRef] [Google Scholar]Muenchhoff J.; Song F.; Poljak A.; Crawford J. D.; Mather K. A.; Kochan N. A.; Yang Z.; Trollor J. N.; Reppermund S.; Maston K.; Theobald A.; Kirchner-Adelhardt S.; Kwok J. B.; Richmond R. L.; McEvoy M.; Attia J.; Schofield P. W.; Brodaty H.; Sachdev P. S.\nPlasma\napolipoproteins\nand physical and cognitive health in very old individuals. Neurobiol. Aging\n2017, 55, 49\u201360. 10.1016/j.neurobiolaging.2017.02.017. [PubMed] [CrossRef] [Google Scholar]Mead T. J.; Apte S. S.\nADAMTS proteins\nin human disorders. Matrix Biol.\n2018, 71\u201372, 225\u2013239. 10.1016/j.matbio.2018.06.002. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Kelwick R.; Desanlis I.; Wheeler G. N.; Edwards D. R.\nThe ADAMTS (A Disintegrin\nand Metalloproteinase with Thrombospondin motifs) family. Genome Biol.\n2015, 16, 113.10.1186/s13059-015-0676-3. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Kunkle B. W.; Grenier-Boley B.; Sims R.; Bis J. C.; Damotte V.; Naj A. C.; Boland A.; Vronskaya M.; van der Lee S. J.; Amlie-Wolf A.; et al. Genetic meta-analysis\nof diagnosed Alzheimer\u2019s disease identifies new risk loci and\nimplicates A\u03b2, tau, immunity and lipid processing. Nat. Genet.\n2019, 51, 414\u2013430. 10.1038/s41588-019-0358-2. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Flister M. J.; Tsaih S.-W.; O\u2019Meara C. C.; Endres B.; Hoffman M. J.; Geurts A. M.; Dwinell M. R.; Lazar J.; Jacob H. J.; Moreno C.\nIdentifying multiple\ncausative genes at a single GWAS\nlocus. Genome Res.\n2013, 23, 1996\u20132002. 10.1101/gr.160283.113. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Bis J. C.; Jian X.; Kunkle B. W.; Chen Y.; Hamilton-Nelson K. L.; Bush W. S.; Salerno W. J.; Lancour D.; Ma Y.; Renton A. E.; et al. Whole exome sequencing study identifies novel\nrare and common Alzheimer\u2019s-Associated variants involved in\nimmune response and transcriptional regulation. Mol. Psychiatry\n2020, 25, 1859\u20131875. 10.1038/s41380-018-0112-7. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Vasquez J. B.; Fardo D. W.; Estus S.\nABCA7 expression\nis associated with\nAlzheimer\u2019s disease polymorphism and disease status. Neurosci. Lett.\n2013, 556, 58\u201362. 10.1016/j.neulet.2013.09.058. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Speliotes E. K.; Willer C. J.; Berndt S. I.; Monda K. L.; Thorleifsson G.; Jackson A. U.; Lango\nAllen H.; Lindgren C. M.; Luan J.; et al. Association\nanalyses of 249,796 individuals reveal 18 new loci associated\nwith body mass index. Nat. Genet.\n2010, 42, 937\u2013948. 10.1038/ng.686. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Han K. E.; Choi S.-i.; Kim T.-i.; Maeng Y.-S.; Stulting R. D.; Ji Y. W.; Kim E. K.\nPathogenesis and treatments of TGFBIH\ncorneal dystrophies. Prog. Retinal Eye Res.\n2016, 50, 67\u201388. 10.1016/j.preteyeres.2015.11.002. [PubMed] [CrossRef] [Google Scholar]Shelton L.; Summers Rada J. A.\nInhibition\nof human scleral fibroblast cell attachment\nto collagen type I by TGFBIp. Invest. Ophthalmol.\nVisual Sci.\n2009, 50, 3542\u20133552. 10.1167/iovs.09-3460. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Venkatraman A.; Murugan E.; Lin S. J.; Peh G. S. L.; Rajamani L.; Mehta J. S.\nEffect of osmolytes\non in-vitro aggregation properties\nof peptides derived from TGFBIp. Sci. Rep.\n2020, 10, 4011.10.1038/s41598-020-60944-0. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Busse-Wicher M.; Wicher K. B.; Kusche-Gullberg M.\nThe extostosin\nfamily: proteins with\nmany functions. Matrix Biol.\n2014, 35, 25\u201333. 10.1016/j.matbio.2013.10.001. [PubMed] [CrossRef] [Google Scholar]Izuhara K.; Nunomura S.; Nanri Y.; Ogawa M.; Ono J.; Mitamura Y.; Yoshihara T.\nPeriostin in inflammation and allergy. Cell. Mol. Life Sci.\n2017, 74, 4293\u20134303. 10.1007/s00018-017-2648-0. [PubMed] [CrossRef] [Google Scholar]Huber F. M.; Hoelz A.\nMolecular basis for protection of ribosomal protein L4 from cellular\ndegradation. Nat. Commun.\n2017, 8, 14354.10.1038/ncomms14354. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Hemmerich P.; Mikecz A. v.; Neumann F.; S\u00f6zeri O.; Wolff-Vorbeck G.; Zoebelein R.; Krawinkel U.\nStructural\nand functional properties of ribosomal protein L7 from humans and\nrodents. Nucleic Acids Res.\n1993, 21, 223\u2013231. 10.1093/nar/21.2.223. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Wu W.-C.; Liu H.-W.; Lin A.\nHuman ribosomal protein L7 displays\nan ER binding property and is involved in ribosome-ER association. FEBS Lett.\n2007, 581, 651\u2013657. 10.1016/j.febslet.2007.01.023. [PubMed] [CrossRef] [Google Scholar]Plafker S. M.; Macara I. G.\nRibosomal protein\nL12 uses a distinct nuclear import\npathway mediated by importin 11. Mol. Cell.\nBiol.\n2002, 22, 1266\u20131275. 10.1128/mcb.22.4.1266-1275.2002. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Chaudhuri S.; Vyas K.; Kapasi P.; Komar A. A.; Dinman J. D.; Barik S.; Mazumder B.\nHuman ribosomal\nprotein L13a is dispensable\nfor canonical ribosome function but indispensable for efficient rRNA\nmethylation. RNA\n2007, 13, 2224\u20132237. 10.1261/rna.694007. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Dhar D.; Mapa K.; Pudi R.; Srinivasan P.; Bodhinathan K.; Das S.\nHuman ribosomal protein L18a interacts\nwith hepatitis C virus internal ribosome entry site. Arch. Virol.\n2006, 151, 509\u2013524. 10.1007/s00705-005-0642-6. [PubMed] [CrossRef] [Google Scholar]Yang E.-J.; Seo J.-W.; Choi I.-H.\nRibosomal\nProtein L19 and L22 Modulate\nTLR3 Signaling. Immune Netw.\n2011, 11, 155\u2013162. 10.4110/in.2011.11.3.155. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Alkhatabi H. A.; McLornan D. P.; Kulasekararaj A. G.; Malik F.; Seidl T.; Darling D.; Gaken J.; Mufti G. J.\nRPL27A is a target\nof miR-595 and may contribute to the myelodysplastic phenotype through\nribosomal dysgenesis. Oncotarget\n2016, 7, 47875\u201347890. 10.18632/oncotarget.10293. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Kowalczyk P.; Woszczy\u0144ski M.; Ostrowski J.\nIncreased expression of ribosomal\nprotein S2 in liver tumors, posthepactomized livers, and proliferating\nhepatocytes in vitro. Acta Biochim. Pol.\n2002, 49, 615\u2013624. 10.18388/abp.2002_3770. [PubMed] [CrossRef] [Google Scholar]Lee A. S. Y.; Kranzusch P. J.; Cate J. H. D.\neIF3 targets\ncell-proliferation messenger\nRNAs for translational activation or repression. Nature\n2015, 522, 111\u2013114. 10.1038/nature14267. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Young D. J.; Guydosh N. R.\nHcr1/eIF3j Is a\n60S Ribosomal Subunit Recycling Accessory\nFactor In Vivo. Cell Rep.\n2019, 28, 39\u201350.e4. 10.1016/j.celrep.2019.05.111. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Choi Y. J.; Lee Y. S.; Lee H. W.; Shim D. M.; Seo S. W.\nSilencing\nof translation initiation factor eIF3b promotes apoptosis in osteosarcoma\ncells. Bone Joint Res.\n2017, 6, 186\u2013193. 10.1302/2046-3758.63.bjr-2016-0151.r2. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Martin L.; Latypova X.; Wilson C. M.; Magnaudeix A.; Perrin M.-L.; Terro F.\nTau protein phosphatases\nin Alzheimer\u2019s\ndisease: the leading role of PP2A. Ageing Res.\nRev.\n2013, 12, 39\u201349. 10.1016/j.arr.2012.06.008. [PubMed] [CrossRef] [Google Scholar]Sontag J.-M.; Sontag E.\nProtein phosphatase\n2A dysfunction in Alzheimer\u2019s\ndisease. Front. Mol. Neurosci.\n2014, 7, 16.10.3389/fnmol.2014.00016. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Taleski G.; Sontag E.\nProtein phosphatase 2A and tau: an\norchestrated \u2018Pas\nde Deux\u2019. FEBS Lett.\n2018, 592, 1079\u20131095. 10.1002/1873-3468.12907. [PubMed] [CrossRef] [Google Scholar]Yu U. Y.; Yoo B. C.; Ahn J.-H.\nRegulatory B subunits of protein\nphosphatase 2A are involved in site-specific regulation of tau protein\nphosphorylation. Korean J. Physiol. Pharmacol.\n2014, 18, 155\u2013161. 10.4196/kjpp.2014.18.2.155. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Das S.; Krainer A. R.\nEmerging functions\nof SRSF1, splicing factor and oncoprotein,\nin RNA metabolism and cancer. Mol. Cancer Res.\n2014, 12, 1195\u20131204. 10.1158/1541-7786.mcr-14-0131. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Saijo S.; Kuwano Y.; Masuda K.; Nishikawa T.; Rokutan K.; Nishida K.\nSerine/arginine-rich\nsplicing factor\n7 regulates p21-dependent growth arrest in colon cancer cells. J. Med. Invest.\n2016, 63, 219\u2013226. 10.2152/jmi.63.219. [PubMed] [CrossRef] [Google Scholar]Yugami M.; Kabe Y.; Yamaguchi Y.; Wada T.; Handa H.\nhnRNP-U enhances\nthe expression of specific genes by stabilizing mRNA. FEBS Lett.\n2007, 581, 1\u20137. 10.1016/j.febslet.2006.11.062. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Aoki N.; Higashi S.; Kawakami I.; Kobayashi Z.; Hosokawa M.; Katsuse O.; Togo T.; Hirayasu Y.; Akiyama H.\nLocalization of fused in sarcoma\n(FUS) protein to the\npost-synaptic density in the brain. Acta Neuropathol.\n2012, 124, 383\u2013394. 10.1007/s00401-012-0984-6. [PubMed] [CrossRef] [Google Scholar]Daigle J. G.; Lanson N. A. Jr.; Smith R. B.; Casci I.; Maltare A.; Monaghan J.; Nichols C. D.; Kryndushkin D.; Shewmaker F.; Pandey U. B.\nRNA-binding ability of FUS regulates\nneurodegeneration, cytoplasmic mislocalization and incorporation into\nstress granules associated with FUS carrying ALS-linked mutations. Hum. Mol. Genet.\n2013, 22, 1193\u20131205. 10.1093/hmg/dds526. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Ling S.-C.; Dastidar S. G.; Tokunaga S.; Ho W. Y.; Lim K.; Ilieva H.; Parone P. A.; Tyan S.-H.; Tse T. M.; Chang J.-C.; Platoshyn O.; Bui N. B.; Bui A.; Vetto A.; Sun S.; McAlonis-Downes M.; Han J. S.; Swing D.; Kapeli K.; Yeo G. W.; Tessarollo L.; Marsala M.; Shaw C. E.; Tucker-Kellogg G.; La Spada A. R.; Lagier-Tourenne C.; Da Cruz S.; Cleveland D. W.\nOverriding\nFUS autoregulation in mice triggers gain-of-toxic dysfunctions in\nRNA metabolism and autophagy-lysosome axis. Elife\n2019, 8, e4081110.7554/elife.40811. [PMC free article] [PubMed] [CrossRef] [Google Scholar]L\u00f3pez-Erauskin J.; Tadokoro T.; Baughn M. W.; Myers B.; McAlonis-Downes M.; Chillon-Marinas C.; Asiaban J. N.; Artates J.; Bui A. T.; Vetto A. P.; Lee S. K.; Le A. V.; Sun Y.; Jambeau M.; Boubaker J.; Swing D.; Qiu J.; Hicks G. G.; Ouyang Z.; Fu X.-D.; Tessarollo L.; Ling S.-C.; Parone P. A.; Shaw C. E.; Marsala M.; Lagier-Tourenne C.; Cleveland D. W.; Da Cruz S.\nALS/FTD-Linked Mutation\nin FUS Suppresses Intra-axonal Protein Synthesis and Drives Disease\nWithout Nuclear Loss-of-Function of FUS. Neuron\n2018, 100, 816\u2013830.e7. 10.1016/j.neuron.2018.09.044. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Ratti A.; Buratti E.\nPhysiological functions\nand pathobiology\nof TDP-43 and FUS/TLS proteins. J. Neurochem.\n2016, 138, 95\u2013111. 10.1111/jnc.13625. [PubMed] [CrossRef] [Google Scholar]Scekic-Zahirovic J.; Sendscheid O.; El Oussini H.; Jambeau M.; Sun Y.; Mersmann S.; Wagner M.; Dieterl\u00e9 S.; Sinniger J.; Dirrig-Grosch S.; Drenner K.; Birling M. C.; Qiu J.; Zhou Y.; Li H.; Fu X. D.; Rouaux C.; Shelkovnikova T.; Witting A.; Ludolph A. C.; Kiefer F.; Storkebaum E.; Lagier-Tourenne C.; Dupuis L.\nToxic gain of function from mutant\nFUS protein is crucial to trigger cell autonomous motor neuron loss. EMBO J.\n2016, 35, 1077\u20131097. 10.15252/embj.201592559. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Squatrito M.; Mancino M.; Donzelli M.; Areces L. B.; Draetta G. F.\nEBP1 is a nucleolar growth-regulating\nprotein that\nis part of pre-ribosomal ribonucleoprotein complexes. Oncogene\n2004, 23, 4454\u20134465. 10.1038/sj.onc.1207579. [PubMed] [CrossRef] [Google Scholar]Hong H.; An O.; Chan T. H. M.; Ng V. H. E.; Kwok H. S.; Lin J. S.; Qi L.; Han J.; Tay D. J. T.; Tang S. J.; Yang H.; Song Y.; Bellido Molias F.; Tenen D. G.; Chen L.\nBidirectional regulation\nof adenosine-to-inosine (A-to-I) RNA editing by DEAH box helicase\n9 (DHX9) in cancer. Nucleic Acids Res.\n2018, 46, 7953\u20137969. 10.1093/nar/gky396. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Brumbaugh J.; Di Stefano B.; Wang X.; Borkent M.; Forouzmand E.; Clowers K. J.; Ji F.; Schwarz B. A.; Kalocsay M.; Elledge S. J.; Chen Y.; Sadreyev R. I.; Gygi S. P.; Hu G.; Shi Y.; Hochedlinger K.\nNudt21 controls\ncell fate by connecting alternative polyadenylation to chromatin signaling. Cell\n2018, 172, 106\u2013120.e21. 10.1016/j.cell.2017.11.023. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Vance C.; Rogelj B.; Hortob\u00e1gyi T.; De Vos K. J.; Nishimura A. L.; Sreedharan J.; Hu X.; Smith B.; Ruddy D.; Wright P.; Ganesalingam J.; Williams K. L.; Tripathi V.; Al-Saraj S.; Al-Chalabi A.; Leigh P. N.; Blair I. P.; Nicholson G.; de Belleroche J.; Gallo J.-M.; Miller C. C.; Shaw C. E.\nMutations\nin FUS, an RNA processing protein, cause familial amyotrophic lateral\nsclerosis type 6. Science\n2009, 323, 1208\u20131211. 10.1126/science.1165942. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Kwiatkowski T. J. Jr.; Bosco D. A.; Leclerc A. L.; Tamrazian E.; Vanderburg C. R.; Russ C.; Davis A.; Gilchrist J.; Kasarskis E. J.; Munsat T.; Valdmanis P.; Rouleau G. A.; Hosler B. A.; Cortelli P.; de Jong P. J.; Yoshinaga Y.; Haines J. L.; Pericak-Vance M. A.; Yan J.; Ticozzi N.; Siddique T.; McKenna-Yasek D.; Sapp P. C.; Horvitz H. R.; Landers J. E.; Brown R. H. Jr.\nMutations in the FUS/TLS gene on chromosome 16 cause\nfamilial amyotrophic lateral sclerosis. Science\n2009, 323, 1205\u20131208. 10.1126/science.1166066. [PubMed] [CrossRef] [Google Scholar]Tanahashi N.; Suzuki M.; Fujiwara T.; Takahashi E.-i.; Shimbara N.; Chung C. H.; Tanaka K.\nChromosomal localization\nand immunological analysis of a family of human 26S proteasomal ATPases. Biochem. Biophys. Res. Commun.\n1998, 243, 229\u2013232. 10.1006/bbrc.1997.7892. [PubMed] [CrossRef] [Google Scholar]Roelofs J.; Park S.; Haas W.; Tian G.; McAllister F. E.; Huo Y.; Lee B.-H.; Zhang F.; Shi Y.; Gygi S. P.; Finley D.\nChaperone-mediated pathway of proteasome\nregulatory particle assembly. Nature\n2009, 459, 861\u2013865. 10.1038/nature08063. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Vilchez D.; Boyer L.; Morantte I.; Lutz M.; Merkwirth C.; Joyce D.; Spencer B.; Page L.; Masliah E.; Berggren W. T.; Gage F. H.; Dillin A.\nIncreased\nproteasome activity in human embryonic stem cells is regulated by\nPSMD11. Nature\n2012, 489, 304\u2013308. 10.1038/nature11468. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Schaefer L.; Beermann M. L.; Miller J. B.\nCoding sequence,\ngenomic organization, chromosomal localization, and expression pattern\nof the signalosome component Cops2: the mouse homologue of Drosophila\nalien. Genomics\n1999, 56, 310\u2013316. 10.1006/geno.1998.5728. [PubMed] [CrossRef] [Google Scholar]Yan T.; Wunder J. S.; Gokgoz N.; Gill M.; Eskandarian S.; Parkes R. K.; Bull S. B.; Bell R. S.; Andrulis I. L.\nCOPS3 amplification\nand clinical outcome in osteosarcoma. Cancer\n2007, 109, 1870\u20131876. 10.1002/cncr.22595. [PubMed] [CrossRef] [Google Scholar]Gaspar L.; Howald C.; Popadin K.; Maier B.; Mauvoisin D.; Moriggi E.; Gutierrez-Arcelus M.; Falconnet E.; Borel C.; Kunz D.; Kramer A.; Gachon F.; Dermitzakis E. T.; Antonarakis S. E.; Brown S. A.\nThe genomic landscape of human cellular circadian variation\npoints to a novel role for the signalosome. Elife\n2017, 6, e2499410.7554/elife.24994. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Wei N.; Deng X. W.\nThe COP9 signalosome. Annu. Rev.\nCell Dev. Biol.\n2003, 19, 261\u2013286. 10.1146/annurev.cellbio.19.111301.112449. [PubMed] [CrossRef] [Google Scholar]Singh A. K.; Chamovitz D. A.\nRole of\nCop9 Signalosome subunits\nin the environmental and hormonal balance of plant. Biomolecules\n2019, 9, 224.10.3390/biom9060224. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Chung D.; Dellaire G.\nThe Role of the COP9\nSignalosome\nand Neddylation in DNA Damage Signaling and Repair. Biomolecules\n2015, 5, 2388\u20132416. 10.3390/biom5042388. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Bech-Otschir D.; Seeger M.; Dubiel W.\nThe COP9 signalosome:\nat the interface between signal transduction and ubiquitin-dependent\nproteolysis. J. Cell Sci.\n2002, 115, 467\u2013473. [PubMed] [Google Scholar]Shi J.; Qian W.; Yin X.; Iqbal K.; Grundke-Iqbal I.; Gu X.; Ding F.; Gong C.-X.; Liu F.\nCyclic AMP-dependent\nprotein kinase regulates the alternative splicing of tau exon 10:\na mechanism involved in tau pathology of Alzheimer disease. J. Biol. Chem.\n2011, 286, 14639\u201314648. 10.1074/jbc.m110.204453. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Welden J. R.; van Doorn J.; Nelson P. T.; Stamm S.\nThe human\nMAPT locus generates circular RNAs. Biochim.\nBiophys. Acta, Mol. Basis Dis.\n2018, 1864, 2753\u20132760. 10.1016/j.bbadis.2018.04.023. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Maziuk B. F.; Apicco D. J.; Cruz A. L.; Jiang L.; Ash P. E. A.; da Rocha E. L.; Zhang C.; Yu W. H.; Leszyk J.; Abisambra J. F.; Li H.; Wolozin B.\nRNA binding\nproteins co-localize with small tau inclusions in tauopathy. Acta Neuropathol. Commun.\n2018, 6, 71.10.1186/s40478-018-0574-5. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Rahman M. R.; Islam T.; Turanli B.; Zaman T.; Faruquee H. M.; Rahman M. M.; Mollah M. N. H.; Nanda R. K.; Arga K. Y.; Gov E.; Moni M. A.\nNetwork-based\napproach\nto identify molecular signatures and therapeutic agents in Alzheimer\u2019s\ndisease. Comput. Biol. Chem.\n2019, 78, 431\u2013439. 10.1016/j.compbiolchem.2018.12.011. [PubMed] [CrossRef] [Google Scholar]Evans H. T.; Benetatos J.; van Roijen M.; Bodea L. G.; G\u00f6tz J.\nDecreased\nsynthesis of ribosomal\nproteins in tauopathy revealed by non-canonical amino acid labelling. EMBO J.\n2019, 38, e10117410.15252/embj.2018101174. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Gr\u00fcnblatt E.; Ruder J.; Monoranu C. M.; Riederer P.; Youdim M. B.; Mandel S. A.\nDifferential alterations\nin metabolism\nand proteolysis-related rroteins in human parkinson\u2019s disease\nsubstantia nigra. Neurotoxic. Res.\n2018, 33, 560\u2013568. 10.1007/s12640-017-9843-5. [PubMed] [CrossRef] [Google Scholar]Randow F.; Seed B.\nEndoplasmic reticulum chaperone gp96\nis required for innate immunity but not cell viability. Nat. Cell Biol.\n2001, 3, 891\u2013896. 10.1038/ncb1001-891. [PubMed] [CrossRef] [Google Scholar]Yang Y.; Liu B.; Dai J.; Srivastava P. K.; Zammit D. J.; Lefran\u00e7ois L.; Li Z.\nHeat shock protein\ngp96 is a master chaperone for toll-like receptors and is important\nin the innate function of macrophages. Immunity\n2007, 26, 215\u2013226. 10.1016/j.immuni.2006.12.005. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Zhang M.; Qian C.; Zheng Z.-G.; Qian F.; Wang Y.; Thu P. M.; Zhang X.; Zhou Y.; Tu L.; Liu Q.; Li H.-J.; Yang H.; Li P.; Xu X.\nJujuboside A promotes\nA\u03b2 clearance and ameliorates cognitive\ndeficiency in Alzheimer\u2019s disease through activating Axl/HSP90/PPAR\u03b3\npathway. Theranostics\n2018, 8, 4262\u20134278. 10.7150/thno.26164. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Blackburn P. R.; Xu Z.; Tumelty K. E.; Zhao R. W.; Monis W. J.; Harris K. G.; Gass J. M.; Cousin M. A.; Boczek N. J.; Mitkov M. V.; Cappel M. A.; Francomano C. A.; Parisi J. E.; Klee E. W.; Faqeih E.; Alkuraya F. S.; Layne M. D.; McDonnell N. B.; Atwal P. S.\nBi-allelic Alterations\nin AEBP1 Lead to Defective Collagen Assembly and Connective Tissue\nStructure Resulting in a Variant of Ehlers-Danlos Syndrome. Am. J. Hum. Genet.\n2018, 102, 696\u2013705. 10.1016/j.ajhg.2018.02.018. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Minghetti P. P.; Ruffner D. E.; Kuang W. J.; Dennison O. E.; Hawkins J. W.; Beattie W. G.; Dugaiczyk A.\nMolecular\nstructure of the human albumin gene is revealed by nucleotide sequence\nwithin q11-22 of chromosome 4. J. Biol. Chem.\n1986, 261, 6747\u20136757. 10.1016/s0021-9258(19)62680-3. [PubMed] [CrossRef] [Google Scholar]Calin G. A.; di Iasio M. G.; Caprini E.; Vorechovsky I.; Natali P. G.; Sozzi G.; Croce C. M.; Barbanti-Brodano G.; Russo G.; Negrini M.\nLow frequency of alterations\nof the\nalpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the\nserine-threonine phosphatase 2A in human neoplasms. Oncogene\n2000, 19, 1191\u20131195. 10.1038/sj.onc.1203389. [PubMed] [CrossRef] [Google Scholar]Javadpour P.; Dargahi L.; Ahmadiani A.; Ghasemi R.\nTo be or not to be: PP2A as a dual player in CNS functions,\nits role in neurodegeneration, and its interaction with brain insulin\nsignaling. Cell. Mol. Life Sci.\n2019, 76, 2277\u20132297. 10.1007/s00018-019-03063-y. [PubMed] [CrossRef] [Google Scholar]El Kadmiri N.; Slassi I.; El Moutawakil B.; Nadifi S.; Tadevosyan A.; Hachem A.; Soukri A.\nGlyceraldehyde-3-phosphate\ndehydrogenase (GAPDH) and Alzheimer\u2019s disease. Pathol. Biol.\n2014, 62, 333\u2013336. 10.1016/j.patbio.2014.08.002. [PubMed] [CrossRef] [Google Scholar]Gerszon J.; Rodacka A.\nOxidatively modified\nglyceraldehyde-3-phosphate\ndehydrogenase in neurodegenerative processes and the role of low molecular\nweight compounds in counteracting its aggregation and nuclear translocation. Ageing Res. Rev.\n2018, 48, 21\u201331. 10.1016/j.arr.2018.09.003. [PubMed] [CrossRef] [Google Scholar]Varma V. R.; Varma S.; An Y.; Hohman T. J.; Seddighi S.; Casanova R.; Beri A.; Dammer E. B.; Seyfried N. T.; Pletnikova O.; Moghekar A.; Wilson M. R.; Lah J. J.; O\u2019Brien R. J.; Levey A. I.; Troncoso J. C.; Albert M. S.; Thambisetty M.\nAlpha-2 macroglobulin\nin Alzheimer\u2019s\ndisease: a marker of neuronal injury through the RCAN1 pathway. Mol. Psychiatry\n2017, 22, 13\u201323. 10.1038/mp.2016.206. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Tanskanen M.; Peuralinna T.; Polvikoski T.; Notkola I. L.; Sulkava R.; Hardy J.; Singleton A.; Kiuru-Enari S.; Paetau A.; Tienari P. J.; Myllykangas L.\nSenile systemic\namyloidosis affects 25% of the very aged and associates with genetic\nvariation in alpha2-macroglobulin and tau: a population-based autopsy\nstudy. Ann. Med.\n2008, 40, 232\u2013239. 10.1080/07853890701842988. [PubMed] [CrossRef] [Google Scholar]Shijo M.; Honda H.; Suzuki S. O.; Hamasaki H.; Hokama M.; Abolhassani N.; Nakabeppu Y.; Ninomiya T.; Kitazono T.; Iwaki T.\nAssociation of adipocyte\nenhancer-binding protein 1 with Alzheimer\u2019s disease pathology\nin human hippocampi. Brain Pathol.\n2018, 28, 58\u201371. 10.1111/bpa.12475. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Recabarren D.; Alarc\u00f3n M.\nGene networks in neurodegenerative\ndisorders. Life Sci.\n2017, 183, 83\u201397. 10.1016/j.lfs.2017.06.009. [PubMed] [CrossRef] [Google Scholar]Yu L.; Petyuk V. A.; Gaiteri C.; Mostafavi S.; Young-Pearse T.; Shah R. C.; Buchman A. S.; Schneider J. A.; Piehowski P. D.; Sontag R. L.; Fillmore T. L.; Shi T.; Smith R. D.; De Jager P. L.; Bennett D. A.\nTargeted brain proteomics\nuncover multiple pathways to Alzheimer\u2019s dementia. Ann. Neurol.\n2018, 84, 78\u201388. 10.1002/ana.25266. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Carro E.\nGelsolin as therapeutic target in\nAlzheimer\u2019s disease. Expert Opin. Ther.\nTargets\n2010, 14, 585\u2013592. 10.1517/14728222.2010.488222. [PubMed] [CrossRef] [Google Scholar]Chauhan V.; Ji L.; Chauhan A.\nAnti-amyloidogenic,\nanti-oxidant and anti-apoptotic role of gelsolin in Alzheimer\u2019s\ndisease. Biogerontology\n2008, 9, 381\u2013389. 10.1007/s10522-008-9169-z. [PubMed] [CrossRef] [Google Scholar]Seki T.; Kanagawa M.; Kobayashi K.; Kowa H.; Yahata N.; Maruyama K.; Iwata N.; Inoue H.; Toda T.\nGalectin 3-binding protein suppresses\namyloid-\u03b2 production by modulating \u03b2-cleavage of amyloid\nprecursor protein. J. Biol. Chem.\n2020, 295, 3678\u20133691. 10.1074/jbc.ra119.008703. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Kamphuis W.; Kooijman L.; Orre M.; Stassen O.; Pekny M.; Hol E. M.\nGFAP and vimentin deficiency alters\ngene expression in astrocytes and microglia in wild-type mice and\nchanges the transcriptional response of reactive glia in mouse model\nfor Alzheimer\u2019s disease. Glia\n2015, 63, 1036\u20131056. 10.1002/glia.22800. [PubMed] [CrossRef] [Google Scholar]Eitzen G.; Will E.; Gallwitz D.; Haas A.; Wickner W.\nSequential action of two GTPases to promote vacuole\ndocking and fusion. EMBO J.\n2000, 19, 6713\u20136720. 10.1093/emboj/19.24.6713. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Garrett M. D.; Zahner J. E.; Cheney C. M.; Novick P. J.\nGDI1 encodes\na GDP dissociation inhibitor that plays an essential role in the yeast\nsecretory pathway. EMBO J.\n1994, 13, 1718\u20131728. 10.1002/j.1460-2075.1994.tb06436.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Owen J. B.; Di Domenico F.; Sultana R.; Perluigi M.; Cini C.; Pierce W. M.; Butterfield D. A.\nProteomics-determined\ndifferences in the concanavalin-A-fractionated proteome of hippocampus\nand inferior parietal lobule in subjects with Alzheimer\u2019s disease\nand mild cognitive impairment: implications for progression of AD. J. Proteome Res.\n2009, 8, 471\u2013482. 10.1021/pr800667a. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Scheper W.; Zwart R.; van der\nSluijs P.; Annaert W.; Gool W. A.; Baas F.\nAlzheimer\u2019s\npresenilin 1 is a putative membrane receptor for rab GDP dissociation\ninhibitor. Hum. Mol. Genet.\n2000, 9, 303\u2013310. 10.1093/hmg/9.2.303. [PubMed] [CrossRef] [Google Scholar]Lackie R. E.; Maciejewski A.; Ostapchenko V. G.; Marques-Lopes J.; Choy W. Y.; Duennwald M. L.; Prado V. F.; Prado M. A. M.\nThe Hsp70/Hsp90 Chaperone Machinery\nin Neurodegenerative Diseases. Front. Neurosci.\n2017, 11, 254.10.3389/fnins.2017.00254. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Schmid A. B.; Lagleder S.; Gr\u00e4wert M. A.; R\u00f6hl A.; Hagn F.; Wandinger S. K.; Cox M. B.; Demmer O.; Richter K.; Groll M.; Kessler H.; Buchner J.\nThe architecture of functional modules\nin the Hsp90 co-chaperone Sti1/Hop. EMBO J.\n2012, 31, 1506\u20131517. 10.1038/emboj.2011.472. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Maciejewski A.; Ostapchenko V. G.; Beraldo F. H.; Prado V. F.; Prado M. A. M.; Choy W.-Y.\nDomains of STIP1 responsible for\nregulating PrPC-dependent amyloid-\u03b2 oligomer toxicity. Biochem. J.\n2016, 473, 2119\u20132130. 10.1042/bcj20160087. [PubMed] [CrossRef] [Google Scholar]Chapman G.; Shanmugalingam U.; Smith P. D.\nThe Role of Neuronal\nPentraxin 2 (NP2) in Regulating Glutamatergic Signaling and Neuropathology. Front. Cell. Neurosci.\n2020, 13, 575.10.3389/fncel.2019.00575. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Lee S.-J.; Wei M.; Zhang C.; Maxeiner S.; Pak C.; Calado Botelho S.; Trotter J.; Sterky F. H.; S\u00fcdhof T. C.\nPresynaptic\nNeuronal Pentraxin Receptor Organizes Excitatory\nand Inhibitory Synapses. J. Neurosci.\n2017, 37, 1062\u20131080. 10.1523/jneurosci.2768-16.2016. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Bjartmar L.; Huberman A. D.; Ullian E. M.; Renter\u00eda R. C.; Liu X.; Xu W.; Prezioso J.; Susman M. W.; Stellwagen D.; Stokes C. C.; Cho R.; Worley P.; Malenka R. C.; Ball S.; Peachey N. S.; Copenhagen D.; Chapman B.; Nakamoto M.; Barres B. A.; Perin M. S.\nNeuronal\npentraxins mediate synaptic refinement in the developing visual system. J. Neurosci.\n2006, 26, 6269\u20136281. 10.1523/jneurosci.4212-05.2006. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Swanson A.; Wolf T.; Sitzmann A.; Willette A. A.\nNeuroinflammation\nin Alzheimer\u2019s disease: Pleiotropic roles for cytokines and\nneuronal pentraxins. Behav. Brain Res.\n2018, 347, 49\u201356. 10.1016/j.bbr.2018.02.015. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Xiao M. F.; Xu D.; Craig M. T.; Pelkey K. A.; Chien C. C.; Shi Y.; Zhang J.; Resnick S.; Pletnikova O.; Salmon D.; Brewer J.; Edland S.; Wegiel J.; Tycko B.; Savonenko A.; Reeves R. H.; Troncoso J. C.; McBain C. J.; Galasko D.; Worley P. F.\nNPTX2 and cognitive dysfunction in Alzheimer\u2019s\nDisease. Elife\n2017, 6, e2379810.7554/eLife.23798. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Wang Z.; Zhang H.; Cheng Q.\nPDIA4: The basic characteristics,\nfunctions and its potential connection with cancer. Biomed. Pharmacother.\n2020, 122, 109688.10.1016/j.biopha.2019.109688. [PubMed] [CrossRef] [Google Scholar]Schwaller M.; Wilkinson B.; Gilbert H. F.\nReduction-reoxidation\ncycles contribute to catalysis of disulfide isomeriza,tion by protein-disulfide\nisomerase. J. Biol. Chem.\n2003, 278, 7154\u20137159. 10.1074/jbc.m211036200. [PubMed] [CrossRef] [Google Scholar]Fujiwara K.; Tilney L. G.\nSubstructural analysis of the microtubule\nand its polymorphic forms. Ann. N.Y. Acad. Sci.\n1975, 253, 27\u201350. 10.1111/j.1749-6632.1975.tb19190.x. [PubMed] [CrossRef] [Google Scholar]Wawro M. E.; Sobierajska K.; Ciszewski W. M.; Wagner W.; Frontczak M.; Wieczorek K.; Niewiarowska J.\nTubulin beta 3 and 4 are involved\nin the generation\nof early fibrotic stages. Cell. Signalling\n2017, 38, 26\u201338. 10.1016/j.cellsig.2017.06.014. [PubMed] [CrossRef] [Google Scholar]Wang C. H.; Su P. T.; Du X. Y.; Kuo M. W.; Lin C. Y.; Yang C. C.; Chan H. S.; Chang S. J.; Kuo C.; Seo K.; Leung L. L.; Chuang Y. J.\nThrombospondin type\nI domain containing 7A (THSD7A) mediates endothelial cell migration\nand tube formation. J. Cell. Physiol.\n2010, 222, 685\u2013694. 10.1002/jcp.21990. [PubMed] [CrossRef] [Google Scholar]Adams J. C.\nThrombospondin-1. Int. J. Biochem.\nCell Biol.\n1997, 29, 861\u2013865. 10.1016/s1357-2725(96)00171-9. [PubMed] [CrossRef] [Google Scholar]Rao K. V. R.; Curtis K. M.; Johnstone J. T.; Norenberg M. D.\nAmyloid-\u03b2 inhibits thrombospondin 1 release from\ncultured astrocytes: effects on synaptic protein expression. J. Neuropathol. Exp. Neurol.\n2013, 72, 735\u2013744. 10.1097/nen.0b013e31829bd082. [PubMed] [CrossRef] [Google Scholar]Kim D. H.; Lim H.; Lee D.; Choi S. J.; Oh W.; Yang Y. S.; Oh J. S.; Hwang H. H.; Jeon H. B.\nThrombospondin-1\nsecreted by human umbilical cord blood-derived mesenchymal stem cells\nrescues neurons from synaptic dysfunction in Alzheimer\u2019s disease\nmodel. Sci. Rep.\n2018, 8, 354.10.1038/s41598-017-18542-0. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Borth W.\nAlpha 2-macroglobulin, a multifunctional\nbinding protein with targeting\ncharacteristics. FASEB J.\n1992, 6, 3345\u20133353. 10.1096/fasebj.6.15.1281457. [PubMed] [CrossRef] [Google Scholar]Borth W.\nAlpha 2-macroglobulin. A multifunctional binding and\ntargeting protein\nwith possible roles in immunity and autoimmunity. Ann. N.Y. Acad. Sci.\n1994, 737, 267\u2013272. 10.1111/j.1749-6632.1994.tb44317.x. [PubMed] [CrossRef] [Google Scholar]Zhang X.; Liu J.; Liang X.; Chen J.; Hong J.; Li L.; He Q.; Cai X.\nHistory and\nprogression of Fat cadherins in health and disease. OncoTargets Ther.\n2016, 9, 7337\u20137343. 10.2147/ott.s111176. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Katoh M.\nFunction and\ncancer genomics of FAT family genes (review). Int. J. Oncol.\n2012, 41, 1913\u20131918. 10.3892/ijo.2012.1669. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Arlaud G. J.; Gaboriaud C.; Thielens N. M.; Rossi V.; Bersch B.; Hernandez J.-F.; Fontecilla-Camps J. C.\nStructural\nbiology of C1: dissection of a complex molecular machinery. Immunol. Rev.\n2001, 180, 136\u2013145. 10.1034/j.1600-065x.2001.1800112.x. [PubMed] [CrossRef] [Google Scholar]Arlaud G.; Gaboriaud C.; Garnier G.; Circolo A.; Thielens N. M.; Budayova-Spano M.; Fontecilla-Camps J. C.; Volanakis J. E.\nStructure, function and molecular\ngenetics of human\nand murine C1r. Immunobiology\n2002, 205, 365\u2013382. 10.1078/0171-2985-00139. [PubMed] [CrossRef] [Google Scholar]Yasojima K.; Schwab C.; McGeer E. G.; McGeer P. L.\nUp-regulated\nproduction and activation of the complement system in Alzheimer\u2019s\ndisease brain. Am. J. Pathol.\n1999, 154, 927\u2013936. 10.1016/s0002-9440(10)65340-0. [PMC free article] [PubMed] [CrossRef] [Google Scholar]V\u00e1zquez-Villa F.; Garc\u00eda-Oca\u00f1a M.; Galv\u00e1n J. A.; Garc\u00eda-Mart\u00ednez J.; Garc\u00eda-Pravia C.; Men\u00e9ndez-Rodr\u00edguez P.; Gonz\u00e1lez-del Rey C.; Barneo-Serra L.; de Los Toyos J. R.\nCOL11A1/(pro)collagen 11A1 expression\nis a remarkable biomarker of human invasive carcinoma-associated stromal\ncells and carcinoma progression. Tumor Biol.\n2015, 36, 2213\u20132222. 10.1007/s13277-015-3295-4. [PubMed] [CrossRef] [Google Scholar]Yoshioka H.; Greenwel P.; Inoguchi K.; Truter S.; Inagaki Y.; Ninomiya Y.; Ramirez F.\nStructural\nand functional\nanalysis of the promoter of the human alpha 1(XI) collagen gene. J. Biol. Chem.\n1995, 270, 418\u2013424. 10.1074/jbc.270.1.418. [PubMed] [CrossRef] [Google Scholar]Gao H.; Tao Y.; He Q.; Song F.; Saffen D.\nFunctional\nenrichment analysis of three Alzheimer\u2019s disease genome-wide\nassociation studies identities DAB1 as a novel candidate liability/protective\ngene. Biochem. Biophys. Res. Commun.\n2015, 463, 490\u2013495. 10.1016/j.bbrc.2015.05.044. [PubMed] [CrossRef] [Google Scholar]Gough R. E.; Goult B. T.\nThe tale of two\ntalins - two isoforms\nto fine-tune integrin signalling. FEBS Lett.\n2018, 592, 2108\u20132125. 10.1002/1873-3468.13081. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Ullrich A.; Sures I.; D\u2019Egidio M.; Jallal B.; Powell T. J.; Herbst R.; Dreps A.; Azam M.; Rubinstein M.; Natoli C.; et al. The secreted\ntumor-associated antigen 90K is a potent immune stimulator. J. Biol. Chem.\n1994, 269, 18401\u201318407. 10.1016/s0021-9258(17)32322-0. [PubMed] [CrossRef] [Google Scholar]Tinari N.; Kuwabara I.; Huflejt M. E.; Shen P. F.; Iacobelli S.; Liu F.-T.\nGlycoprotein 90K/MAC-2BP interacts\nwith galectin-1 and mediates galectin-1-induced cell aggregation. Int. J. Cancer\n2001, 91, 167\u2013172. 10.1002/1097-0215(200002)9999:9999<::aid-ijc1022>3.0.co;2-z. [PubMed] [CrossRef] [Google Scholar]De Cat B.; David G.\nDevelopmental roles\nof the glypicans. Semin. Cell Dev. Biol.\n2001, 12, 117\u2013125. 10.1006/scdb.2000.0240. [PubMed] [CrossRef] [Google Scholar]Filmus J.; Capurro M.; Rast J.\nGlypicans. Genome Biol.\n2008, 9, 224.10.1186/gb-2008-9-5-224. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Wang T.; Xu S.-F.; Fan Y.-G.; Li L.-B.; Guo C.\nIron Pathophysiology in Alzheimer\u2019s\nDiseases. Adv. Exp. Med. Biol.\n2019, 1173, 67\u2013104. 10.1007/978-981-13-9589-5_5. [PubMed] [CrossRef] [Google Scholar]Crichton R. R.; Charloteaux-Wauters M.\nIron transport\nand storage. Eur. J. Biochem.\n1987, 164, 485\u2013506. 10.1111/j.1432-1033.1987.tb11155.x. [PubMed] [CrossRef] [Google Scholar]Wang T.; Xu S.-F.; Fan Y.-G.; Li L.-B.; Guo C.\nIron Pathophysiology in Alzheimer\u2019s\nDiseases. Adv. Exp. Med. Biol.\n2019, 1173, 67\u2013104. 10.1007/978-981-13-9589-5_5. [PubMed] [CrossRef] [Google Scholar]Cahill C. M.; Lahiri D. K.; Huang X.; Rogers J. T.\nAmyloid\nprecursor protein and alpha synuclein translation, implications for\niron and inflammation in neurodegenerative diseases. Biochim. Biophys. Acta\n2009, 1790, 615\u2013628. 10.1016/j.bbagen.2008.12.001. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Twyffels L.; Gueydan C.; Kruys V.\nTransportin-1\nand Transportin-2:\nprotein nuclear import and beyond. FEBS Lett.\n2014, 588, 1857\u20131868. 10.1016/j.febslet.2014.04.023. [PubMed] [CrossRef] [Google Scholar]Wilson K. L.\nNuclear import pathway key to rescuing\ndominant progerin\nphenotypes. Sci. Signaling\n2018, 11, eaat944810.1126/scisignal.aat9448. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Wang Z.; Qiu H.; He J.; Liu L.; Xue W.; Fox A.; Tickner J.; Xu J.\nThe emerging roles\nof hnRNPK. J. Cell. Physiol.\n2020, 235, 1995\u20132008. 10.1002/jcp.29186. [PubMed] [CrossRef] [Google Scholar]Xu Y.; Wu W.; Han Q.; Wang Y.; Li C.; Zhang P.; Xu H.\nNew Insights into the Interplay between\nnon-coding RNAs and RNA-binding protein HnRNPK in regulating cellular\nfunctions. Cells\n2019, 8, 62.10.3390/cells8010062. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Kwiatkowski D. J.\nFunctions of gelsolin: motility,\nsignaling, apoptosis,\ncancer. Curr. Opin. Cell Biol.\n1999, 11, 103\u2013108. 10.1016/s0955-0674(99)80012-x. [PubMed] [CrossRef] [Google Scholar]Yin H. L.\nGelsolin: calcium- and polyphosphoinositide-regulated\nactin-modulating protein. Bioessays\n1987, 7, 176\u2013179. 10.1002/bies.950070409. [PubMed] [CrossRef] [Google Scholar]Orphanides G.; Wu W.-H.; Lane W. S.; Hampsey M.; Reinberg D.\nThe chromatin-specific transcription elongation factor\nFACT comprises human SPT16 and SSRP1 proteins. Nature\n1999, 400, 284\u2013288. 10.1038/22350. [PubMed] [CrossRef] [Google Scholar]Keller D. M.; Zeng X.; Wang Y.; Zhang Q. H.; Kapoor M.; Shu H.; Goodman R.; Lozano G.; Zhao Y.; Lu H.\nA DNA damage-induced\np53 serine 392\nkinase complex contains CK2, hSpt16, and SSRP1. Mol. Cell\n2001, 7, 283\u2013292. 10.1016/s1097-2765(01)00176-9. [PubMed] [CrossRef] [Google Scholar]Lopez-Alemany R.; Suelves M.; Diaz-Ramos A.; Vidal B.; Munoz-Canoves P.\nAlpha-enolase plasminogen receptor\nin myogenesis. Front. Biosci.\n2005, 10, 30\u201336. 10.2741/1503. [PubMed] [CrossRef] [Google Scholar]Ji H.; Wang J.; Guo J.; Li Y.; Lian S.; Guo W.; Yang H.; Kong F.; Zhen L.; Guo L.; Liu Y.\nProgress in the biological function of alpha-enolase. Anim. Nutr.\n2016, 2, 12\u201317. 10.1016/j.aninu.2016.02.005. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Butterfield D. A.; Poon H. F.; St. Clair D.; Keller J. N.; Pierce W. M.; Klein J. B.; Markesbery W. R.\nRedox proteomics\nidentification of oxidatively modified hippocampal proteins in mild\ncognitive impairment: insights into the development of Alzheimer\u2019s\ndisease. Neurobiol. Dis.\n2006, 22, 223\u2013232. 10.1016/j.nbd.2005.11.002. [PubMed] [CrossRef] [Google Scholar]Zeng C.; Xing W.; Liu Y.\nIdentification of UGP2\nas a progression marker that promotes cell growth and motility in\nhuman glioma. J. Cell. Biochem.\n2019, 120, 12489\u201312499. 10.1002/jcb.28515. [PubMed] [CrossRef] [Google Scholar]Perenthaler E.; Nikoncuk A.; Yousefi S.; Berdowski W. M.; Alsagob M.; Capo I.; van der Linde H. C.; van den Berg P.; Jacobs E. H.; Putar D.; et al. Loss of\nUGP2 in brain leads to a severe epileptic encephalopathy, emphasizing\nthat bi-allelic isoform-specific start-loss mutations of essential\ngenes can cause genetic diseases. Acta Neuropathol.\n2020, 139, 415\u2013442. 10.1007/s00401-019-02109-6. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Slavotinek A. M.\nEye development genes and known syndromes. Mol. Genet. Metab.\n2011, 104, 448\u2013456. 10.1016/j.ymgme.2011.09.029. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Makridakis M.; Roubelakis M. G.; Vlahou A.\nStem cells: insights\ninto the secretome. Biochim. Biophys. Acta\n2013, 1834, 2380\u20132384. 10.1016/j.bbapap.2013.01.032. [PubMed] [CrossRef] [Google Scholar]Della Noce I.; Carra S.; Brusegan C.; Critelli R.; Frassine A.; De Lorenzo C.; Giordano A.; Bellipanni G.; Villa E.; Cotelli F.; Pistocchi A.; Schepis F.\nThe Coiled-Coil Domain Containing\n80 (ccdc80) gene\nregulates gadd45\u03b22 expression in the developing somites of zebrafish\nas a new player of the hedgehog pathway. J.\nCell. Physiol.\n2015, 230, 821\u2013830. 10.1002/jcp.24810. [PubMed] [CrossRef] [Google Scholar]Fansa E. K.; Wittinghofer A.\nSorting of\nlipidated cargo by the\nArl2/Arl3 system. Small GTPases\n2016, 7, 222\u2013230. 10.1080/21541248.2016.1224454. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Graham T. R.\nMembrane targeting: getting Arl to the Golgi. Curr. Biol.\n2004, 14, R483\u2013R485. 10.1016/j.cub.2004.06.017. [PubMed] [CrossRef] [Google Scholar]Llorca O.; McCormack E. A.; Hynes G.; Grantham J.; Cordell J.; Carrascosa J. L.; Willison K. R.; Fernandez J. J.; Valpuesta J. M.\nEukaryotic\ntype II chaperonin CCT interacts with actin\nthrough specific subunits. Nature\n1999, 402, 693\u2013696. 10.1038/45294. [PubMed] [CrossRef] [Google Scholar]Pavel M.; Imarisio S.; Menzies F. M.; Jimenez-Sanchez M.; Siddiqi F. H.; Wu X.; Renna M.; O\u2019Kane C. J.; Crowther D. C.; Rubinsztein D. C.\nCCT complex restricts neuropathogenic\nprotein aggregation via autophagy. Nat. Commun.\n2016, 7, 13821.10.1038/ncomms13821. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Fujibuchi T.; Abe Y.; Takeuchi T.; Imai Y.; Kamei Y.; Murase R.; Ueda N.; Shigemoto K.; Yamamoto H.; Kito K.\nAIP1/WDR1 supports mitotic cell rounding. Biochem. Biophys. Res. Commun.\n2005, 327, 268\u2013275. 10.1016/j.bbrc.2004.11.156. [PubMed] [CrossRef] [Google Scholar]Kato A.; Kurita S.; Hayashi A.; Kaji N.; Ohashi K.; Mizuno K.\nCritical roles of actin-interacting\nprotein 1 in cytokinesis and chemotactic migration of mammalian cells. Biochem. J.\n2008, 414, 261\u2013270. 10.1042/bj20071655. [PubMed] [CrossRef] [Google Scholar]Hammond G. L.; Bocchinfuso W. P.\nSex hormone-binding\nglobulin: gene\norganization and structure/function analyses. Horm. Res.\n1996, 45, 197\u2013201. 10.1159/000184787. [PubMed] [CrossRef] [Google Scholar]Caldwell J.; Jirikowski G.\nSex hormone\nbinding globulin and\naging. Horm. Metab. Res.\n2009, 41, 173\u2013182. 10.1055/s-0028-1093351. [PubMed] [CrossRef] [Google Scholar]Holland J.; Bandelow S.; Hogervorst E.\nTestosterone\nlevels and cognition in elderly men: a review. Maturitas\n2011, 69, 322\u2013337. 10.1016/j.maturitas.2011.05.012. [PubMed] [CrossRef] [Google Scholar]Huang C. Y.-M.; Zhang C.; Ho T. S.-Y.; Oses-Prieto J.; Burlingame A. L.; Lalonde J.; Noebels J. L.; Leterrier C.; Rasband M. N.\n\u03b1II Spectrin Forms a Periodic\nCytoskeleton at\nthe Axon Initial Segment and Is Required for Nervous System Function. J. Neurosci.\n2017, 37, 11311\u201311322. 10.1523/jneurosci.2112-17.2017. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Ackermann A.; Brieger A.\nThe Role of Nonerythroid\nSpectrin\n\u03b1II in Cancer. J. Oncol.\n2019, 2019, 7079604.10.1155/2019/7079604. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Nakamura F.; Kumeta K.; Hida T.; Isono T.; Nakayama Y.; Kuramata-Matsuoka E.; Yamashita N.; Uchida Y.; Ogura K.; Gengyo-Ando K.; Mitani S.; Ogino T.; Goshima Y.\nAmino- and carboxyl-terminal\ndomains of Filamin-A interact with CRMP1 to mediate Sema3A signalling. Nat. Commun.\n2014, 5, 5325.10.1038/ncomms6325. [PubMed] [CrossRef] [Google Scholar]Yamashita N.; Goshima Y.\nCollapsin response\nmediator proteins\nregulate neuronal development and plasticity by switching their phosphorylation\nstatus. Mol. Neurobiol.\n2012, 45, 234\u2013246. 10.1007/s12035-012-8242-4. [PubMed] [CrossRef] [Google Scholar]Hooli B. V.; Kovacs-Vajna Z. M.; Mullin K.; Blumenthal M. A.; Mattheisen M.; Zhang C.; Lange C.; Mohapatra G.; Bertram L.; Tanzi R. E.\nRare autosomal copy number variations\nin early-onset familial Alzheimer\u2019s disease. Mol. Psychiatry\n2014, 19, 676\u2013681. 10.1038/mp.2013.77. [PubMed] [CrossRef] [Google Scholar]Bradshaw N. J.; Korth C.\nProtein misassembly\nand aggregation\nas potential convergence points for non-genetic causes of chronic\nmental illness. Mol. Psychiatry\n2019, 24, 936\u2013951. 10.1038/s41380-018-0133-2. [PubMed] [CrossRef] [Google Scholar]Ray A.; Treloar H. B.\nIgSF8: a developmentally and functionally\nregulated\ncell adhesion molecule in olfactory sensory neuron axons and synapses. Mol. Cell. Neurosci.\n2012, 50, 238\u2013249. 10.1016/j.mcn.2012.05.007. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Murdoch J. N.; Doudney K.; Gerrelli D.; Wortham N.; Paternotte C.; Stanier P.; Copp A. J.\nGenomic\norganization\nand embryonic expression of Igsf8, an immunoglobulin superfamily member\nimplicated in development of the nervous system and organ epithelia. Mol. Cell. Neurosci.\n2003, 22, 62\u201374. 10.1016/s1044-7431(02)00021-0. [PubMed] [CrossRef] [Google Scholar]Lo A. S.-Y.; Liew C.-T.; Ngai S.-M.; Tsui S. K.-W.; Fung K.-P.; Lee C.-Y.; Waye M. M.-Y.\nDevelopmental\nregulation and cellular distribution of human cytosolic malate dehydrogenase\n(MDH1). J. Cell. Biochem.\n2005, 94, 763\u2013773. 10.1002/jcb.20343. [PubMed] [CrossRef] [Google Scholar]Lee S.-M.; Dho S. H.; Ju S.-K.; Maeng J.-S.; Kim J.-Y.; Kwon K.-S.\nCytosolic malate dehydrogenase regulates\nsenescence in human fibroblasts. Biogerontology\n2012, 13, 525\u2013536. 10.1007/s10522-012-9397-0. [PubMed] [CrossRef] [Google Scholar]Mullarky E.; Mattaini K. R.; Vander\nHeiden M. G.; Cantley L. C.; Locasale J. W.\nPHGDH amplification\nand altered glucose\nmetabolism in human melanoma. Pigm. Cell Melanoma\nRes.\n2011, 24, 1112\u20131115. 10.1111/j.1755-148x.2011.00919.x. [PubMed] [CrossRef] [Google Scholar]Zhao X.; Fu J.; Du J.; Xu W.\nThe Role of\nD-3-Phosphoglycerate Dehydrogenase in Cancer. Int. J. Biol. Sci.\n2020, 16, 1495\u20131506. 10.7150/ijbs.41051. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Yan Z.; Zhou Z.; Wu Q.; Chen Z. B.; Koo E. H.; Zhong S.\nPresymptomatic Increase\nof an Extracellular RNA in Blood Plasma Associates\nwith the Development of Alzheimer\u2019s Disease. Curr. Biol.\n2020, 30, 1771\u20131782.e3. 10.1016/j.cub.2020.02.084. [PubMed] [CrossRef] [Google Scholar]Chaudhuri J.; Chakrabarti A.; Maitra U.\nBiochemical characterization\nof mammalian translation initiation factor 3 (eIF3). Molecular cloning\nreveals that p110 subunit is the mammalian homologue of Saccharomyces\ncerevisiae protein Prt1. J. Biol. Chem.\n1997, 272, 30975\u201330983. 10.1074/jbc.272.49.30975. [PubMed] [CrossRef] [Google Scholar]Feng X.; Li J.; Liu P.\nThe Biological Roles\nof Translation Initiation Factor 3b. Int. J.\nBiol. Sci.\n2018, 14, 1630\u20131635. 10.7150/ijbs.26932. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Baumk\u00f6tter F.; Schmidt N.; Vargas C.; Schilling S.; Weber R.; Wagner K.; Fiedler S.; Klug W.; Radzimanowski J.; Nickolaus S.; Keller S.; Eggert S.; Wild K.; Kins S.\nAmyloid precursor\nprotein dimerization\nand synaptogenic function depend on copper binding to the growth factor-like\ndomain. J. Neurosci.\n2014, 34, 11159\u201311172. 10.1523/jneurosci.0180-14.2014. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Nguyen K. V.\n\u03b2-Amyloid precursor protein\n(APP) and the human\ndiseases. AIMS Neurosci.\n2019, 6, 273\u2013281. 10.3934/Neuroscience.2019.4.273. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Haass C.; Kaether C.; Thinakaran G.; Sisodia S.\nTrafficking and proteolytic processing of APP. Cold Spring Harbor Perspect. Med.\n2012, 2, a006270.10.1101/cshperspect.a006270. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Lott I.; Head E.; Doran E.; Busciglio J.\nBeta-amyloid,\noxidative stress and down syndrome. Curr. Alzheimer\nRes.\n2006, 3, 521\u2013528. 10.2174/156720506779025305. [PubMed] [CrossRef] [Google Scholar]Lu J.; Stewart A. J.; Sadler P. J.; Pinheiro T. J.; Blindauer C. A.\nAlbumin\nas a zinc carrier: properties of its high-affinity zinc-binding site. Biochem. Soc. Trans.\n2008, 36, 1317\u20131321. 10.1042/BST0361317. [PubMed] [CrossRef] [Google Scholar]Erickson M. A.; Banks W. A.\nBlood-brain barrier dysfunction as\na cause and consequence of Alzheimer\u2019s disease. J. Cereb. Blood Flow Metab.\n2013, 33, 1500\u20131513. 10.1038/jcbfm.2013.135. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Lazarides E.\nIntermediate filaments: a chemically heterogeneous,\ndevelopmentally regulated class of proteins. Annu. Rev. Biochem.\n1982, 51, 219\u2013250. 10.1146/annurev.bi.51.070182.001251. [PubMed] [CrossRef] [Google Scholar]Steinert P. M.; Jones J. C.; Goldman R. D.\nIntermediate\nfilaments. J. Cell Biol.\n1984, 99, 22s\u201327s. 10.1083/jcb.99.1.22s. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Nicholls C.; Li H.; Liu J. P.\nGAPDH: a common\nenzyme with uncommon functions. Clin. Exp. Pharmacol.\nPhysiol.\n2012, 39, 674\u2013679. 10.1111/j.1440-1681.2011.05599.x. [PubMed] [CrossRef] [Google Scholar]Seidler N. W.\nBasic biology of GAPDH. Adv.\nExp. Med. Biol.\n2013, 985, 1\u201336. 10.1007/978-94-007-4716-6_1. [PubMed] [CrossRef] [Google Scholar]Tong Y.; Hota P. K.; Penachioni J. Y.; Hamaneh M. B.; Kim S.; Alviani R. S.; Shen L.; He H.; Tempel W.; Tamagnone L.; Park H.-W.; Buck M.\nStructure\nand function of the intracellular region of the plexin-b1 transmembrane\nreceptor. J. Biol. Chem.\n2009, 284, 35962\u201335972. 10.1074/jbc.m109.056275. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Janssen B. J. C.; Robinson R. A.; P\u00e9rez-Brangul\u00ed F.; Bell C. H.; Mitchell K. J.; Siebold C.; Jones E. Y.\nStructural\nbasis of semaphorin-plexin signalling. Nature\n2010, 467, 1118\u20131122. 10.1038/nature09468. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Kannabiran C.; Klintworth G. K.\nTGFBI gene mutations in corneal dystrophies. Hum. Mutat.\n2006, 27, 615\u2013625. 10.1002/humu.20334. [PubMed] [CrossRef] [Google Scholar]Karring H.; Runager K.; Valnickova Z.; Th\u00f8gersen I. B.; M\u00f8ller-Pedersen T.; Klintworth G. K.; Enghild J. J.\nDifferential expression and processing of transforming\ngrowth factor beta induced protein (TGFBIp) in the normal human cornea\nduring postnatal development and aging. Exp.\nEye Res.\n2010, 90, 57\u201362. 10.1016/j.exer.2009.09.011. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Skidgel R. A.; Erd\u00f6s E. G.\nCellular\ncarboxypeptidases. Immunol. Rev.\n1998, 161, 129\u2013141. 10.1111/j.1600-065x.1998.tb01577.x. [PubMed] [CrossRef] [Google Scholar]Diano S.\nNew aspects of melanocortin signaling:\na role for PRCP in \u03b1-MSH\ndegradation. Front. Neuroendocrinol.\n2011, 32, 70\u201383. 10.1016/j.yfrne.2010.09.001. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Maki M.; Kitaura Y.; Satoh H.; Ohkouchi S.; Shibata H.\nStructures, functions and molecular\nevolution of the\npenta-EF-hand Ca2+-binding proteins. Biochim.\nBiophys. Acta\n2002, 1600, 51\u201360. 10.1016/s1570-9639(02)00444-2. [PubMed] [CrossRef] [Google Scholar]Ursini-Siegel J.; Rajput A. B.; Lu H.; Sanguin-Gendreau V.; Zuo D.; Papavasiliou V.; Lavoie C.; Turpin J.; Cianflone K.; Huntsman D. G.; Muller W. J.\nElevated expression of DecR1 impairs\nErbB2/Neu-induced mammary tumor development. Mol. Cell. Biol.\n2007, 27, 6361\u20136371. 10.1128/mcb.00686-07. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Young C. D.; Anderson S. M.\nSugar and fat\u2014that\u2019s\nwhere it\u2019s at: metabolic changes in tumors. Breast Cancer Res.\n2008, 10, 202.10.1186/bcr1852. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Layne M. D.; Endege W. O.; Jain M. K.; Yet S.-F.; Hsieh C.-M.; Chin M. T.; Perrella M. A.; Blanar M. A.; Haber E.; Lee M.-E.\nAortic carboxypeptidase-like\nprotein,\na novel protein with discoidin and carboxypeptidase-like domains,\nis up-regulated during vascular smooth muscle cell differentiation. J. Biol. Chem.\n1998, 273, 15654\u201315660. 10.1074/jbc.273.25.15654. [PubMed] [CrossRef] [Google Scholar]Sorisky A.; Gagnon A.; Abaiian K.\nAortic carboxypeptidase-like\nprotein (ACLP): what is a protein with a name like that doing in adipose\ntissue?. Horm. Metab. Res.\n2002, 34, 764\u2013766. 10.1055/s-2002-38243. [PubMed] [CrossRef] [Google Scholar]Majdalawieh A.; Ro H. S.\nRegulation of IkappaBalpha function\nand NF-kappaB signaling: AEBP1 is a novel proinflammatory mediator\nin macrophages. Mediators Inflammation\n2010, 2010, 823821.10.1155/2010/823821. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Li P.; Zhang M.; Zou Y.; Sun Z.; Sun C.; Geng Z.; Xu W.; Wang D.\nInteraction of heat\nshock protein 90 B1 (Hsp90B1) with liposome reveals its potential\nrole in protection the integrity of lipid membranes. Int. J. Biol. Macromol.\n2018, 106, 1250\u20131257. 10.1016/j.ijbiomac.2017.08.121. [PubMed] [CrossRef] [Google Scholar]Zhang M.; Qian C.; Zheng Z.-G.; Qian F.; Wang Y.; Thu P. M.; Zhang X.; Zhou Y.; Tu L.; Liu Q.; Li H.-J.; Yang H.; Li P.; Xu X.\nJujuboside\nA promotes A\u03b2 clearance and ameliorates cognitive\ndeficiency in Alzheimer\u2019s disease through activating Axl/HSP90/PPAR\u03b3\npathway. Theranostics\n2018, 8, 4262\u20134278. 10.7150/thno.26164. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Liu Z.; Dai X.; Tao W.; Liu H.; Li H.; Yang C.; Zhang J.; Li X.; Chen Y.; Ma C.; Pei J.; Mao H.; Chen K.; Zhang Z.\nAPOE influences\nworking memory in non-demented elderly through an interaction with\nSPON1 rs2618516. Hum. Brain Mapp.\n2018, 39, 2859\u20132867. 10.1002/hbm.24045. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Ho A.; S\u00fcdhof T. C.\nBinding of F-spondin to amyloid-beta\nprecursor protein: a candidate amyloid-beta precursor protein ligand\nthat modulates amyloid-beta precursor protein cleavage. Proc. Natl. Acad. Sci. U.S.A.\n2004, 101, 2548\u20132553. 10.1073/pnas.0308655100. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Fraser P. E.; Yang D.-S.; Yu G.; L\u00e9vesque L.; Nishimura M.; Arawaka S.; Serpell L. C.; Rogaeva E.; St George-Hyslop P.\nPresenilin structure, function and role in Alzheimer\ndisease. Biochim. Biophys. Acta\n2000, 1502, 1\u201315. 10.1016/s0925-4439(00)00028-4. [PubMed] [CrossRef] [Google Scholar]Chen Y. Z.\nAPP induces neuronal apoptosis through APP-BP1-mediated\ndownregulation of beta-catenin. Apoptosis\n2004, 9, 415\u2013422. 10.1023/b:appt.0000031447.05354.9f. [PubMed] [CrossRef] [Google Scholar]Chiba K.; Araseki M.; Nozawa K.; Furukori K.; Araki Y.; Matsushima T.; Nakaya T.; Hata S.; Saito Y.; Uchida S.; Okada Y.; Nairn A. C.; Davis R. J.; Yamamoto T.; Kinjo M.; Taru H.; Suzuki T.\nQuantitative analysis\nof APP axonal transport in neurons:\nrole of JIP1 in enhanced APP anterograde transport. Mol. Biol. Cell\n2014, 25, 3569\u20133580. 10.1091/mbc.e14-06-1111. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Sun Q.-Y.; Schatten H.\nRole of NuMA in vertebrate cells:\nreview of an intriguing multi-functional protein. Front. Biosci.\n2006, 11, 1137\u20131146. 10.2741/1868. [PubMed] [CrossRef] [Google Scholar]Meuwissen M. E. C.; Halley D. J. J.; Smit L. S.; Lequin M. H.; Cobben J. M.; de Coo R.; van Harssel J.; Sallevelt S.; Woldringh G.; van der Knaap M. S.; de Vries L. S.; Mancini G. M. S.\nThe expanding phenotype of COL4A1\nand COL4A2 mutations: clinical data on 13 newly identified families\nand a review of the literature. Genet. Med.\n2015, 17, 843\u2013853. 10.1038/gim.2014.210. [PubMed] [CrossRef] [Google Scholar]Mathieu C.; de la Sierra-Gallay I.\nL.; Duval R.; Xu X.; Cocaign A.; L\u00e9ger T.; Woffendin G.; Camadro J.-M.; Etchebest C.; Haouz A.; Dupret J.-M.; Rodrigues-Lima F.\nInsights into brain glycogen metabolism: the structure\nof human brain glycogen phosphorylasse. J. Biol.\nChem.\n2016, 291, 18072\u201318083. 10.1074/jbc.m116.738898. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Newgard C. B.; Littman D. R.; van Genderen C.; Smith M.; Fletterick R. J.\nHuman brain glycogen phosphorylase.\nCloning, sequence analysis, chromosomal mapping, tissue expression,\nand comparison with the human liver and muscle isozymes. J. Biol. Chem.\n1988, 263, 3850\u20133857. 10.1016/s0021-9258(18)69003-9. [PubMed] [CrossRef] [Google Scholar]San Segundo-Acosta P.; Montero-Calle A.; Fuentes M.; R\u00e1bano A.; Villalba M.; Barderas R.\nIdentification of Alzheimer\u2019s\nDisease Autoantibodies and Their Target Biomarkers by Phage Microarrays. J. Proteome Res.\n2019, 18, 2940\u20132953. 10.1021/acs.jproteome.9b00258. [PubMed] [CrossRef] [Google Scholar]Feinstein Y.; Klar A.\nThe neuronal class 2 TSR proteins\nF-spondin and Mindin: a small family with divergent biological activities. Int. J. Biochem. Cell Biol.\n2004, 36, 975\u2013980. 10.1016/j.biocel.2004.01.002. [PubMed] [CrossRef] [Google Scholar]Adams J. C.; Tucker R. P.\nThe thrombospondin type 1 repeat\n(TSR) superfamily: diverse proteins with related roles in neuronal\ndevelopment. Dev. Dyn.\n2000, 218, 280\u2013299. 10.1002/(sici)1097-0177(200006)218:2<280::aid-dvdy4>3.0.co;2-0. [PubMed] [CrossRef] [Google Scholar]Ho A.; S\u00fcdhof T. C.\nBinding\nof F-spondin to amyloid-beta\nprecursor protein: a candidate amyloid-beta precursor protein ligand\nthat modulates amyloid-beta precursor protein cleavage. Proc. Natl. Acad. Sci. U.S.A.\n2004, 101, 2548\u20132553. 10.1073/pnas.0308655100. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Hoe H.-S.; Rebeck G. W.\nRegulated proteolysis of APP and\nApoE receptors. Mol. Neurobiol.\n2008, 37, 64\u201372. 10.1007/s12035-008-8017-0. [PubMed] [CrossRef] [Google Scholar]Bahmanyar S.; Kaplan D. D.; Deluca J. G.; Giddings T. H. Jr.; O\u2019Toole E. T.; Winey M.; Salmon E. D.; Casey P. J.; Nelson W. J.; Barth A. I. M.\n\u03b2-Catenin\nis a Nek2 substrate involved in centrosome separation. Genes Dev.\n2008, 22, 91\u2013105. 10.1101/gad.1596308. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Weiske J.; Albring K. F.; Huber O.\nThe tumor\nsuppressor\nFhit acts as a repressor of beta-catenin transcriptional activity. Proc. Natl. Acad. Sci. U.S.A.\n2007, 104, 20344\u201320349. 10.1073/pnas.0703664105. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Fuentealba R. A.; Farias G.; Scheu J.; Bronfman M.; Marzolo M. P.; Inestrosa N. C.\nSignal transduction during amyloid-beta-peptide\nneurotoxicity: role in Alzheimer disease. Brain\nRes. Rev.\n2004, 47, 275\u2013289. 10.1016/j.brainresrev.2004.07.018. [PubMed] [CrossRef] [Google Scholar]Chen Y. Z.\nAPP induces neuronal apoptosis through\nAPP-BP1-mediated\ndownregulation of beta-catenin. Apoptosis\n2004, 9, 415\u2013422. 10.1023/b:appt.0000031447.05354.9f. [PubMed] [CrossRef] [Google Scholar]Geroldi D.; Minoretti P.; Bianchi M.; Di Vito C.; Reino M.; Bertona M.; Emanuele E.\nGenetic association\nof alpha2-Heremans-Schmid glycoprotein polymorphism with late-onset\nAlzheimer\u2019s disease in Italians. Neurosci.\nLett.\n2005, 386, 176\u2013178. 10.1016/j.neulet.2005.06.014. [PubMed] [CrossRef] [Google Scholar]Splinter D.; Tanenbaum M. E.; Lindqvist A.; Jaarsma D.; Flotho A.; Yu K. L.; Grigoriev I.; Engelsma D.; Haasdijk E. D.; Keijzer N.; Demmers J.; Fornerod M.; Melchior F.; Hoogenraad C. C.; Medema R. H.; Akhmanova A.\nBicaudal D2, dynein, and kinesin-1\nassociate with nuclear pore complexes and regulate centrosome and\nnuclear positioning during mitotic entry. PLoS\nBiol.\n2010, 8, e100035010.1371/journal.pbio.1000350. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Kamal A.; Almenar-Queralt A.; LeBlanc J. F.; Roberts E. A.; Goldstein L. S. B.\nKinesin-mediated\naxonal transport of a membrane compartment\ncontaining beta-secretase and presenilin-1 requires APP. Nature\n2001, 414, 643\u2013648. 10.1038/414643a. [PubMed] [CrossRef] [Google Scholar]Zheng Y.; Tian S.; Peng X.; Yang J.; Fu Y.; Jiao Y.; Zhao J.; He J.; Hong T.\nKinesin-1\ninhibits the aggregation of amyloid-\u03b2 peptide as detected by\nfluorescence cross-correlation spectroscopy. FEBS Lett.\n2016, 590, 1028\u20131037. 10.1002/1873-3468.12137. [PubMed] [CrossRef] [Google Scholar]Huang J.; Gong Z.; Ghosal G.; Chen J.\nSOSS complexes\nparticipate in the maintenance of genomic stability. Mol. Cell\n2009, 35, 384\u2013393. 10.1016/j.molcel.2009.06.011. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Kuo Y.-C.; Shen Y.-R.; Chen H.-I.; Lin Y.-H.; Wang Y.-Y.; Chen Y.-R.; Wang C.-Y.; Kuo P.-L.\nSEPT12\norchestrates the formation of mammalian sperm annulus by organizing\ncore octameric complexes with other SEPT proteins. J. Cell Sci.\n2015, 128, 923\u2013934. 10.1242/jcs.158998. [PubMed] [CrossRef] [Google Scholar]Retzlaff M.; Stahl M.; Eberl H. C.; Lagleder S.; Beck J.; Kessler H.; Buchner J.\nHsp90 is regulated\nby a switch point in the C-terminal domain. EMBO Rep.\n2009, 10, 1147\u20131153. 10.1038/embor.2009.153. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Verma S.; Goyal S.; Jamal S.; Singh A.; Grover A.\nHsp90: Friends, clients and natural\nfoes. Biochimie\n2016, 127, 227\u2013240. 10.1016/j.biochi.2016.05.018. [PubMed] [CrossRef] [Google Scholar]Schaffer A. E.; Breuss M. W.; Caglayan A. O.; Al-Sanaa N.; Al-Abdulwahed H. Y.; Kaymak\u00e7alan H.; Y\u0131lmaz C.; Zaki M. S.; Rosti R. O.; Copeland B.; et al. Biallelic\nloss of human CTNNA2, encoding \u03b1N-catenin, leads to ARP2/3 complex\noveractivity and disordered cortical neuronal migration. Nat. Genet.\n2018, 50, 1093\u20131101. 10.1038/s41588-018-0166-0. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Cummings A. C.; Jiang L.; Velez Edwards D. R.; McCauley J. L.; Laux R.; McFarland L. L.; Fuzzell D.; Knebusch C.; Caywood L.; Reinhart-Mercer L.; Nations L.; Gilbert J. R.; Konidari I.; Tramontana M.; Cuccaro M. L.; Scott W. K.; Pericak-Vance M. A.; Haines J. L.\nGenome-wide association and linkage study in the Amish\ndetects a novel candidate late-onset Alzheimer disease gene. Ann. Hum. Genet.\n2012, 76, 342\u2013351. 10.1111/j.1469-1809.2012.00721.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Moseley A. E.; Lieske S. P.; Wetzel R. K.; James P. F.; He S.; Shelly D. A.; Paul R. J.; Boivin G. P.; Witte D. P.; Ramirez J. M.; Sweadner K. J.; Lingrel J. B.\nThe Na,K-ATPase\nalpha 2 isoform is expressed in neurons, and its absence disrupts\nneuronal activity in newborn mice. J. Biol.\nChem.\n2003, 278, 5317\u20135324. 10.1074/jbc.m211315200. [PubMed] [CrossRef] [Google Scholar]Sopko R.; McNeill H.\nThe skinny on Fat:\nan enormous cadherin\nthat regulates cell adhesion, tissue growth, and planar cell polarity. Curr. Opin. Cell Biol.\n2009, 21, 717\u2013723. 10.1016/j.ceb.2009.07.001. [PubMed] [CrossRef] [Google Scholar]Avil\u00e9s E. C.; Goodrich L. V.\nConfiguring a robust\nnervous system\nwith Fat cadherins. Semin. Cell Dev. Biol.\n2017, 69, 91\u2013101. 10.1016/j.semcdb.2017.06.001. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Crabos M.; Yamakado T.; Heizmann C. W.; Cerletti N.; B\u00fchler F. R.; Erne P.\nThe calcium binding\nprotein tropomyosin\nin human platelets and cardiac tissue: elevation in hypertensive cardiac\nhypertrophy. Eur. J. Clin. Invest.\n1991, 21, 472\u2013478. 10.1111/j.1365-2362.1991.tb01397.x. [PubMed] [CrossRef] [Google Scholar]Karsenty G.; Park R.-W.\nRegulation of type\nI collagen genes\nexpression. Int. Rev. Immunol.\n1995, 12, 177\u2013185. 10.3109/08830189509056711. [PubMed] [CrossRef] [Google Scholar]Kehrel B.\nPlatelet-collagen interactions. Semin. Thromb. Hemostasis\n1995, 21, 123\u2013129. 10.1055/s-2007-1000386. [PubMed] [CrossRef] [Google Scholar]Coulson E. J.; Barrett G. L.; Storey E.; Bartlett P. F.; Beyreuther K.; Masters C. L.\nDown-regulation\nof the amyloid protein\nprecursor of Alzheimer\u2019s disease by antisense oligonucleotides\nreduces neuronal adhesion to specific substrata. Brain Res.\n1997, 770, 72\u201380. 10.1016/s0006-8993(97)00757-9. [PubMed] [CrossRef] [Google Scholar]Yamagata M.; Weiner J. A.; Sanes J. R.\nSidekicks:\nsynaptic\nadhesion molecules that promote lamina-specific connectivity in the\nretina. Cell\n2002, 110, 649\u2013660. 10.1016/s0092-8674(02)00910-8. [PubMed] [CrossRef] [Google Scholar]Tang H.; Chang H.; Dong Y.; Guo L.; Shi X.; Wu Y.; Huang Y.; He Y.\nArchitecture of cell-cell\nadhesion mediated by sidekicks. Proc. Natl.\nAcad. Sci. U.S.A.\n2018, 115, 9246\u20139251. 10.1073/pnas.1801810115. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Ahel I.; Ahel D.; Matsusaka T.; Clark A. J.; Pines J.; Boulton S. J.; West S. C.\nPoly(ADP-ribose)-binding\nzinc finger motifs in DNA repair/checkpoint proteins. Nature\n2008, 451, 81\u201385. 10.1038/nature06420. [PubMed] [CrossRef] [Google Scholar]Reinemund J.; Seidel K.; Steckelings U. M.; Zaade D.; Klare S.; Rompe F.; Katerbaum M.; Schacherl J.; Li Y.; Menk M.; Schefe J. H.; Goldin-Lang P.; Szabo C.; Olah G.; Unger T.; Funke-Kaiser H.\nPoly(ADP-ribose) polymerase-1 (PARP-1) transcriptionally\nregulates angiotensin AT2 receptor (AT2R) and AT2R binding protein\n(ATBP) genes. Biochem. Pharmacol.\n2009, 77, 1795\u20131805. 10.1016/j.bcp.2009.02.025. [PubMed] [CrossRef] [Google Scholar]Martire S.; Mosca L.; d\u2019Erme M.\nPARP-1 involvement\nin neurodegeneration: A focus on Alzheimer\u2019s and Parkinson\u2019s\ndiseases. Mech. Ageing Dev.\n2015, 146\u2013148, 53\u201364. 10.1016/j.mad.2015.04.001. [PubMed] [CrossRef] [Google Scholar]Zeng J.; Libien J.; Shaik F.; Wolk J.; Hern\u00e1ndez A. I.\nNucleolar PARP-1 Expression Is Decreased in Alzheimer\u2019s\nDisease: Consequences for Epigenetic Regulation of rDNA and Cognition. Neural Plast.\n2016, 2016, 8987928.10.1155/2016/8987928. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Vafadar-Isfahani B.; Ball G.; Coveney C.; Lemetre C.; Boocock D.; Minthon L.; Hansson O.; Miles A. K.; Janciauskiene S. M.; Warden D.; Smith A. D.; Wilcock G.; Kalsheker N.; Rees R.; Matharoo-Ball B.; Morgan K.\nIdentification of SPARC-like 1 protein as part of a\nbiomarker panel for Alzheimer\u2019s disease in cerebrospinal fluid. J. Alzheimer\u2019s Dis.\n2012, 28, 625\u2013636. 10.3233/jad-2011-111505. [PubMed] [CrossRef] [Google Scholar]Levy-Rimler G.; Viitanen P.; Weiss C.; Sharkia R.; Greenberg A.; Niv A.; Lustig A.; Delarea Y.; Azem A.\nThe effect of nucleotides and mitochondrial chaperonin 10 on the\nstructure and chaperone activity of mitochondrial chaperonin 60. Eur. J. Biochem.\n2001, 268, 3465\u20133472. 10.1046/j.1432-1327.2001.02243.x. [PubMed] [CrossRef] [Google Scholar]Walls K. C.; Coskun P.; Gallegos-Perez J. L.; Zadourian N.; Freude K.; Rasool S.; Blurton-Jones M.; Green K. N.; LaFerla F. M.\nSwedish Alzheimer mutation induces\nmitochondrial dysfunction mediated by HSP60 mislocalization of amyloid\nprecursor protein (APP) and beta-amyloid. J.\nBiol. Chem.\n2012, 287, 30317\u201330327. 10.1074/jbc.m112.365890. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Campanella C.; Pace A.; Caruso Bavisotto C.; Marzullo P.; Marino Gammazza A.; Buscemi S.; Palumbo\nPiccionello A.\nHeat Shock Proteins in Alzheimer\u2019s Disease:\nRole and Targeting. Int. J. Mol. Sci.\n2018, 19, 2603.10.3390/ijms19092603. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Kishimoto Y.; Hiraiwa M.; O\u2019Brien J.\nSaposins:\nstructure, function, distribution, and molecular genetics. J. Lipid Res.\n1992, 33, 1255\u20131267. 10.1016/s0022-2275(20)40540-1. [PubMed] [CrossRef] [Google Scholar]Paushter D. H.; Du H.; Feng T.; Hu F.\nThe lysosomal\nfunction of progranulin, a guardian against neurodegeneration. Acta Neuropathol.\n2018, 136, 1\u201317. 10.1007/s00401-018-1861-8. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Nicholson A. M.; Finch N. A.; Almeida M.; Perkerson R. B.; van Blitterswijk M.; Wojtas A.; Cenik B.; Rotondo S.; Inskeep V.; Almasy L.; Dyer T.; Peralta J.; Jun G.; Wood A. R.; Frayling T. M.; Fuchsberger C.; Fowler S.; Teslovich T. M.; Manning A. K.; Kumar S.; Rademakers R.\nProsaposin\nis a regulator of progranulin levels and\noligomerization. Nat. Commun.\n2016, 7, 11992.10.1038/ncomms11992. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Andersson A.; Remnest\u00e5l J.; Nellg\u00e5rd B.; Vunk H.; Kotol D.; Edfors F.; Uhl\u00e9n M.; Schwenk J. M.; Ilag L. L.; Zetterberg H.; Blennow K.; M\u00e5nberg A.; Nilsson P.; Fredolini C.\nDevelopment\nof parallel reaction monitoring assays for cerebrospinal fluid proteins\nassociated with Alzheimer\u2019s disease. Clin. Chim. Acta\n2019, 494, 79\u201393. 10.1016/j.cca.2019.03.243. [PubMed] [CrossRef] [Google Scholar]Csiszar K.\nLysyl oxidases: a novel multifunctional\namine oxidase\nfamily. Prog. Nucleic Acid Res. Mol. Biol.\n2001, 70, 1\u201332. 10.1016/s0079-6603(01)70012-8. [PubMed] [CrossRef] [Google Scholar]Lee J.-E.; Kim Y.\nA tissue-specific variant\nof the\nhuman lysyl oxidase-like protein 3 (LOXL3) functions as an amine oxidase\nwith substrate specificity. J. Biol. Chem.\n2006, 281, 37282\u201337290. 10.1074/jbc.m600977200. [PubMed] [CrossRef] [Google Scholar]Simionescu-Bankston A.; Pichavant C.; Canner J. P.; Apponi L. H.; Wang Y.; Steeds C.; Olthoff J. T.; Belanto J. J.; Ervasti J. M.; Pavlath G. K.\nCreatine\nkinase B is necessary to\nlimit myoblast fusion during myogenesis. Am.\nJ. Physiol.: Cell Physiol.\n2015, 308, C919\u2013C931. 10.1152/ajpcell.00029.2015. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Hern\u00e1ndez F.; Cuadros R.; Oll\u00e1 I.; Garc\u00eda C.; Ferrer I.; Perry G.; Avila J.\nDifferences\nin structure and function between human and murine tau. Biochim. Biophys. Acta, Mol. Basis Dis.\n2019, 1865, 2024\u20132030. 10.1016/j.bbadis.2018.08.010. [PubMed] [CrossRef] [Google Scholar]Ju T.-C.; Lin Y.-S.; Chern Y.\nEnergy dysfunction\nin Huntington\u2019s disease: insights from PGC-1\u03b1, AMPK,\nand CKB. Cell. Mol. Life Sci.\n2012, 69, 4107\u20134120. 10.1007/s00018-012-1025-2. [PubMed] [CrossRef] [Google Scholar]Montgomery M. K.; Bayliss J.; Keenan S.; Rhost S.; Ting S. B.; Watt M. J.\nThe role ofAp2a2\nin PPAR\u03b1-mediated\nregulation of lipolysis in adipose tissue. FASEB\nJ.\n2019, 33, 13267\u201313279. 10.1096/fj.201900909rr. [PubMed] [CrossRef] [Google Scholar]Ting S. B.; Deneault E.; Hope K.; Cellot S.; Chagraoui J.; Mayotte N.; Dorn J. F.; Laverdure J.-P.; Harvey M.; Hawkins E. D.; Russell S. M.; Maddox P. S.; Iscove N. N.; Sauvageau G.\nAsymmetric\nsegregation and self-renewal\nof hematopoietic stem and progenitor cells with endocytic Ap2a2. Blood\n2012, 119, 2510\u20132522. 10.1182/blood-2011-11-393272. [PubMed] [CrossRef] [Google Scholar]Espinosa A.; Hern\u00e1ndez-Olasagarre B.; Moreno-Grau S.; Kleineidam L.; Heilmann-Heimbach S.; Hern\u00e1ndez I.; Wolfsgruber S.; Wagner H.; Rosende-Roca M.; Maule\u00f3n A.; et al. Exploring genetic associations of Alzheimer\u2019s\ndisease Loci With Mild cognitive impairment neurocognitive endophenotypes. Front. Aging Neurosci.\n2018, 10, 340.10.3389/fnagi.2018.00340. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Katsumata Y.; Fardo D. W.; Bachstetter A. D.; Artiushin S. C.; Wang W. X.; Wei A.; Brzezinski L. J.; Nelson B. G.; Huang Q.; Abner E. L.; Anderson S.; Patel I.; Shaw B. C.; Price D. A.; Niedowicz D. M.; Wilcock D. W.; Jicha G. A.; Neltner J. H.; Van Eldik L. J.; Estus S.; Nelson P. T.\nAlzheimer disease pathology-associated\npolymorphism in a complex variable Number of tandem repeat region\nwithin the MUC6 gene, near the AP2A2 gene. J.\nNeuropathol. Exp. Neurol.\n2020, 79, 3\u201321. 10.1093/jnen/nlz116. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Reissner C.; Runkel F.; Missler M.\nNeurexins. Genome Biol.\n2013, 14, 213.10.1186/gb-2013-14-9-213. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Sindi I. A.; Tannenberg R. K.; Dodd P. R.\nA Role for the neurexin-neuroligin\ncomplex in Alzheimer\u2019s disease. Neurobiol.\nAging\n2014, 35, 746\u2013756. 10.1016/j.neurobiolaging.2013.09.032. [PubMed] [CrossRef] [Google Scholar]Martinez-Mir A.; Gonz\u00e1lez-P\u00e9rez A.; Gay\u00e1n J.; Ant\u00fanez C.; Mar\u00edn J.; Boada M.; Lopez-Arrieta J. M.; Fern\u00e1ndez E.; Ram\u00edrez-Lorca R.; S\u00e1ez M. E.; Ruiz A.; Scholl F. G.; Real L. M.\nGenetic study of neurexin and neuroligin genes in Alzheimer\u2019s\ndisease. J. Alzheimer\u2019s Dis.\n2013, 35, 403\u2013412. 10.3233/jad-122257. [PubMed] [CrossRef] [Google Scholar]Bouter A.; Carmeille R.; Gounou C.; Bouvet F.; Degrelle S. A.; Evain-Brion D.; Brisson A. R.\nReview: Annexin-A5\nand cell membrane repair. Placenta\n2015, 36, S43\u2013S49. 10.1016/j.placenta.2015.01.193. [PubMed] [CrossRef] [Google Scholar]Boersma H. H.; Kietselaer B. L.; Stolk L. M.; Bennaghmouch A.; Hofstra L.; Narula J.; Heidendal G. A.; Reutelingsperger C. P.\nPast, present, and future of annexin\nA5: from protein\ndiscovery to clinical applications. J. Nucl.\nMed.\n2005, 46, 2035\u20132050. [PubMed] [Google Scholar]Correani V.; Di Francesco L.; Mignogna G.; Fabrizi C.; Leone S.; Giorgi A.; Passeri A.; Casata R.; Fumagalli L.; Maras B.; Schinin\u00e0 M. E.\nPlasma\nmembrane protein profiling in beta-amyloid-treated microglia cell\nline. Proteomics\n2017, 17, 1600439.10.1002/pmic.201600439. [PubMed] [CrossRef] [Google Scholar]Muraoka S.; DeLeo A. M.; Sethi M. K.; Yukawa-Takamatsu K.; Yang Z.; Ko J.; Hogan J. D.; Ruan Z.; You Y.; Wang Y.; Medalla M.; Ikezu S.; Chen M.; Xia W.; Gorantla S.; Gendelman H. E.; Issadore D.; Zaia J.; Ikezu T.\nProteomic\nand biological profiling of extracellular vesicles from\nAlzheimer\u2019s disease human brain tissues. Alzheimer\u2019s Dementia\n2020, 16, 896\u2013907. 10.1002/alz.12089. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Diez-Fernandez C.; R\u00fcfenacht V.; H\u00e4berle J.\nMutations\nin the human argininosuccinate synthetase (ASS1) gene, impact on patients,\ncommon changes, and structural considerations. Hum. Mutat.\n2017, 38, 471\u2013484. 10.1002/humu.23184. [PubMed] [CrossRef] [Google Scholar]Engel K.; H\u00f6hne W.; H\u00e4berle J.\nMutations\nand polymorphisms in the human argininosuccinate synthetase (ASS1)\ngene. Hum. Mutat.\n2009, 30, 300\u2013307. 10.1002/humu.20847. [PubMed] [CrossRef] [Google Scholar]Haas J.; Storch-Hagenlocher B.; Biessmann A.; Wildemann B.\nInducible\nnitric oxide synthase and argininosuccinate\nsynthetase: co-induction in brain tissue of patients with Alzheimer\u2019s\ndementia and following stimulation with beta-amyloid 1-42 in vitro. Neurosci. Lett.\n2002, 322, 121\u2013125. 10.1016/s0304-3940(02)00095-2. [PubMed] [CrossRef] [Google Scholar]Ye F.; Chen Y.; Xia L.; Lian J.; Yang S.\nAldolase A\noverexpression is associated with poor prognosis and promotes tumor\nprogression by the epithelial-mesenchymal transition in colon cancer. Biochem. Biophys. Res. Commun.\n2018, 497, 639\u2013645. 10.1016/j.bbrc.2018.02.123. [PubMed] [CrossRef] [Google Scholar]Zafar S.; Shafiq M.; Younas N.; Schmitz M.; Ferrer I.; Zerr I.\nPrion protein interactome: identifying\nnovel targets in slowly and rapidly progressive forms of Alzheimer\u2019s\ndisease. J. Alzheimer\u2019s Dis.\n2017, 59, 265\u2013275. 10.3233/jad-170237. [PubMed] [CrossRef] [Google Scholar]Jossin Y.; Lee M.; Klezovitch O.; Kon E.; Cossard A.; Lien W.-H.; Fernandez T. E.; Cooper J. A.; Vasioukhin V.\nLlgl1 connects\ncell polarity with\ncell-cell adhesion in embryonic neural stem cells. Dev. Cell\n2017, 41, 481\u2013495.e5. 10.1016/j.devcel.2017.05.002. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Russ A.; Louderbough J. M. V.; Zarnescu D.; Schroeder J. A.\nHugl1 and\nHugl2 in mammary epithelial cells: polarity, proliferation, and differentiation. PLoS One\n2012, 7, e4773410.1371/journal.pone.0047734. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Edgell C.-J. S.; BaSalamah M. A.; Marr H. S.\nTestican-1: a differentially\nexpressed proteoglycan with protease inhibiting activities. Int. Rev. Cytol.\n2004, 236, 101\u2013122. 10.1016/s0074-7696(04)36003-1. [PubMed] [CrossRef] [Google Scholar]R\u00f6ll S.; Seul J.; Paulsson M.; Hartmann U.\nTestican-1\nis dispensable for mouse development. Matrix\nBiol.\n2006, 25, 373\u2013381. 10.1016/j.matbio.2006.05.004. [PubMed] [CrossRef] [Google Scholar]Barrera-Ocampo A.; Arlt S.; Matschke J.; Hartmann U.; Puig B.; Ferrer I.; Z\u00fcrbig P.; Glatzel M.; Sepulveda-Falla D.; Jahn H.\nAmyloid-\u03b2 precursor\nprotein modulates the sorting of testican-1 and contributes to Its\naccumulation in brain tissue and cerebrospinal fluid from patients\nwith Alzheimer disease. J. Neuropathol. Exp.\nNeurol.\n2016, 75, 903\u2013916. 10.1093/jnen/nlw065. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Shenolikar S.; Weinman E. J.\nNHERF: targeting\nand trafficking\nmembrane proteins. Am. J. Physiol.: Renal Physiol.\n2001, 280, F389\u2013F395. 10.1152/ajprenal.2001.280.3.f389. [PubMed] [CrossRef] [Google Scholar]Weinman E. J.; Hall R. A.; Friedman P. A.; Liu-Chen L.-Y.; Shenolikar S.\nThe association of NHERF adaptor\nproteins with g protein-coupled\nreceptors and receptor tyrosine kinases. Annu.\nRev. Physiol.\n2006, 68, 491\u2013505. 10.1146/annurev.physiol.68.040104.131050. [PubMed] [CrossRef] [Google Scholar]Kriz V.; Korinek V.\nWnt, RSPO and hippo\nsignalling in\nthe intestine and intestinal stem cells. Genes\n2018, 9, 20.10.3390/genes9010020. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Courtneidge S. A.; Dhand R.; Pilat D.; Twamley G. M.; Waterfield M. D.; Roussel M. F.\nActivation of Src family kinases\nby colony stimulating factor-1, and their association with its receptor. EMBO J.\n1993, 12, 943\u2013950. 10.1002/j.1460-2075.1993.tb05735.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Xu M.; Liu Y.; Huang Y.; Wang J.; Yan J.; Zhang L.; Zhang C.\nRe-exploring\nthe core genes and modules\nin the human frontal cortex during chronological aging: insights from\nnetwork-based analysis of transcriptomic studies. Aging\n2018, 10, 2816\u20132831. 10.18632/aging.101589. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Roberts S. A.; Strande N.; Burkhalter M. D.; Strom C.; Havener J. M.; Hasty P.; Ramsden D. A.\nKu is a\n5\u2032-dRP/AP lyase that excises nucleotide damage near broken\nends. Nature\n2010, 464, 1214\u20131217. 10.1038/nature08926. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Tuteja N.; Tuteja R.; Ochem A.; Taneja P.; Huang N. W.; Simoncsits A.; Susic S.; Rahman K.; Marusic L.; Chen J.; et al. Human DNA helicase II:\na novel DNA unwinding enzyme identified as the Ku autoantigen. EMBO J.\n1994, 13, 4991\u20135001. 10.1002/j.1460-2075.1994.tb06826.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Stanescu V.\nThe small proteoglycans of cartilage\nmatrix. Semin. Arthritis Rheum.\n1990, 20, 51\u201364. 10.1016/0049-0172(90)90047-j. [PubMed] [CrossRef] [Google Scholar]Snow A. D.; Mar H.; Nochlin D.; Kresse H.; Wight T. N.\nPeripheral distribution of dermatan sulfate proteoglycans\n(decorin) in amyloid-containing plaques and their presence in neurofibrillary\ntangles of Alzheimer\u2019s disease. J. Histochem.\nCytochem.\n1992, 40, 105\u2013113. 10.1177/40.1.1370306. [PubMed] [CrossRef] [Google Scholar]Lam V.; Takechi R.; Pallebage-Gamarallage M. M. S.; Galloway S.; Mamo J. C. L.\nColocalisation of plasma derived\napo B lipoproteins\nwith cerebral proteoglycans in a transgenic-amyloid model of Alzheimer\u2019s\ndisease. Neurosci. Lett.\n2011, 492, 160\u2013164. 10.1016/j.neulet.2011.02.001. [PubMed] [CrossRef] [Google Scholar]Timpl R.\nStructure and biological activity of basement membrane\nproteins. Eur. J. Biochem.\n1989, 180, 487\u2013502. 10.1111/j.1432-1033.1989.tb14673.x. [PubMed] [CrossRef] [Google Scholar]Narindrasorasak S.; Altman R. A.; Gonzalez-DeWhitt P.; Greenberg B. D.; Kisilevsky R.\nAn interaction between basement membrane\nand Alzheimer amyloid precursor proteins suggests a role in the pathogenesis\nof Alzheimer\u2019s disease. Lab. Invest.\n1995, 72, 272\u2013282. [PubMed] [Google Scholar]Averaimo S.; Milton R. H.; Duchen M. R.; Mazzanti M.\nChloride intracellular\nchannel 1 (CLIC1): Sensor and effector during oxidative stress. FEBS Lett.\n2010, 584, 2076\u20132084. 10.1016/j.febslet.2010.02.073. [PubMed] [CrossRef] [Google Scholar]Novarino G.; Fabrizi C.; Tonini R.; Denti M. A.; Malchiodi-Albedi F.; Lauro G. M.; Sacchetti B.; Paradisi S.; Ferroni A.; Curmi P. M.; Breit S. N.; Mazzanti M.\nInvolvement of the intracellular ion channel CLIC1\nin microglia mediated beta-amyloid-induced neurotoxicity. J. Neurosci.\n2004, 24, 5322\u20135330. 10.1523/jneurosci.1170-04.2004. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Sabha B. H.; Alzahrani F.; Almehdar H. A.; Uversky V. N.; Redwan E. M.\nDisorder in milk\nproteins: lactadherin multifunctionality\nand structure. Curr. Protein Pept. Sci.\n2018, 19, 983\u2013997. 10.2174/1389203719666180608091849. [PubMed] [CrossRef] [Google Scholar]Neniskyte U.; Brown G. C.\nLactadherin/MFG-E8\nis essential for\nmicroglia-mediated neuronal loss and phagoptosis induced by amyloid\n\u03b2. J. Neurochem.\n2013, 126, 312\u2013317. 10.1111/jnc.12288. [PubMed] [CrossRef] [Google Scholar]Filmus J.; Capurro M.; Rast J.\nGlypicans. Genome Biol.\n2008, 9, 224.10.1186/gb-2008-9-5-224. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Lorente-Gea L.; Garc\u00eda B.; Mart\u00edn C.; Ordiales H.; Garc\u00eda-Su\u00e1rez O.; Pi\u00f1a-Batista K. M.; Merayo-Lloves J.; Quir\u00f3s L. M.; Fern\u00e1ndez-Vega I.\nHeparan sulfate proteoglycans\nundergo differential expression alterations in Alzheimer disease brains. J. Neuropathol. Exp. Neurol.\n2020, 79, 474\u2013483. 10.1093/jnen/nlaa016. [PubMed] [CrossRef] [Google Scholar]Berns D. S.; DeNardo L. A.; Pederick D. T.; Luo L.\nTeneurin-3\ncontrols topographic circuit assembly in the hippocampus. Nature\n2018, 554, 328\u2013333. 10.1038/nature25463. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Antinucci P.; Nikolaou N.; Meyer M. P.; Hindges R.\nTeneurin-3\nspecifies morphological and functional connectivity of retinal ganglion\ncells in the vertebrate visual system. Cell\nRep.\n2013, 5, 582\u2013592. 10.1016/j.celrep.2013.09.045. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Walker L. C.; Overstreet M. A.; Siddiqui A.; De Paepe A.; Ceylaner G.; Malfait F.; Symoens S.; Atsawasuwan P.; Yamauchi M.; Ceylaner S.; Bank R. A.; Yeowell H. N.\nA novel\nmutation in the lysyl hydroxylase 1 gene causes decreased lysyl hydroxylase\nactivity in an Ehlers-Danlos VIA patient. J.\nInvest. Dermatol.\n2005, 124, 914\u2013918. 10.1111/j.0022-202x.2005.23727.x. [PubMed] [CrossRef] [Google Scholar]Chong M. S.; Goh L. K.; Lim W. S.; Chan M.; Tay L.; Chen G.; Feng L.; Ng T. P.; Tan C. H.; Lee T. S.\nGene expression\nprofiling of peripheral blood leukocytes\nshows consistent longitudinal downregulation of TOMM40 and upregulation\nof KIR2DL5A, PLOD1, and SLC2A8 among fast progressors in early Alzheimer\u2019s\ndisease. J. Alzheimer\u2019s Dis.\n2013, 34, 399\u2013405. 10.3233/jad-121621. [PubMed] [CrossRef] [Google Scholar]Martin L.; Latypova X.; Wilson C. M.; Magnaudeix A.; Perrin M.-L.; Yardin C.; Terro F.\nTau protein kinases:\ninvolvement in Alzheimer\u2019s disease. Ageing\nRes. Rev.\n2013, 12, 289\u2013309. 10.1016/j.arr.2012.06.003. [PubMed] [CrossRef] [Google Scholar]Braithwaite S. P.; Stock J. B.; Lombroso P. J.; Nairn A. C.\nProtein\nphosphatases and Alzheimer\u2019s disease. Prog. Mol. Biol. Transl. Sci.\n2012, 106, 343\u2013379. 10.1016/b978-0-12-396456-4.00012-2. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Taymans J.-M.; Baekelandt V.\nPhosphatases\nof alpha-synuclein,\nLRRK2, and tau: important players in the phosphorylation-dependent\npathology of Parkinsonism. Front. Genet.\n2014, 5, 382.10.3389/fgene.2014.00382. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Xu Y.; Chen Y.; Zhang P.; Jeffrey P. D.; Shi Y.\nStructure\nof a protein phosphatase 2A holoenzyme: insights into B55-mediated\nTau dephosphorylation. Mol. Cell\n2008, 31, 873\u2013885. 10.1016/j.molcel.2008.08.006. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Sontag E.; Luangpirom A.; Hladik C.; Mudrak I.; Ogris E.; Speciale S.; White C. L. 3rd\nAltered expression levels of the protein phosphatase 2A ABalphaC\nenzyme are associated with Alzheimer disease pathology. J. Neuropathol. Exp. Neurol.\n2004, 63, 287\u2013301. 10.1093/jnen/63.4.287. [PubMed] [CrossRef] [Google Scholar]Steinhilb M. L.; Dias-Santagata D.; Mulkearns E. E.; Shulman J. M.; Biernat J.; Mandelkow E.-M.; Feany M. B.\nS/P and T/P phosphorylation is critical for tau neurotoxicity\nin Drosophila. J. Neurosci. Res.\n2007, 85, 1271\u20131278. 10.1002/jnr.21232. [PubMed] [CrossRef] [Google Scholar]Wu J. M.; Chen Y. P.; An S. J.; Perruccio L.; Abdelghany M.; Carter T. H.\nPhosphorylation of protein tau by\ndouble-stranded DNA-dependent protein kinase. Biochem. Biophys. Res. Commun.\n1993, 193, 13\u201318. 10.1006/bbrc.1993.1583. [PubMed] [CrossRef] [Google Scholar]Yin L.; Zeng Y.; Xiao Y.; Chen Y.; Shen H.; Dong J.\nCyclin-dependent kinase\n1-mediated phosphorylation of SET at serine\n7 is essential for its oncogenic activity. Cell\nDeath Dis.\n2019, 10, 385.10.1038/s41419-019-1621-2. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Zhang Q.; Xia Y.; Wang Y.; Shentu Y.; Zeng K.; Mahaman Y. A. R.; Huang F.; Wu M.; Ke D.; Wang Q.; Zhang B.; Liu R.; Wang J. Z.; Ye K.; Wang X.\nCK2 phosphorylating\nI2(PP2A)/SET mediates tau pathology\nand cognitive impairment. Front. Mol. Neurosci.\n2018, 11, 146.10.3389/fnmol.2018.00146. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Lee G.\nTau and src family tyrosine kinases. Biochim.\nBiophys. Acta\n2005, 1739, 323\u2013330. 10.1016/j.bbadis.2004.09.002. [PubMed] [CrossRef] [Google Scholar]Lee G.; Thangavel R.; Sharma V. M.; Litersky J. M.; Bhaskar K.; Fang S. M.; Andreadis A.; Van Hoesen G.; Ksiezak-Reding H.\nPhosphorylation\nof tau by fyn: implications for Alzheimer\u2019s\ndisease. J. Neurosci.\n2004, 24, 2304\u20132312. 10.1523/jneurosci.4162-03.2004. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Ferrer I.; Blanco R.; Carmona M.; Ribera R.; Goutan E.; Puig B.; Rey M. J.; Cardozo A.; Vi\u00f1als F.; Ribalta T.\nPhosphorylated map\nkinase (ERK1,\nERK2) expression is associated with early tau deposition in neurones\nand glial cells, but not with increased nuclear DNA vulnerability\nand cell death, in Alzheimer disease, Pick\u2019s disease, progressive\nsupranuclear palsy and corticobasal degeneration. Brain Pathol.\n2001, 11, 144\u2013158. 10.1111/j.1750-3639.2001.tb00387.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Qi H.; Prabakaran S.; Cantrelle F.-X.; Chambraud B.; Gunawardena J.; Lippens G.; Landrieu I.\nCharacterization of\nNeuronal Tau Protein as a Target of Extracellular Signal-regulated\nKinase. J. Biol. Chem.\n2016, 291, 7742\u20137753. 10.1074/jbc.m115.700914. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Wang J.-Z.; Xia Y. Y.; Grundke-Iqbal I.; Iqbal K.\nAbnormal hyperphosphorylation of tau: sites, regulation, and molecular\nmechanism of neurofibrillary degeneration. J.\nAlzheimer\u2019s Dis.\n2013, 33, S123\u2013S139. 10.3233/JAD-2012-129031. [PubMed] [CrossRef] [Google Scholar]Ballatore C.; Lee V. M.-Y.; Trojanowski J. Q.\nTau-mediated\nneurodegeneration in Alzheimer\u2019s disease and related disorders. Nat. Rev. Neurosci.\n2007, 8, 663\u2013672. 10.1038/nrn2194. [PubMed] [CrossRef] [Google Scholar]De Strooper B.; Iwatsubo T.; Wolfe M. S.\nPresenilins\nand\n\u03b3-secretase: structure, function, and role in Alzheimer Disease. Cold Spring Harbor Perspect. Med.\n2012, 2, a006304.10.1101/cshperspect.a006304. [PMC free article] [PubMed] [CrossRef] [Google Scholar]Wolfe M. S.\nProcessive\nproteolysis by \u03b3-secretase and the\nmechanism of Alzheimer\u2019s disease. Biol.\nChem.\n2012, 393, 899\u2013905. 10.1515/hsz-2012-0140. [PubMed] [CrossRef] [Google Scholar]"}